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Recent accessibility of microbial genome sequencing data has enabled broad investigations into 
the nature of microbial physiology and their consequences on humans and their environment. 
Through an approach known as genome mining, an in silico technique that enables the 
identification of uncharacterized gene clusters based on sequence homology, the investigations 
described herein provide new insight into two important groups of microbes, namely human 
bacterial pathogens and cyanobacteria. In Part I of this dissertation, genome mining techniques 
have identified two evolutionarily-conserved cryptic biosynthetic operons in the human 
pathogens Acinetobacter baumannii and Pseudomonas aeruginosa.  Interestingly, the findings 
demonstrate the significance of these gene clusters and their small molecule products to be 
important contributors to the pathogenesis of these organisms. As a result, the proteins encoded 
by these gene clusters are expected to be important targets in the development of next-generation 
antibiotics. In Part II, a novel platform for the investigation of natural products biosynthesis from 
cyanobacteria is described. Cyanobacteria have proven to be important yet relatively unexplored 
sources of bioactive compounds. Recent genome sequencing has indicated the substantial 
potential of these microbes to synthesize compounds that can be developed into new medicines. 
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The collective findings in this dissertation demonstrate the considerable utility of emerging 
microbial genome sequencing information and its future impact on human health and disease. 
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1.0  PART I INTRODUCTION: THE DISCOVERY AND CHARACTERIZATION OF 
SECONDARY METABOLITE VIRULENCE FACTORS 
There has been an unprecedented emergence of multidrug resistant (MDR) pathogenic bacteria 
that is taking place in hospitals worldwide. These “superbugs” have acquired resistance to the 
most commonly used antibiotics and continue to be the cause of rapidly increasing numbers of 
hospital-acquired infections. MDR bacterial strains have been identified from a number of 
different bacterial species with some of the most prevalent including methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE) as well as 
pan-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.[1] Pathogenic strains 
exhibiting pandrug resistance (PDR) are especially alarming, as they are resistant to all classes of 
antibiotics and represent the significant gap between antibiotics discovery and the treatment of 
MDR pathogens. 
 
Traditional antibiotics function by inhibiting essential processes of bacterial metabolism 
(e.g., cell wall synthesis, protein synthesis, RNA transcription). This leads to the elimination of 
antibiotic sensitive strains and provides enhanced opportunities for the subpopulation of resistant 
and virulent strains to proliferate in the host. The introduction of new antibiotics to this microbial 
population leads to the continuous selection of increasingly resistant bacterial members. 
 
Drug resistance arises due to random mutations within their genome or from the 
acquisition of drug resistance genes from other bacteria. These resistance genes function to 
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export the antibiotic outside of the cell, to inactivate the drug, to alter the drug target site, or to 
prevent the compound from entering the cell.[2, 3] The propagation of drug resistance genes and 
their phenotypes is facilitated by the exchange, transport, and acquisition of DNA, namely 
plasmids and other mobile DNA vectors.[4] 
 
Because current antibiotics target vital components of the organism, a substantial 
selective pressure exists for the emergence of strains that can survive the effects of the drug. 
Consequently, antibiotic resistant strains can readily propagate and exhibit virulence. An 
inherent drawback of these types of antibiotics, therefore, is the continuous emergence of drug 
resistant bacterial strains. Therefore, there is expanding interest in next generation antibiotics that 
can selectively target pathogens without exerting substantial selective pressure for drug 
resistances.  
1.1 NEXT GENERATION ANTIBIOTICS: ANTIVIRULENCE DRUGS 
One promising approach is to develop drugs that inhibit targets that are non-essential to the 
overall survival of the cell but essential in its pathogenicity (i.e., virulence factors). 
Theoretically, the inhibition of bacterial virulence factors is nonlethal and places minimal 
pressure for the pathogen to develop resistance but is effective in combating bacterial 
pathogenesis. [5, 6] Some of these targets include genes and molecules that are involved in: 
adhesion (colonization and invasion), toxicity, biofilm formation, secretion and cell-to-cell 
communication (quorum sensing). Inhibitors directed against adhesion molecules, toxins, cell 
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communication systems, and secretory mechanisms have proven to be especially promising. 























1.1.1 Pilus System 
For example, proteinaceous hair-like cell surface appendages known as pili are the major 
structures of gram-negative bacteria responsible for adhesion and invasion of human cells and 
are also responsible for biofilm formation and macromolecular transport [7]. Uropathogenic 
Escherichia coli utilize these structures to cause urinary tract infections (UTI).[8] The design and 
development of several small molecule inhibitors of pili have been one promising route toward 
antivirulence approaches against UTI that circumvent the selection of antibiotic resistant 
pathogenic strains.[9-11]  
1.1.2 Toxins  
Toxins are another class of virulence factors that are attractive targets for drug development due 
to their direct effects on bacterial pathogenicity. Two well-characterized protein toxins include 
the Shiga toxin from E. coli[12] and the anthrax toxin from Bacillus anthracis[13]. Both exert 
their effects by entering into and then disrupting normal cell function in the infected human cell: 
the Shiga toxin interferes with intracellular signaling to ultimately cause over-accumulation of 
cellular fluid and cell death[14], while the anthrax toxin halts host protein synthesis, also 
resulting in cell death[15]. Successful antivirulence approaches to combat the Shiga and anthrax 
toxins have included the inhibition of toxin entry into the cell[16, 17] as well as the inhibition of 
protein-protein interactions or enzymatic activity[18, 19] that lead to cell death. Developments in 
these antivirulence therapeutics have included both antibodies as well as small molecule 
inhibitors targeting functional subunits of these toxins. 
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1.1.3 Biofilm  
Biofilms are complex bacterial community structures that are composed of a matrix consisting of 
polysaccharides, proteins, nucleic acids, and various nutrients and small molecules. These 
structures impede the diffusion of molecules and has been shown to confer drug resistance to 
their microbial inhabitants. Biofilms are an important clinical challenge due to their persistence 
in a number of bacterial infections, including those of the middle ear due to Haemophilus 
influenzae[20], Helicobacter pylori biofilms of gastric ulcers[21], as well as biofilms of P. 
aeruginosa that contribute to lung infections of cystic fibrosis patients[22, 23]. Antivirulence 
approaches that target biofilms have included attenuation of quorum sensing systems as well as 
the inhibition of polysaccharide and protein biosynthesis that give rise to the extracellular matrix 
of the biofilm.[24] In addition to ubiquitous biological macromolecules, small molecules 
biosurfactants, such as the rhamnolipids from P. aeruginosa, have been demonstrated to be 
essential in the proper architectural development of these complex microstructures [25]. 
1.1.4 Secretory Systems  
Type III secretion systems (TTSS) have been another bacterial target in the development of next 
generation antibiotics. TTSS are composed of protein complexes that enable the transport of 
toxins and other effectors from the pathogenic bacteria directly into the human cell to elicit 
virulence; they can also secrete molecules into the surrounding environment to facilitate 
microbial motility.[26, 27] Drug screening studies have identified several classes of compounds 
that can effectively inhibit these TTSS mechanisms from two prominent human pathogens, 
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Chlamydia trachomatis and Yersinia pseudotuberculosis, preventing their development as well 
as the progression of disease.[28, 29] 
1.1.5 Quorum Sensing 
Lastly, antivirulence approaches to target quorum sensing (QS) systems have also been explored. 
QS molecules are autoinducing signals that upregulate their own biosynthesis and is dependent 
on bacteria population densities. QS regulates gene expression and enables bacteria to coordinate 
diverse group behaviors, such as those involved in virulence. The pleiotrophic roles of QS in 
bacterial pathogenicity makes this target especially attractive, because multiple virulence factors 
could be silenced by inhibiting QS. Synthetic QS inhibitors, whose designs are based on their 
natively synthesized structures, have been developed and demonstrate inhibition against 
virulence phenotypes from human bacterial pathogens, such as in the production of toxic shock 
syndrome toxin-1, a toxin from Staphylococcus aureus [30], and as well in the production of 
small molecule virulence factors, pyocyanin and rhamnolipids, from P. aeruginosa [31]. Other 
inhibitors of the widely distributed QseC histidine sensor kinase QS system, found in over two 
dozen bacterial species, have been identified by library screening and is believed to be one ideal 
target as a broad spectrum antibiotic.[32] 
 
Next generation antibiotics based on antivirulence approaches circumvent a significant 
shortcoming of current antimicrobial therapeutics: the substantial pressure placed on microbes to 
acquire drug resistances. As opposed to targeting essential processes, they are designed to inhibit 
mechanisms involved primarily in virulence, and ideally, render these microbes non-pathogenic. 
Although the antivirulence approach is still in nascent developmental stages, there is increasing 
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promise in this method of addressing human pathogen drug resistance. Moving forward, 
however, will require the elucidation of several unknown aspects. Although in theory 
antivirulence drugs will alleviate selective pressure for drug resistant strains, it is unknown 
whether or how rapidly resistant strains will emerge. Furthermore, it is unknown how such 
antivirulence drugs will affect the commensal population of the human microbiota and whether 
there will be detrimental effects toward the host. This latter concern could be addressed by the 
selective targeting of bacterial species (narrow spectrum) as opposed to targeting of general 
microbial mechanisms (broad spectrum). Narrow spectrum antibiotics are particularly ideal when 
the aetiological agent of the infection is known and when disturbance of the normal microbiota is 
unwanted. 
1.1.6 Siderophores 
A notable class of microbial secondary metabolites that are widely distributed amongst bacterial 
species and have essential roles (e.g., DNA synthesis, cellular respiration) in survival include 
iron-chelating molecules, known as siderophores. Iron is a micronutrient that serves as a cofactor 
for a variety of enzymatic functions within the cell. Although abundant in the environment, the 
bioavailability of iron to the microbe is limited, as it is most commonly present as the insoluble 
Fe
3+
 ion [33]. Therefore, access to iron requires a specialized carrier and transport system. 
 
The E. coli siderophore, enterobactin, and its transport system serve as the archetype for 
analogous systems in other microbial species. Enterobactin is biosynthesized by the ent operon 
and is regulated by the presence of free iron [34-36]; this siderophore demonstrates a binding 
affinity for Fe
3+








, it can be recognized by outer and inner membrane protein systems (Fep 
and Ton-Exb systems) to transport the chelated iron into the cell for utilization [38]. Given the 
essential role of iron for the cellular growth and survival of the cell, its uptake inhibition has 
been associated with decreased bacterial viability [39, 40]. Their essential roles have also 
highlighted these important targets in the development of antivirulence therapeutics [41]. 
 
1.1.7 Discovery of Novel Secondary Metabolite Virulence Factors Quorum Sensing 
The increasing availability of whole microbial genome information in recent years has enabled 
the unprecedented bioinformatic discovery of enzymatic machinery purported in the biosynthesis 
of secondary metabolites [42]. Metagenome information has been utilized to identify 
pathogenicity islands (DNA sequences predicted to encode virulence traits) [43]. Genome 
mining approaches have been employed in the discovery of novel microbial secondary 
metabolite virulence factors from such human bacterial pathogens as S. aureus [44], P. 
aeruginosa [45], and Burkholderia pseudomallei [46]. The utilization of complete genome 
sequencing data to characterize microbial virulence factors is particularly advantageous over 
traditional methods in the discovery of microbial virulence factors, which rely on the laborious 
and time-consuming generation and phenotypic screening of numerous transposon mutants [47]. 
 
In addition to bioinformatic analyses of factors that contribute to microbial pathogenesis, 
access to genome sequencing information can also enable the rapid and facile characterization of 
cryptic, virulent secondary metabolites. Specifically, novel genes with sequence homology to 
enzymes involved in the generation of nonribosomal peptides (NRPs), polyketides (PKs), and 
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ribosomally synthesized and posttranslationally modified peptides (RiPPs) can be identified via 
genome-mining approaches. Biosynthetic enzymes responsible for the generation of NRPs, PKs, 
or RiPPs are highly similar, and therefore, new genes responsible for their generation can be 
identified through comparative sequence analysis to known genes within these enzyme families. 
Genome-guided discovery of microbial virulence factors allows de-replication of small molecule 
discovery and the targeted elucidation of novel small molecules. In contrast, traditional 
approaches require bioassay-guided purification efforts, which are non-systematic and prone to 
the re-discovery of known compounds. The rapid characterization of large operons encoding 
virulence factors can be facilitated by employing cloning techniques that are capable of co-
assembling biosynthetic entire gene clusters. Such techniques proved to be successful in the 
following chapters, investigating microbial virulence factors. This research will discuss the 
genome-guided discovery and characterization of cryptic secondary metabolites from human 
bacterial pathogens Acinetobacter baumannii and P. aeruginosa. 
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2.0  CRYPTIC ACINETOBACTER TOXIN: BIOGENESIS, FUNCTION AND 
STRUCTURE 
Multidrug resistant (MDR) Acinetobacter baumannii has emerged in recent years as the hallmark 
“superbug”: a pathogen difficult or impossible to treat with traditional clinical antibiotics. Its 
persistence as a human pathogen can be attributed to its rapid ability to acquire antibiotic 
resistance phenotypes and to thrive in diverse environments of the hospital setting for extended 
periods of time. [48] Specifically, MDR A. baumannii has been implicated in a number of 
infections (including respiratory, skin, and bloodstream) of immunocompromised patients. [48, 
49] Furthermore, MDR A. baumannii is known to colonize different abiotic surfaces, such as 
catheters, respiratory lines, and glass [50-52]. The decreasing efficacy of current antibiotics to 
treat MDR A. baumannii infections has served as the impetus toward elucidating its mechanisms 
of pathogenesis in order to develop therapeutics that can target these mechanisms and render the 
microbes non-virulent. 
 
Despite its recognized association with various infections of the human body, there is 
relatively little known about the mechanisms of A. baumannii pathogenesis. Nonetheless, several 
virulence factors, including proteins and small molecules, have been characterized in their roles 
in contributing to A. baumannii pathogenesis. Notably, A. baumannii has acquired a number of 
mechanisms to confer resistance to all of the major classes of antibiotics, thereby facilitating its 
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pathogenesis. [48, 53, 54] Genome sequencing of MDR A. baumannii clinical strains has 
revealed that a major proportion of the genes that encode antibiotic resistance are situated on a 
resistance island. [55, 56] This genetic island is absent in antibiotic-susceptible strains and 
appears to be readily transferred due to the presence of transposase genes encoded within this 
locus. Transposases can facilitate transfer of these genes onto a plasmid that can then be 
distributed to other isolates. 
 
Several protein virulence factors from A. baumannii have also been identified. One of the 
most extensively characterized includes members of a family of cell surface proteins, known as 
outer membrane proteins (OMPs). OMPs have been demonstrated to contribute to pathogenesis 
through the induction of host cell apoptosis [57] and cytotoxicity [58], mediation of antibiotic 
resistance [59-61], cell invasion [62], as well as biofilm formation on abiotic surfaces [63]. 
Another significant protein virulence factor of A. baumannii includes the type IV pili system, 
which comprise a complex of proteins that project from the microbial cell and commonly work 
to enable the microbe to attach to surfaces. These proteins have been identified as central 
components in biofilm formation [64] as well as in motility [65]. 
 
Other important targets for the development of anti-virulence antibiotics include small 
molecule secondary metabolites that enable the survival of pathogens. Two common classes of 
microbial secondary metabolites include 1) siderophores in the acquisition of iron and 2) 
quorum-sensing (QS) molecules that are responsible for population-dependent coordinated 
behaviors. Two such secondary metabolites from A. baumannii have been characterized: the 
siderophore acinetobactin [66]
 
and quorum sensing molecule N-(3-hydroxydodecanoyl)-L-
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homoserine lactone (3-OH-C12-HSL) [67]. Acinetobactin was recently demonstrated to be 
important in host infection and animal death against mice and the wax worm Galleria 
mellonella. [68] QS molecule 3-OH-C12-HSL has been linked to both biofilm formation [69] 
and surface motility [65]. QS antagonists against the A. baumannii QS receptor have been 
demonstrated to reduce both biofilm formation and motility [70]. 
 
The genome of A. baumannii strain ATCC 17978 was sequenced in 2007 [71]. We 
utilized the genome mining approach on this strain in order to identify genes for enzymes in the 
nonribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) families. Genome 
mining of this A. baumannii strain revealed the presence of a conserved locus (A1S_0112 to 
A1S_0119), containing NRPS and PKS enzymes, which is hypothesized to be involved in the 
biosynthesis of a lipopeptide. This locus was then discovered to not only be present in all 
sequenced strains of A. baumannii but also to be unique to this organism. The evolutionarily 
conserved and unique nature of this locus in A. baumannii has led us to hypothesize that its gene 
products and secondary metabolite contribute to the virulence of this pathogen. 
 
This locus contains a putative efflux pump of the RND superfamily (A1S_0116) and an 
OMP porin protein (A1S_0117). A previous investigation had demonstrated that this gene cluster 
played a role in surface motility and was also regulated by an upstream LuxR-type QS regulator, 
AbaR [65]. Furthermore, others have shown that an acyl carrier protein of this locus (A1S_0114) 
was transcriptionally upregulated in biofilms [72]. In this study, we generated an insertional 
mutation in the A1S_0112 gene that conferred altered phenotypes for virulence traits, including 
surface motility, hemolysis, desiccation resistance, virulence against G. mellonella, and heat 
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shock resistance. Transcriptional analysis of this mutant and comparative phenotypic analysis 
with a markerless, in-frame deletion mutant revealed a polar effect, resulting in the 
transcriptional downregulation of the entire A1S_0112-9 gene cluster. Its pleiotropic roles in the 
pathogenesis of A. baumannii prompted us to designate this gene cluster the “cryptic 
Acinetobacter toxin” (CAT). 
2.1 RESULTS AND DISCUSSION 
2.1.1 Cryptic Acinetobacter Toxin Gene Cluster 
Genome mining of the A. baumannii ATCC 17978 strain revealed a gene cluster A1S_0112-9 
predicted to encode for enzymes in the biosynthesis of a hybrid polyketide-nonribosomal peptide 
(PKS-NRPS) small molecule (Figure 2.1). Sequence homology analysis via Basic Local 
Alignment Search Tool (BLAST) revealed this gene cluster to be specific to A. baumannii and 
absent in other Acinetobacter sp. The CAT and acinetobactin gene clusters were also discovered 













Gene Proposed Function 
catA Acyl-CoA synthetase (Fatty acid ligase-thiolation domains) 
catB Acyl-CoA dehydrogenase 
catC Acyl carrier protein 
catD NRPS (Adenylation-condensation-thioesterase domains) 
catE Efflux pump (RND superfamily) 
catF Outer membrane protein (porin) 
catG Esterase-lipase 
catH Phosphopantetheinyl transferase 
 
Figure 2.1 cat gene cluster organization from strain ATCC17978 A. baumannii with proposed 
functions for each open reading frame. Genes colored blue are proposed to be directly involved 
in the biosynthesis of the putative lipopeptide, while red colored genes are proposed to be 




The CAT operon consists of eight genes (catA-H). Although the functions of these genes 
have not be demonstrated, they can be predicted base on sequence homology. Aside from catE 
and catF that are predicted to function in substrate transport across the outer membrane, all of 
the other six genes are predicted to encode proteins related to the PKS and NRPS superfamily 
and involved in the biosynthesis of the putative lipopeptide. CatA is predicted to be an acyl-CoA 
synthetase composed of fatty acid ligase-thiolation domains, responsible for the incorporation of 
a fatty acid substrate. CatB is predicted to be an acyl-CoA dehydrogenase, responsible for 
dehydration. CatC is predicted to be an acyl carrier protein, which shuttles intermediates from 
one catalytic domain to the next. CatD is predicted to be an NRPS enzyme composed of 
adenylation, condensation and thioesterase domains. CatG is predicted to be an esterase-lipase 
enzyme and involved in the hydrolysis of an ester bond. CatH is predicted to be the 
phosphopantetheinyl transferase, responsible for posttranslational modification of the acyl carrier 
protein with 4’-phosphopantetheine prosthetic moiety. 
 
2.1.2 Generation of CAT Pathway Mutants and Transcriptional Analysis to Assess Polar 
Effects from the ΔcatA::Km Mutant 
To understand the role of the CAT pathway, we used an approach reported previously [73] to 
generate an insertional mutant of A. baumannii that replaced the catA gene with a kanamycin 
resistance cassette to yield mutant ΔcatA::Km. Briefly, a linear, chimeric DNA fragment was 
generated by overlap-extension polymerase chain reaction (OE-PCR). This fragment contained 
5’ and 3’ DNA sequences, approximately 500bp in size, homologous to the flanking regions of 
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the catA gene with internal sequences for the kanamycin resistance cassette (Figure A1). 
Kanamycin-resistant clones recombined with the OE-PCR product were subsequently verified 
through DNA sequencing. In order to assess polar effects conferred by the insertional mutant, a 
markerless, in-frame deletion mutant of the catA gene (ΔcatA) was generated using a yeast 
recombineering-based suicide vector pMQ30, described previously (Figure A2). [74] 
Markerless, in-frame deletion mutants were also verified through DNA sequencing. Prior to 
sequence verification, candidate mutants were screened via colony PCR (Figure A3). 
 
Insertional mutants generated via gene replacement with antibiotic resistance cassettes 
have been reported previously to exert polar effects on genes downstream of the replaced gene 
[75-77]. To investigate the possible polar effects of the ΔcatA::Km mutant, reverse transcriptase-
polymerase chain reaction (RT-PCR) was performed to assess the transcription of downstream 
genes (Figure A4). The inability to generate amplicons from the cDNA library from the 
ΔcatA::Km mutant demonstrates a strong polar effect on the transcription of genes within the 
CAT pathway. This observation also suggests that these genes are co-regulated as an operon. 
Interestingly, transcription for catH was undetectable under the conditions used. CatH is 
predicted to be a phosphopantetheinyl transferase required for posttranslational modification of 
acyl and peptidyl carrier proteins with the 4’ phosphopantetheine prosthetic group. 
 
2.1.3 Phenotypic Analysis of CAT Pathway Mutants 
Through comparative phenotypic analysis of the wildtype, ΔcatA::Km mutant and ΔcatA mutant, 
we attribute a number of virulence traits of A. baumannii to the CAT pathway. These phenotypes 
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include desiccation resistance, motility, hemolysis, colony morphology, cytotoxicity against the 
wax worm Galleria mellonella, and heat shock viability. 
2.1.3.1 Desiccation 
Desiccation entails the removal of intracellular water. Desiccation resistance is characteristic of 
A. baumannii and contributes to its pathogenecity and ability to thrive in hospital settings. [78] 
Although details into the molecular mechanisms of desiccation resistance are largely unknown, a 
number of factors related to the preservation of cell structure and function have been attributed to 
this phenotype in bacteria. In particular, desiccation is known to cause extensive damage to the 
cell membrane, nucleic acids, and proteins. [79-81] Viability after 24hr of desiccation was 
assessed for the wildtype, ∆catA mutant, ∆catA::Km mutant, and the ∆catA::Km mutant 




Figure 2.2 Desiccation resistance of wildtype A. baumannii ATCC 17978, the ∆catA mutant, the 
∆catA::Km mutant, and the ∆catA::Km mutant containing a complementation plasmid consisting 
of the sfp gene and the catA-H gene cluster. Bacteria were desiccated for 24hr at 37°C on filter 


















Compared to the wild type, a marked decrease in desiccation resistance was observed in 
the ∆catA::Km mutant, as demonstrated by an inability to grow following desiccation. 
Furthermore, introduction of a complementation plasmid partially restored viability of the 
desiccated ∆catA::Km mutant. On the contrary, desiccation resistance was comparable between 
the wildtype and ∆catA mutant, suggesting that this phenotype is not significantly attributable to 
CatA but likely due to other genes in the operon, such as CatE or CatF. 
 
The complementation plasmid introduced into the ∆catA::Km mutant contained the entire 
cat operon as well as the sfp gene. The sfp gene encodes a phosphopantetheinyl transferase from 
B. subtilis that posttranslationally modifies apoenzymes of acyl and peptidyl carrier proteins with 
phosphopantetheinyl prosthetic groups to afford the holoenzyme. [82] Due to the absence of 
catH transcription (Figure A1.4), the sfp gene was introduced to ensure posttranslational 
modification of CatA and CatD. 
2.1.3.2 Motility 
The ability of pathogens to move across surfaces is a critical aspect of its pathogenesis against its 
hosts and its ability to colonize new environments. This behavior is known to be mediated via 
complex processes that involve proteinaceous surface appendages, such as flagella and pili [83, 
84], as well as biosurfactants [85, 86]. Both ∆catA::Km and ∆catA mutants exhibited complete 




Figure 2.3 Motility phenotypes of the wildtype, ∆catA::Km mutant, and ∆catA mutant were 
assessed on low percentage agar plates after 24 to 48hr incubation at 37°C. The ∆catA::Km 
mutant introduced with plasmids containing either the catA gene alone or the entire operon (sfp 
and catA-H) was also assessed. The ∆catA mutant introduced with a plasmid containing the 








∆catA::Km ∆catA::Km + catA ∆catA::Km + catA-H 
∆catA ∆catA + catA 
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Restoration of the wild-type motility phenotype in the ∆catA::Km mutant with the 
introduction of a complementation plasmid containing the entire operon (catA-H) but not with a 
plasmid containing the catA gene alone is consistent with the polar effect introduced by this 
insertional mutation. Restoration of the wild-type phenotype in the ∆catA mutant with the 
introduction of a complementation plasmid containing the catA gene alone supports a previous 
finding that suggests a lipopeptide is involved in the motility of A. baumannii [65]. 
2.1.3.3 Hemolysis 
Hemolysis involves the destruction of red blood cells and is an important virulence trait that 
enables pathogens to acquire nutrients from the infected host. Increased hemolytic activity of the 
wild type compared to the ∆catA::Km mutant was observed after incubation for 48 to 72hr at 




Figure 2.4 Hemolytic activity of the wildtype and ∆catA::Km mutant was assessed following 48 
to 72hr at 37°C post-inoculation on horse blood agar. Hemolysis was assessed by the presence of 
a transparent zone around each colony. A gridded background was used to enhance the contrast 
of the hemolysed region. 
 
A possible mechanism of enhanced hemolytic activity from the wild type could be 
attributed to the putative CAT lipopeptide and/or CatF, a proposed OMP surface protein. 
Wild type ∆catA::Km 
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Microbial lipopeptides have been demonstrated to be hemolytic [87]. CatF, a predicted outer 
membrane protein, could facilitate the transport of the putative CAT lipopeptide or another 
hemolytic compound. To test this possibility, a catF mutant could be assessed for the hemolytic 
phenotype. 
2.1.3.4 Colony Morphology 
Bacterial colony morphology has been shown to be an important indicator of environmental 
stress and virulence.
 
Previous investigations in Pseudomonas fluorescens have demonstrated that 
the undulate margin bacterial morphology is associated with microbial fitness. [88] 
 
 
Figure 2.5 The colony morphologies of the wildtype and ΔcatA::Km mutant were observed. 
 
The wild type strain exhibits an undulate morphology along its margin; while on the other 
hand, that of the ΔcatA::Km mutant is etire. Differences in colony morphology of the A. 
baumannii wild type and ΔcatA::Km mutant (Figure 2.5) suggest that the CAT operon is 
associated with microbial fitness. This observation suggests that the CAT operon confers 






Wild type ∆catA::Km 
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2.1.3.5 Virulence Against Galleria mellonella 
Galleria mellonella, also known as the greater wax moth, has recently become an important 
invertebrate model host to investigate pathogenesis of A. baumannii. [89] To assess the virulence 
of the cat gene cluster of A. baumannii, the wildtype and ΔcatA::Km mutant were introduced 
into wax moth larvae and the number of surviving larvae were measured periodically over a span 
of four days (Figure 2.6). 
 
 
Figure 2.6 The wax worm Galleria mellonella was infected with either the wild type or 
ΔcatA::Km mutant and the survival rate of G. mellonella was monitored over four days. 
 
The survival rate of G. mellonella challenged with wild-type A. baumannii ATCC 17978 
decreased from 48.2% to 22.8% to 13.2% to 8.8% after 24, 48, 72, to 96hr of incubation, 
respectively. The survival rate of G. mellonella challenged with the ΔcatA::Km mutant decreased 
from 79.8% to 48.2% to 43.0% to 43.0% after 24, 48, 72, to 96hr of incubation, respectively. 
After each time point, the survival of G. mellonella were markedly decreased with the greatest 
difference in survivability observed after 24hr with a difference of 31.6% in survival rate 
between the G. mellonella challenged with the ΔcatA::Km mutant versus the wild type. 
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2.1.3.6 Heat Shock Resistance 
Viability of bacteria following heat shock is an important virulence trait, as microorganisms that 
invade a host are often exposed to elevated temperature, among other environmental changes. 
Heat shock induces the upregulation of heat shock regulators that serve to maintain cellular 
protein structure, primarily through the expression of chaperone proteins. [90] In addition, the 
heat shock response is known to upregulate the expression of virulence factors. A prominent 
example of this response is in the increased expression of listeriolysin, a central toxin of the 
human pathogen Listeria monocytogenes. [91] 
 
 
Figure 2.7 Viability following heat shock treatment was assessed for the wild type and 
∆catA::Km mutant after heating at 55°C for 10 minutes. 
 
The viability of A. baumannii was assessed following heat shock at 55°C for 10 minutes 
(Figure 2.7). Quantification of colony forming units (CFUs) of the wildtype and the ∆catA::Km 









2.1.3.7 Regulation of the Motility Phenotype 
A Lux-type QS system was recently identified and characterized in A. baumannii and its 
activation has been attributed to virulence-associated phenotypes, including biofilm formation 
[67] and
 
motility [92]. In addition, disruption of the autoinducer synthase abaI resulted in the 
motility deficiency phenotype, which was restored upon exogenous addition of N-(3-hydroxy)-
dodecanoylhomoserine lactone (3-OH C12-HSL). [65] In this same study, it was reported that 




Figure 2.8 Motility deficiency of the ΔcatA and ΔcatA::Km mutants was not restored when a 
neighboring transcriptional regulator abaR was overexpressed in the presence of 3-OH C12-HSL. 
 
To ascertain whether expression of abaR or the cat operon presides over the motility phenotype 
of A. baumannii, we attempted to restore the mutant phenotype from the ∆catA::Km and ∆catA 
mutants via the overexpression of abaR in the presence of 3-OH C12-HSL (Figure 2.8). The 
motility phenotype was not restored in either of these mutants, suggesting that AbaR regulation 
of swarming requireds the CAT operon. 
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2.2 DISCUSSION 
This study has characterized the roles in pathogenesis of a cryptic pathway of A. baumannii that 
is involved in the biosynthesis of a putative lipopeptide. Phenotypic analysis of an insertional 
mutant (∆catA::Km) of A. baumannii ATCC 17978 for the catA gene (A1S_0112) revealed that 
the roles of the catA-H locus (A1S_0112-9) are pleiotropic and include desiccation resistance, 
motility, hemolysis, colony morphology, heat shock viability, and wax worm virulence. 
Transcriptional (Figure A1.4) and comparative phenotypic (desiccation, motility) analysis with 
an in-frame deletion mutant of the catA gene (∆catA) support the finding of a strong polar effect 
in the insertional mutant ∆catA::Km that significantly diminished expression of the cat operon. 
In addition to cat genes proposed to be directly involved in the biosynthesis of the CAT 
lipopeptide toxin (catA-D and catG-H), there is a predicted efflux pump (CatE) and porin protein 
(CatF) situated medially within the gene cluster. The observed virulence phenotypes of the CAT 
pathway are proposed to be attributed to the functions of the CAT lipopeptide, CatE, and/or 
CatF. 
 
Microbial lipid secondary metabolites commonly exhibit biosurfactant activity. For 
example, the cyclodepsi-lipopeptide serratamolide of Serratia sp. [87], the lipopeptide surfactin 
of B. subtilus [85, 93], and the rhamnolipids of P. aeruginosa [86, 94] are all involved in both 
the hemolysis response as well as in bacterial motility. The biological properties of these 
microbial lipid-based metabolites supports the view that the motility and hemolysis phenotypes 




Motility was significantly impaired in both the insertional mutant ∆catA::Km and the 
deletion mutant ∆catA. Motility impairment in the ∆catA mutant suggests that the CAT 
lipopeptide is required for motility, an observation that is consistent with that of Clemmer et. al, 
who showed that transposon mutants of catB (A1S_0113) and catD (A1S_0115) also exhibit 
deficient motility [65]. CatA, CatB, and CatD correspond to an acyl-CoA synthetase, acyl-CoA 
dehydrogenase, and NRPS, respectively, and are predicted to be directly involved in the 
biosynthesis of the CAT lipopeptide. Further, restoration of the motility phenotype in the 
∆catA::Km mutant only after introduction of a complementation plasmid containing the entire 
cat operon and not one with only the catA gene is consistent with the polar effect of the 
insertional mutation. 
 
Desiccation resistance was comparable between the wildtype and ∆catA mutant, but this 
phenotype was absent in the ∆catA::Km mutant (Figure 2.2). Because CatA is the acyl-CoA 
synthetase presumed to be involved in the biosynthesis of the lipopeptide, this observation 
suggests that the lipopeptide does not significantly contribute to the desiccation resistance 
phenotype. It follows that either CatE or CatF may be responsible for this virulence trait. 
Salmonella sp. are known for their ability to persist under desiccation conditions for extended 
periods of time. Characterization of these mechanisms has proceeded through investigations of 
the osmoregulation response of these bacteria. [95] In one investigation, it was shown that a 
porin protein (OmpC) of S. enterica was upregulated under osmotic stress, presumably as a 
response to maintain cytoplasmic water. [96] A plausible mechanism for the observed mutant 
desiccation resistance phenotype of the ∆catA::Km mutant could be explained by the 
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significantly diminished expression of the porin protein CatF and mal-regulation of osmotic 
stress. 
 
Consistent with the motile, hemolytic, and desiccation resistance phenotypes 
characterized from the CAT gene cluster, other general virulence phenotypes, including heat 
shock viability, colony morphology, and wax moth larvae virulence, were also associated with 
the CAT gene cluster. Heat shock viability and the rugose colony morphology have been 
associated with regulatory systems that function to enhance the virulence of the pathogen. [91, 
97] Furthermore, our attempts to isolate the CAT lipopeptide from liquid culture broth and 
bacteria cells via heterologous expression in E. coli as well as in A. baumannii were unsuccessful 
(data not shown). Collectively, these findings demonstrate that the CAT gene cluster is involved 
in the pathogenesis of A. baumannii. 
2.3 CONCLUSIONS 
We have characterized the virulence-associated phenotypes attributable to a cryptic operon 
(CAT) involved in the biosynthesis of a secondary metabolite lipopeptide of the human pathogen 
A. baumannii. The roles of the CAT locus in the pathogenesis of A. baumannii are pleiotropic 
and include desiccation resistance, motility, hemolysis, colony morphology, heat shock viability, 
and wax worm virulence. In addition to the lipopeptide toxin, some of these virulence traits are 
hypothesized to be attributed to the function of a predicted efflux pump and/or porin protein that 
are co-regulated with the biosynthesis of the lipopeptide. 
 29 
There exist several future directions that may be pursued to further characterize the 
physiological significance of the CAT toxin. Notably, the exact genes responsible for virulence 
phenotypes may be scrutinized by overexpression of individual genes in the wild type and also 
through complementation studies of the insertional mutant containing the CAT pathway 
modified with systematic mutations of individual genes of the operon. Additionally, additional 
secondary metabolite isolation experiments would need to be employed in order to characterize 
the toxin of interest. Lastly, the contribution of the CAT operon to the virulence of A. baumannii 
can be assessed through invertebrate animal models, e.g., silkworm, fruity fly, roundworm. 
Nonetheless, these findings demonstrate that the CAT pathway is a desirable drug target for the 






3.0  DISCOVERY AND CHARACTERIZATION OF A GENE CLUSTER ENCODING 
A CRYPTIC PSEUDOMONAS VIRULENCE FACTOR 
Pseudomonas aeruginosa is a gram-negative opportunistic human pathogen, most notably 
responsible for chronic infections of the airways of patients who are immunocompromised 
and/or afflicted with cystic fibrosis. [98] Numerous protein and small molecule virulence factors 
of P. aeruginosa enable it to persist and exert pathogenesis in biotic and abiotic environments. 
Furthermore, a number of protein toxins (exotoxin A, exoenzyme) as well as proteases (elastase, 
alkaline protease) are known to contribute to its pathogenesis. The success of this pathogen in 
diverse environments has been attributed to its ability to utilize an array of different virulence 
factors. 
 
A prominent virulence factor of P. aeruginosa includes the formation of biofilms. 
Biofilms are complex microbial communities housed in polymeric matrices consisting of 
polysaccharides, proteins, and nucleic acids. The formation of these community structures 
contributes to the pathogenesis of P. aeruginosa and has been shown to develop on both biotic—
including tissues of the cystic fibrosis lung [98]—as well as abiotic surfaces, such as catheter 
lines [99, 100]. Biofilms are especially recalcitrant due to their roles in host colonization and 
antibiotic resistance that these structures confer to their microbial denizens [101]. 
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In addition to protein virulence factors, a number of secondary metabolites of P. 
aeruginosa also contribute to its pathogenesis. The most prevalent include the rhamnolipids, 
pyocyanin, quorum sensing molecules (specifically, homoserine lactones), quinolones, 
lipopolysaccharides, as well as siderophores (Figure 3.1). The rhamnolipids are biosurfactants 
that exert pleiotropic pathogenic consequences against the host, including interference with the 
immune system [102], inhibition with normal tracheal ciliary function [103], and lysis of blood 
cells [94]. Furthermore, rhamnolipids have been shown to facilitate motility [104] and the 
development of biofilm structures [25]. Due to their direct roles in P. aeruginosa pathogenesis, 
the biosynthetic and regulatory pathways of secondary metabolites have been the targets in the 



















Pyocyanin is a redox-active metabolite and is the compound that is frequently attributed 
to the blue-green color of P. aeruginosa [105]. The exact role of pyocyanin in the pathogenesis 
of P. aeruginosa is still under investigation, but it has, most notably, been demonstrated to be 
crucial toward infections of the lung [106]. Furthermore, in vitro studies have shown that 
pyocyanin modulates glutathione recycling within lung epithelial and endothelial cells [107] and 
can also disrupt catalase activity [108]. 
 
Lipopolysaccharides (LPS) are membrane-bound structures embedded on the outer 
membrane of gram-negative bacteria and elicit strong immune responses from the host. LPS is 
primarily comprised of a membrane-bound lipid, lipid A, as well as a variable polysaccharide 
moiety, known as the O-antigen side chain, that is largely responsible for its immunological 
response in the body [109]. Specifically, lipid A is known to elicit a strong immune response via 
activation of the Toll-like receptors (TLR), specifically TLR-4. [110] Severe bacterial infections 
can lead to systemic shock induced by the recognition of high levels of LPS by the host immune 
system [111]. Due to its roles as a virulence factor, vaccines targeted toward P. aeruginosa LPS 
have been pursued, although with limited success. For example, extracts derived from P. 
aeruginosa growth cultures representing a mixture of LPS showed initial promise as a vaccine 
candidate by conferring protection yet were also shown to be toxic. [112] A recent example of a 
promising vaccine candidate is based on a P. aeruginosa mutant deficient in aromatic amino acid 
biosynthesis [113]. It was discovered that while this strain exhibited no adverse immunological 
effects, it was still able to generate antibodies against LPS and provide protection against 
cytotoxic P. aeruginosa strains [113, 114]. 
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Quorum sensing (QS) in P. aeruginosa is regulated by three QS systems, two of which 
are independent systems that utilize homoserine lactone co-factors to direct the concerted gene 
expression of virulence factors in a population-dependent manner. Notable virulence traits 
regulated by QS in P. aeruginosa include biofilm formation [115] and motility [116]. These 
include the las and rhl systems, which rely upon N-(3-oxododecanoyl)-L-homoserine lactone and 
N-butyryl-L-homoserine lactone, respectively, for autoinduction. Due to its hierarchical 
regulatory roles, QS pathways are attractive targets in the development of anti-virulence 
therapeutics. [117] 
 
Quinolones exhibit antibiotic activity but have also been shown to be involved in P. 
aeruginosa cell-to-cell signaling pathways that interact with the las and rhl QS systems of P. 
aeruginosa. The most prevalent quinolone of P. aeruginosa includes 2-heptyl-3-hydroxy-4-
quinolone, which, due to its roles in regulating virulence gene expression, has been known as the 
Pseudomonas quinolone signal (PQS) [118]. Major virulence traits that have been upregulated 
by the presence of PQS include the LasB elastase [118], vesicles that transport antimicrobials 
and toxins [119], and DNA transport [120]. 
 
Siderophores are a class of compounds produced by microbes to assist in the acquisition 
of iron from the environment. As a micronutrient found predominantly as the Fe
3+
 ion, iron is a 
co-factor for numerous essential enzymatic processes in the cell. Siderophores function by 
forming soluble complexes with Fe
3+
 and that are transported into the cell via cell surface 
receptor proteins. There are two major siderophores from P. aeruginosa: the pyoverdines and 
pyochelin. The pyoverdines comprise a structurally diverse group of related siderophores 
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produced from Pseudomonas sp. [121] and have been demonstrated to be the major siderophore 
produced in clinical isolates of P. aeruginosa [122, 123]. In addition to its direct function as a 
siderophore, pyoverdine production has been shown to be essential in P. aeruginosa virulence 
against mice [124]. Furthermore, pyoverdine has been demonstrated to regulate the expression of 
other virulence factors, including exotoxin A and endoprotease [125]. The roles that siderophores 
play in P. aeruginosa cellular processes have also made them an attractive target for anti-
virulence antibiotic development [126, 127]. 
 
A similar approach to identify the CAT locus of A. baumannii was utilized to mine the 
genome of P. aeruginosa for species-specific NRPS and PKS loci (Refer to A. baumannii, 
Chapter 2). Genome mining of the P. aeruginosa PAO1 strain revealed the presence of a cryptic 
biosynthetic gene cluster consisting of genes PA4078-80 that are conserved within the P. 
aeruginosa species and predicted to biosynthesize a nonribosomal peptide secondary metabolite. 
The highly conserved nature of this cryptic biosynthetic gene cluster is suggestive to its roles in 
the survival and persistence of P. aeruginosa. In this study, the PA4078-80 locus is demonstrated 
to be involved in pathogenesis of this organism, notably in its roles in biofilm formation, 
motility, and colony morphology. Due to its influence on virulence traits of P. aeruginosa and its 
cryptic nature, this locus has been named CPT for its roles in the biosynthesis of a Cryptic 
Pseudomonas Toxin. Its roles in P. aeruginosa pathogenesis suggest that the CPT pathway is an 
attractive target for the development of anti-virulence antibiotics. 
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3.1 RESULTS AND DISCUSSION 
3.1.1 Genome Mining of the Cryptic Pseudomonas Toxin (CPT) 
PA4078, PA4079, and PA4080 consist of predicted nonribosomal peptide synthetase (NRPS), 




Figure 3.2 Organization of the CPT gene cluster with proposed functions in the 
biosynthesis and regulation of the CPT toxin. 
 
The NRPS enzyme is responsible for the synthesis of a peptide secondary metabolite that 
is presumably oxidized by the CptB, a dehydrogenase. The CptC a quorum-sensing modulated, 
LuxR-type transcriptional regulator is presumably involved in the regulation of CptAB. NRPS 
enzymes require a posttranslational modification that involves the covalent attachment of the 4’-
phosphopantetheine prosthetic moiety, which is facilitated by a phosphopantetheinyl (ppan) 
transferase. Interestingly, a ppan transferase is not encoded within this locus and is presumable 
located elsewhere in the chromosome. 
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3.1.2 CPT Pathway Mutant Generation and Phenotype Complementation 
To assess phenotypes attributed to the CPT pathway, an in-frame markerless deletion mutant of 
the cptAB locus was generated. This mutant was generated by construction of a suicide plasmid 
based on yeast recombineering [74]. Complementation studies were executed by construction of 
a plasmid containing the cptAB genes. The complementation plasmid was assembled based on 
the Pseudomonas replicable yeast recombineering shuttle plasmid, pMQ124 [74]. 
3.1.3 CPT Regulates Biofilm Formation on Abiotic Surfaces 
Biofilm represents a bacterial community encased in a matrix composed of polysaccharides, 
nucleic acids, and proteins. The ability for P. aeruginosa to subsist on abiotic surfaces, such as 
catheter lines [99, 100], has enabled this pathogen to subsist in the hospital setting. Biofilm 
formation is a significant virulence factor due to its ability to confer enhanced antibiotic 
tolerance to its microbes [101]. To assess P. aeruginosa biofilm formation on an abiotic surface, 
cultures were grown in a polyvinyl chloride 96-well plate at 30°C for 18hr. The biofilm was 
assessed via crystal violet (CV) staining and quantified by measuring the absorbance of 
solubilized CV at a wavelength of 540 nm and normalizing to the optical density (OD) of the 




Figure 3.3 Biofilm formation of P. aeruginosa strains after 18hr at 30°C growth under static 
conditions (N = 6). The complementation plasmid includes cptAB in pMQ124. 
 
Biofilm formation of the wildtype and mutant P. aeruginosa strains were measured 
(Figure 3.3). The P. aeruginosa PAO1 wildtype exhibited greater biofilm formation (OD540nm 
= 0.243 ± 0.046) compared to the ΔcptAB mutant (OD540nm = 0.073 ± 0.017) (p < 0.0001). The 
wildtype biofilm formation phenotype was restored in the ΔcptAB mutant (OD540nm = 0.224 ± 
0.066) by introduction of a complementation plasmid containing the cptAB genes (ΔcptAB + 
cptAB), indicating that the cptAB genes contribute to abiotic biofilm formation in P. aeruginosa. 
Furthermore, overexpression of cptAB in the wild type (OD540nm = 0.361 ± 0.090) increased 
biofilm formation over the wild type alone (p < 0.05). Collectively, these data indicate that 
biofilm formation is in part positively regulated by the CPT peptide. 
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3.1.4 Twitching Motility is Impaired in the CPT Mutant 
Common bacterial surface structures, such as pili and fimbriae, are known to be involved in the 
ability of the microbe to adhere to surfaces. The type IV pili are distinct in their ability to 
promote flagellum-independent motility [128]. It was later discovered that type IV pili enable 
bacterial translocation via a mechanism where the pili adhere to and retract from its adjacent 
surface, enabling propulsion of the cell [129]. Motility is an important phenotype that contributes 
to the pathogenesis of P. aeruginosa, as it enables the bacteria to spread throughout the host, 




Figure 3.4 Twitching of the PAO1 wildtype and ΔcptAB mutant after incubation at 37°C for 
48hr and 25°C for 24hr. Twitching zones were visualized via crystal violet staining. 
 
To assess the twitching motility phenotype in the PAO1 wildtype and ΔcptAB mutant, 
each were stab inoculated into agar plates and incubated at 37°C for 48hr and then at 25°C for 
24hr. Zones of twitching motility were visualized by crystal violet staining (Figure 3.4). The 
twitching motility phenotype was observed to be reduced in the ΔcptAB mutant (twitching zone 
Wild type           ΔcptAB mutant 
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diameter = 1.95 cm ± 0.15, N = 3) compared to that in the P. aeruginosa PAO1 wild type 
(twitching zone diameter = 2.83 cm ± 0.18, N = 3) (p < 0.05).  
3.1.5 Colony Morphology and Autolysis 
The roles and mechanisms of bacterial autolysis are unclear but it has been suggested to be a 
response to environmental stress [130-132]. Specifically, it has been implicated as a mechanism 
to eliminate unfit members of the population, which reduces nutrient consumption by the unfit, 
leaving more for the fit and enhances their probability of survival [133]. In gram-positive 




Figure 3.5 Autolysis colony morphology of PAO1 wildtype and the ΔcptAB mutant after 
incubation at 37°C for 48hr on LB agar. 
 
Colony morphologies of the P. aeruginosa PAO1 wildtype and the ΔcptAB mutant were 
assessed by stab inoculating LB agar plates and allowing the bacteria to grow at 37°C for 48hr 
and then at 25°C for 24hr. Following the incubation period, the ΔcptAB mutant exhibited 
marked autolysis, exhibited by plaque-like formations in the center of the growing colony, which 
Wild type           ΔcptAB mutant 
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is indicated by the red arrow in Figure 3.5. In contrast, the PAO1 wildtype strain did not display 
any autolytic phenotype and instead appeared smooth. 
3.2 DISCUSSION 
In this study, a cryptic biosynthetic pathway that is evolutionarily conserved in P. aeruginosa 
was discovered via genome mining. To investigate the role of this NRP secondary peptide, an in-
frame markerless deletion mutant (ΔcptAB) of P. aeruginosa strain PAO1 was generated. 
Comparative phenotypic analysis revealed that the deletion of these genes results in reduced 
virulence traits of this human pathogen. Presumably, the secondary metabolite biosynthesized by 
CptA and CptB contribute to the pathogenesis of P. aeruginosa. Notably, the mutant resulted in 
reduced abiotic biofilm formation, diminished twitching motility, and the appearance of a colony 
morphology exhibiting autolysis. 
 
Biofilm formation is an especially prominent virulence trait of P. aeruginosa that 
contributes to its pathogenesis against immunocompromised patients as well as patients afflicted 
with cystic fibrosis [98]. Abiotic biofilm formation is an important virulence trait, as it enables P. 
aeruginosa to persist in the hospital setting and because PVC is a common material used for 
medical equipment, including intravenous bags, catheters, collection bags, enteral feeding sets, 
gloves, and tubing [135]. Compared to wild-type PAO1, the ΔcptAB mutant exhibited 
significantly reduced abiotic biofilm formation (Figure 3.3) on polyvinyl chloride (PVC) plastic. 
Furthermore, in trans complementation of the ΔcptAB mutant phenotype to restore wildtype 
biofilm formation is evidence that a mutation in cptAB, and not elsewhere in the chromosome, is 
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responsible for attenuated biofilm formation. Overexpression of the cptAB genes in the wild type 
also resulted in biofilm formation that exceeded that observed in the wild type without 
overexpression of these genes. Decreased biofilm formation from the ΔcptAB mutant and 
enhanced biofilm formation when the cptAB genes are overexpressed suggest that this locus is 
responsible for abiotic biofilm formation. 
 
The ability for P. aeruginosa to twitch across surfaces is dependent on surface proteins of 
the type IV pili system and involves the attachment to and retraction from its adjacent surface. 
Compared to the PAO1 wild type, twitching motility was observed to be impaired in the ΔcptAB 
mutant (Figure 3.4). Both impaired twitching motility and biofilm formation from the ΔcptAB 
mutant could be explained by reduced functionality in the type IV pili. Specifically, it has been 
shown that mutants of the pil genes that encode for the biogenesis and function of P. aeruginosa 
pili proteins were twitching-deficient and unable to form complete biofilms on abiotic surfaces 
[136]. The role of type IV pili in P. aeruginosa in biofilm formation was hypothesized to be 
involved in either surface attachment stabilization and/or cell-cell interactions in the growing 
biofilm. In one role, the CPT toxin could directly augment surface attachment, thereby 
promoting twitching and biofilm formation. The NRP secondary metabolite indigoidine of the 
marine bacteria Phaeobacter sp. have been shown to be important in surface attachment [137]. 
Alternatively, the CPT peptide could behave as a signaling molecule that regulates biofilm 
formation, such as the case in QS-dependent cell-cell communication in biofilm formation [115]. 
Cell signaling roles of CPT could also explain the increased autolysis observed in the ΔcptAB 
mutant. The Pseudomonas quinolone signal (PQS) has been implicated as a signaling molecule 
that, in addition to several other phenotypes, regulates the autolytic behavior of bacterial 
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populations. [133] Collectively, comparative phenotypic analysis of the ΔcptAB mutant and 
PAO1 wild type strains suggest that the CPT secondary metabolite contributes to the 
pathogenesis of P. aeruginosa and may be an attractive target in the development of 
antivirulence therapeutics. 
3.3 CONCLUSIONS 
In the present study, a conserved locus of P. aeruginosa was identified through the genome 
mining of P. aeruginosa strain PAO1. This locus encodes for the biosynthesis of a nonribosomal 
peptide and it has been implicated in pleiotropic roles in the pathogenesis of P. aeruginosa. 
Specifically, it has been shown to be an important contributor to virulence phenotypes, including 
biofilm formation, twitching motility, as well as autolysis. Its significance toward the 
pathogenesis of P. aeruginosa suggests that this biosynthetic pathway can be the target for the 
development of next generation antibiotics that attenuate virulence traits of human pathogens. 
3.4 PART I: OUTLOOK AND FUTURE DIRECTIONS 
The increasing emergence of new antibiotic-resistant human microbial pathogens is a serious 
public health threat. Treatment strategies will require innovative approaches to the discovery and 
development of novel, next generation antibiotics that circumvent the major drawback of 
traditional antibiotics—the ability for microbial pathogens to develop drug resistance over time.  
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A promising approach is to target virulence phenotypes that are nonessential to the cell, 
thereby minimizing evolutionary selective pressures that give rise to pan-resistant pathogenic 
strains. Secondary metabolite small molecules have been shown to be attractive targets in the 
development of next generation antibiotics, some of which contribute toward the pathogenesis of 
human hosts. The developments from Chapter 2 and 3 extend upon the current understanding of 
mechanisms in the pathogenesis of human bacterial pathogens Acinetobacter baumannii and 
Pseudomonas aeruginosa. Notably, evolutionarily conserved and cryptic gene clusters from 
these bacterial species were discovered via genome mining approaches. Such conserved gene 
sequences are proposed to confer survival advantages to these microbes, and indeed phenotypic 
analysis revealed that these silent gene clusters contribute to human pathogenesis. An important 
direction forward will entail the isolation and chemical characterization of the secondary 
metabolites biosynthesized from these gene clusters. 
 
Initial efforts to characterize the metabolites of interest via heterologous expression were 
unsuccessful. Several major challenges exist in the isolation and elucidation of novel 
compounds. First, native or heterologous expression of the biosynthetic pathway may require 
particular chemical inducers or environmental conditions that may require exhaustive 
optimization in order to achieve. Pathways may be regulated at the transcriptional, translational, 
and/or posttranslational levels. Second, laboratory culture conditions may lack sufficient 
quantities of a precursor necessary for the biosynthesis of the secondary metabolite of interest. 
Lastly, production of the desired compound may be successful but inadequate quantities preclude 
their detection or pragmatic isolation. Nonetheless, established roles in the phenotypes conferred 
by these metabolites could aid in the elucidation of their structures. For example, collectively, 
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current evidence suggests that the CAT virulence factor could be a lipopeptide, based on both 
bioinformatic predictions as well as phenotypic analysis (e.g., hemolysis and surface motility).  
 
The findings from both of these chapters have demonstrated the essential roles of these 
cryptic operons toward the virulence of these pathogens, i.e., have revealed a number of genes 
that may be attractive targets in the development of novel antibiotics. 
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4.0  PART II INTRODUCTION: BIOSYNTHESIS OF CYANOBACTERIAL 
NATURAL PRODUCTS 
Historically, natural products have been a pivotal source of drug leads, as nearly half of all new 
chemical entities introduced in the last three decades were natural products, semi-synthetic 
natural product analogues or natural products-based synthetic compounds.[138] Microorganisms, 
in particular, have been a prolific reservoir of antibiotics, immunosuppressants, statins, 
anthelmintics as well as antiviral, anticancer and antiparasitic drugs.[139, 140] These therapeutic 
compounds originate as secondary metabolites, molecules produced by its host for auxillary and 
non-essential functions that confer competitive advantages for its producer, but have also 
realized their potential as therapeutic agents in human medicine.  
 
Before the availability of genomic data, most natural products were discovered through 
the laboratory cultivation of the producing organism, extraction of the growth media and/or 
microbes, and then bioassay-guided purification of active compounds—a compound-centric 
approach. This was highly successful at the time, however, by the 1980s, the number of newly 
discovered natural products declined rapidly.[141] This decline can be attributed to the re-
discovery of natural products commonly produced by a wide range of species as well as the 
inability to grow and/or produce secondary metabolites under laboratory conditions. An 
estimated 99% of all bacterial species cannot be cultured.[142] As a result of this decline, 
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pharmaceutical companies largely abandoned natural products research and development 
programs. 
4.1 NATURAL PRODUCTS DISCOVERY IN THE GENOMICS ERA 
A renaissance in natural products discovery has been realized in recent years. This emerging era 
leverages genomic data to afford novel and compelling approaches toward the characterization of 
secondary metabolites that were inaccessible by traditional methods. Specifically, bioinformatic 
analyses have enabled rationally-driven mining of secondary metabolic pathways in which the 
genes of putative regulatory proteins and biosynthetic enzymes can be identified in silico based 
on sequence homology. These genes can then be explored experimentally through expression 
studies in a heterologous host or through comparative analyses with defined mutants lacking 
essential biosynthetic genes. Heterologous expression is advantageous if the compounds are 
structurally complex and difficult to obtain synthetically or if the native producer is difficult to 
culture in the laboratory and yields are low. 
 
Genome mining is especially effective in prokaryotes, because biosynthetic genes 
involved in the same pathway are physically clustered together on the chromosome. A genomics-
centric approach is valuable, because it enables the discovery of products from silent 
biosynthetic gene clusters (i.e., those not expressed under standard laboratory conditions) and 
also circumvents the common problem of natural products re-discovery. These strategies were 
employed in the successful characterization of secondary metabolites from Streptomyces species, 
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but they were not without their own challenges, many of which are common in natural products 
discovery from various microbial sources. 
4.2 THE SUCCESS OF STREPTOMYCES AS A SOURCE OF NATURAL 
PRODUCTS 
A hallmark characteristic of microorganisms of the Actinomycetales order is their ability to 
produce numerous secondary metabolites, and members of the Streptomyces genus exemplify 
this trait through their prominent production of antibiotics, over two dozen of which are used 
clinically.[140] Recent genome sequencing of several Streptomyces strains revealed their 
remarkable capacity to produce over twenty secondary metabolites, most of which are unknown, 
i.e., cryptic. Notably, investigations into the model strain, S. coelicolor A3(2), genome revealed 
the presence of eighteen silent biosynthetic gene clusters to which their products are cryptic—by 
comparison, this strain was only known to produce three secondary metabolites prior to the 
elucidation of its genome sequence.[143] The rich biosynthetic faculties of Streptomyces served 
as an impetus to access these new molecules, but major technical challenges impeded early 
investigations. 
 
Streptomyces are gram-positive bacteria that undergo complex lifecycles, from 
germinating spores to multinucleoid substrate mycelium and aerial hyphae.[144, 145] 
Furthermore, notable features of the Streptomyces genome include their relatively high GC 
content[143] as well as linear chromosomes[146]. Their genetic instability has been known for 
decades[147], but only recently has its molecular basis been elucidated. Specifically, it was 
 49 
discovered that numerous tandem inverted repeat sequences located at the ends of these linear 
chromosomes were responsible for recombination events that caused circularization and re-
linearization of the chromosome, resulting in frequent and spontaneous acquisition as well as 
loss of large segments of DNA.[148-151] Therefore, early investigations that involved the direct 
genetic manipulation of many Streptomyces members were fundamentally challenging. 
However, because of the compelling need to access these molecules, numerous genetic tools 
have been developed in order to isolate and characterize novel secondary metabolites from these 
organisms. 
4.2.1 Heterologous Expression Systems for Streptomyces 
As a consequence of the significance of Streptomyces secondary metabolites, many expression 
plasmids and heterologous hosts have been developed in order to elucidate the biosyntheses of 
these compounds. Due to the ease of their acquisition of foreign DNA molecules, S. coelicolor, 
S. lividans, and S. albus were early suitable candidates for the cloning and heterologous 
expression of Streptomyces genes.[152] Later, the sequencing of the S. coelicolor A3(2) genome 
established the framework for further systematic genetic investigations. These Streptomyces 
species were further optimized for heterologous expression by deleting endogenous secondary 
metabolite biosynthetic pathways that can compete for substrates [153, 154] and also by 
minimizing the genome to only essential genes, thereby reducing the probability of undesirable 
genome shuffling [155]. The success of Streptomyces natural products discovery has set an 
example for the investigation of elusive secondary metabolites from new microbial sources, 
notably other Actinomycetes, cyanobacteria, and unculturable bacteria. The strategies employed 
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in accessing valuable natural products from Streptomyces highlight the principle methods 
necessary to unlock cryptic compounds from other elusive sources. 
4.3 ENZYMOLOGY OF NATURAL PRODUCTS BIOSYNTHESIS 
Despite the remarkable diversity of natural products, their core assemblies arise from a relatively 
few number of enzyme families and biosynthetic pathways, which can be further diversified via 
various auxiliary modifications and utilization of atypical substrates. The widespread occurrence 
of these biosynthetic pathways is evidence to their physiological significance and underscores 
the importance of these molecules in drug discovery and development. The following 
subsections will highlight several major classes of natural products and general features of their 
biosyntheses. 
 
4.3.1 Microbial Nonribosomal Peptide and Polyketide Secondary Metabolite Biosynthesis 
Of all the microbial natural products, which are represented from several major classes of 
molecules, including terpenoids, oligosaccharides, alkaloids, and ribosomally synthesized 
peptides, nonribosomal peptides (NRPs) and polyketides (PKs) have been especially fascinating 
due to their vast structural diversity from rather simple building blocks. Further, NRP synthetase 
(NRPS) and PK synthase (PKS) enzymes proceed by predictable enzymatic logic in an assembly 
line-like fashion to generate their product(s) of interest. In this assembly line, the substrates are 
tethered via a thioester linkage to a carrier protein (acyl or peptidyl carrier protein, ACP or PCP, 
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for PKS and NRPS enzymes, respectively) and transferred to downstream enzymes for 
subsequent chemical transformations. An important feature of ACPs and PCPs includes the 
prosthetic group 4'-phosphopantetheine, which is covalently attached in a conserved serine 
residue of these proteins. This moiety results from posttranslational modification by a 
phosphopantetheinyl transferase and serves as the “swinging arm”, shuttling intermediates from 
one catalytic domain of the PKS or NRPS to the next. 
 
The backbone of these NRP and PK compounds comprise of amides and C–C linkages 
via condensation reactions. Other transformations include oxidations and halogenations as well 
as decorations with acyl, glycosyl, and prenyl moieties among others. NRPS substrates can also 
vary widely from all proteinogenic as well as non-proteinogenic amino acids, including D-
isomers. Likewise, PKS substrates can often differ by carbon number and subsequent enzymatic 
modifications can yield saturated and unsaturated acyl moieties. 
 
Decarboxylation and Claisen condensation yield the backbone linkages between PKS 
substrates, but other common enzymatic reactions exist to generate diversity (Figure 4.1). To 
begin PK assembly, a ketide unit is tethered to the ACP domain via thioester bond with support 
from an acyl transferase (AT) domain and is subsequently transferred to the first ketosynthase 
(KS) domain. Decarboxylation of a downstream ketide unit affords a nucleophilic α-carbon that 
attacks the thioester linkage of an upstream ketide-S-ACP intermediate to generate the diketide. 
The ketide can also undergo reduction and dehydration processes to yield saturated or 
unsaturated products via ketoreduction, dehydration, and enoyl reduction by ketoreductase, 
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dehydratase, and enoyl reductase domains, respectively. In this way, PKS pathways strongly 
resemble fatty acid biosynthetic pathways.[156] 
 
Figure 4.1 The key steps in the assembly of polyketides is shown. Note that the biosynthesis of 






The 6-deoxyerythronolide B synthase (DEBS) of Saccharopolyspora erythraea is the hallmark 
type I PKS assembly line and illustrates the elegance of PK assembly. DEBS is responsible for 
the biosynthesis of the aglycon component of antibiotic erythromycin A (Figure 4.2).[157, 158] 
A thioesterase (TE) domain at the C-terminus of DEBS facilitates cyclization and chain release, 
a common feature of both PKS and NRPS assemblies. 
  
 
Figure 4.2 The biosynthesis of the aglycon structure of erythromycin A is facilitated by PKS 
enzymes in an assembly line-like fashion. Figures adapted from [157, 158]. 
 
NRP assembly is similar to ribosomal peptide biosynthesis in which amino acid 
monomers are activated as mixed esters and proceeds condensation to form amide bonds 
between individual units (Figure 4.3a).[159] Specifically, amino acid monomers are activated to 
form the adenylyl-amino acid mixed anhydride via the adenylation domain, which is responsible 
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for amino acid specificity. Adenosine triphosphate (ATP) is required for this process, yielding 
the adenosine monophosphate (AMP) product. The activated monomer is subsequently tethered 
to the PCP domain via a thioester linkage and is ready for nucleophilic attack by an upstream 
amino acid with the aid of the condensation domain. The biosynthesis of the cyclic lipopeptide 
surfactin A illustrates the assembly of various amino acids to produce a final cyclic lipopeptide 
























Figure 4.3 (a) The key steps in the assembly of NRPs. (b) The biosynthesis of the cyclic 
nonribosomal peptide surfactin from the srf operon. Figures adapted from [159-161]. 
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In addition to the domains responsible for substrate incorporation, a vital component of 
many PKS and NRPS assembly lines is the C-terminal TE domain. Not only is this important 
component responsible for chain release of the mature PK or NRP product but, when necessary, 
it can also cyclize the product to its active form. In both of the previous examples of aglycon 
erythromycin A and surfactin A biosynthesis, cyclization and chain release occur upon 
nucleophilic attack from a side chain hydroxyl moiety to the thioester tether, both mediated by 
the TE domain. 
4.3.2 Ribosomal peptides 
Similar to nonribosomal peptides (NRPs), ribosomally synthesized and posttranslationally 
modified peptides (RiPPs) exhibit diverse biological roles (cofactors, antibiotics, cytotoxins, 
quorum sensing[162]) and originate from diverse sources, such as prokaryotes 
(lantipeptides[163], linaridins[164], thiopeptides[165], microcins[166]), fungi (amatoxins, 
phallotoxins[167]), plants (cyclotides[168]), and animals (conopeptides[169]). Their extensive 
distribution throughout many species testifies to their physiological significance. Unlike NRPs, 
RiPPs are composed exclusively of proteinogenic and D- amino acids that are assembled by the 
ribosome to afford a peptide scaffold. They can sometimes undergo posttranslational 
modification, including heterocyclization, oxidation, and prenylation, that can yield products that 
may resemble their NRP counterparts. 
 
With over one hundred structures elucidated, cyanobactins are RiPPS that belong to one 
of the largest families of bioactive small molecules from cyanobacteria, having been identified in 
up to 30% of all cyanobacterial species.[170, 171] Cyanobactins are especially important 
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because not only can they be explored as therapeutics, such as antibiotics as well as antiviral, 
antimalarial, and anticancer lead compounds [170, 172, 173] but also because they are known to 
be toxic to animals [174]. The initial characterization of the patellamides and its biosynthetic 
gene cluster from Prochloron didemni a cyanobacterial symbiont of the ascidian Lissoclinum 
patella, established the groundwork for the subsequent bioinformatics-guided discovery of 
numerous other cyanobactin gene clusters (Figure 4.4). [175] Hallmark features elucidated from 
the patellamide biosynthetic pathway include a precursor peptide that matures to the final 
cyanobactin structures and two proteases, one of which is also responsible for N-to-C 
macrocyclization.[175, 176] The characterization of other cyanobactin gene clusters revealed 
that these three features were conserved, but others exist, such as enzymes responsible for 
prenylation and methylation [177] as well as for heterocyclization [178] to afford thiazol(in)e 
and oxazol(in)es from cysteine and serine or threonine residues, respectively. Recently, it was 
discovered that some cyanobactin pathways can also afford highly modified linear peptides. 
[177] 
 
Each cyanobactin biosynthetic gene cluster has been known to produce multiple related 
structures. This early observation was followed by intense interest in understanding how 
structural diversity is generated from a single precursor peptide gene encoded in the pathway. 
Notably, the tailoring enzymes are conserved amongst various cyanobactin gene clusters, yet the 
substrate precursor peptides are highly diverse within a gene cluster and amongst different gene 
clusters. This suggested that the precursor peptide gene itself contained the information required 








Figure 4.4 (a) Organization of the patellamide gene cluster and established gene functions. (b) 
Structures of patellamides A and C from the pat gene cluster and structure of patellin from a pat-
like gene cluster tru, which is responsible for the biosynthesis of the cyanobactins trunkamides 
and patellins. Note that the presence of a prenyltransferase (patF) does not result in prenylation 
of the final patellamide structures. In contrast, the prenyltransferase of the tru gene cluster is 
responsible for reverse prenylation of patellin. Figure adapted from [179]. 
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Sequence analysis of various precursor peptides from different cyanobactin gene clusters 
revealed highly conserved consensus sequences, later established to be leader and recognition 
sequences [180-183], and hypervariable regions, corresponding to the core peptides present in 
the final structures [184, 185] (Figure 4.5). Although the N-terminal leader sequence has no 
effect on product formation [186], the recognition sequences proved to be essential for 
proteolytic cleavage of the precursor as well as macro- and heterocyclization modifications [180-
182]. Notable divergence in the core peptide sequence and the translation of multiple precursor 















Figure 4.5 The precursor peptide sequence contains instructions for subsequent posttranslational 
modification to yield the final cyanobactin structure. These include three recognition sequences 
(RS1-3), a leader peptide, and the core peptide. The heterocyclase encoded in the cyanobactin 
gene cluster is recognizes RS1 to cyclize threonine, serine, and cysteines to their corresponding 
azolines. Subsequently, the N-terminal protease binds to RS2 and cleaves the leader peptide. 
Lastly, the C-terminal protease binds to RS3 and is also responsible for macrocyclization. 









Therefore, once the precursor peptides are translated, the PatA homolog (protease of the 
patellamide gene cluster) cleaves the cyanobactin precursors at the N-terminus. [187] Following 
cleavage, the PatG protease homolog recognizes the C terminus of the precursors and 
subsequently executes macrocyclization [187, 188]. In some cyanobactin biosynthetic pathways, 
PatG is also responsible for oxidation of the heterocycle to afford the azole. [187, 188] 
Collectively, these findings are significant because the tailoring enzymes are highly conserved 
yet the precursor peptide sequences exhibit substantial divergence. This substrate promiscuity 
can enable the rational engineering of the cyanobactin biosynthetic platform to generate defined 
libraries of macrocyclic peptides with therapeutic applications. In one investigation, unnatural 
amino acids were introduced into the backbone of the cyanobactin trunkamide to afford a library 
of novel macrocyclic structures that could theoretically number in the tens of thousands.[189] 
4.4 HETEROLOGOUS EXPRESSION OF CYANOBACTERIAL BIOSYNTHETIC 
PATHWAYS 
It has long been observed that cyanobacteria are prolific producers of bioactive natural products. 
Given the inhospitable and often extreme environments in which cyanobacteria species subsist, it 
is believed that a diverse repertoire of secondary metabolites confer survival advantages against 
their competitors in what can be considered “chemical warfare”.[190] Furthermore, recent 
genome sequencing of several dozen strains revealed that cyanobacteria are, in fact, capable of 
producing significantly more secondary metabolites than have been characterized, with some 
strains dedicating at least 5% of their genomes exclusively to secondary metabolite 
biosynthesis.[171] 
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Despite the immense potential for natural products discovery from cyanobacteria, access 
to these molecules has been challenging, due to their cryptic nature and/or scarce quantities 
obtained through laboratory cultivation. There are several notable features of cyanobacteria that 
have hindered their use in genetic investigations. They can be unicellular or multicellular and can 
possess multiple copies of their chromosomes per cell, complicating genetic manipulations with 
high fidelity.[191] Additionally, they present extracellular mucilaginous sheaths that inhibit the 
introduction of exogenous molecules, including DNA. Any exogenous DNA that can surpass the 
physical barriers of the cyanobacterial cell would then be challenged by restriction nucleases that 
can degrade them.[192] Furthermore, cyanobacteria grow slowly, some strains with doubling 
times approaching six days[193] (in comparison, E. coli can double in twenty minutes under 
ideal growth conditions). Lastly, few regulatory genetic elements, such as promoters, 
terminators, transcription factors, and ribosome binding sites have been characterized in 
cyanobacteria, making genetic engineering difficult to obtain in these organisms. 
 
Given the incentive to characterize these potentially valuable natural products but also the 
major challenges to their direct access through genetic manipulation, the development of cloning 
methods and heterologous hosts for the production of these compounds has become an 
increasing attractive approach. However, there are few reported examples of cloning and 
expression systems proven to successfully assembly and express entire cyanobacterial 
biosynthetic pathways containing complex enzymes, such as NRPS or PKS. In one invest igation, 
the gene cluster for the molluscicidal agent barbamide from cyanobacterium Moorea producens 
was successfully produced in a Streptomyces host.[194] In this study, the 26 kilobase (kb) 
barbamide gene cluster was assembled via a series of sub-cloning steps. Expression yielded a 
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novel derivative of the hybrid NRP/PK natural product, 4-O-demethylbarbamide, that was shown 
to exhibit more potent activity than the parent molecule. In another study, the gene cluster for the 
NRP-terpene hybrid and protein kinase C activator lyngbyatoxin from M. producens was 
expressed in E. coli [195]. Promoter engineering of the fosmid containing the lyngbyatoxin 
biosynthetic pathway (ltxABCD) afforded high titers (25.6 mg L
-1
) of the final product. This 
finding was especially significant because a previous investigation of the heterologous 
expression of the ltxABCD pathway in a Streptomyces host resulted in premature transcriptional 
termination of ltxA, resulting in no production of lyngbyatoxin.[193] This example underscores 
the significance in the choice of heterologous host as well as some of the regulatory complexities 
that can be encountered in establishing a cloning and expression system for cyanobacterial 
natural products. 
 
Unlike for the complex mechanisms of NRP and PK assembly, the cloning and 
heterologous expression of cyanobacterial RiPPs, specifically ribosomally synthesized 
cyanobactins, have proven more successful, particularly due to their comparatively simpler 
biosynthesis. The successful expression and characterization of the patellamide biosynthetic 
pathway from Prochloron didemnii, a cyanobacterial symbiont of the ascidian Lissoclinum 
patella, revealed the canonical gene cluster organization that enabled the facile identification of 
other cyanobactin gene clusters [175]. Other cyanobactin biosynthetic pathways that have been 
cloned and heterologously expressed in E. coli include those for the piricyclamides[196], 
microcyclamides [197], microviridins [198], trunkamides [184], and anacyclamides [199]. Given 
the highly conserved tailoring enzymes amongst the various cyanobactin biosynthetic pathways 
and the common building blocks upon which they are assembled (i.e., proteinogenic amino 
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acids), the expression of one cyanobactin gene clusters highly suggested that subsequent clusters 
could also be expressed successfully. 
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5.0  A PLASMID TOOLKIT FOR THE RAPID CHARACTERIZATION OF 
CYANOBACTERIAL NATURAL PRODUCTS BIOSYNTHESIS 
Cyanobacteria are prolific producers of bioactive natural products, including antibiotics, 
anticancer, and anthelmintics. Recent genome sequencing of dozens of cyanobacterial strains 
revealed they are capable of producing significantly more secondary metabolites than have been 
characterized. Some strains dedicate at least 5% of their genomes exclusively to secondary 
metabolite biosynthesis, notably through nonribosomal peptide synthetases (NRPS), polyketide 
synthases (PKS), and cyanobactin biosynthetic pathways.[171] However, despite this vast 
reservoir, biochemical investigation into many of these cyanobacterial products has been elusive, 
primarily due to their cryptic nature and the scarce quantities that can be obtained through 
laboratory cultivation. Furthermore, the physiological characteristics of cyanobacteria have 
proven these organisms to be difficult to manipulate genetically, further complicating 
investigations into their secondary metabolism. Notably, they can be unicellular or multicellular 
and can possess multiple copies of their chromosomes per cell.[191] They also exhibit 
extracellular mucilaginous sheaths that inhibit the introduction of exogenous molecules, 
including DNA. DNA that can surpass the physical barriers of the cyanobacterial cell can be 
challenged by restriction nucleases.[192] Furthermore, cyanobacteria grow slowly, some strains 
with doubling times approaching six days[193]. Lastly, few regulatory genetic elements 
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(promoters, terminators, transcription factors, ribosome binding sites) have been characterized in 
cyanobacteria. 
These major challenges have prompted the development of new cloning methods and the 
exploration of suitable heterologous expression hosts. There are few proven examples of cloning 
and expression systems that can successfully assembly and express entire cyanobacterial 
biosynthetic pathways. In one investigation, the gene cluster for the molluscicidal agent 
barbamide from cyanobacterium Moorea producens was successfully produced in a 
Streptomyces host.[194] The large barbamide gene cluster (26 kbp) was assembled via a series of 
sub-cloning steps. Expression yielded a novel derivative of the hybrid NRP/PK natural product, 
4-O-demethylbarbamide, that was shown to exhibit more potent activity than the parent 
molecule. In another study, the gene cluster for the protein kinase C activator lyngbyatoxin (an 
NRP-terpene hybrid) from M. producens was expressed in E. coli [195]. Promoter engineering of 
the fosmid containing the lyngbyatoxin biosynthetic pathway (ltxABCD) afforded high titers 
(25.6 mg L
-1
) of the final product. A number of cyanobactins of ribosomal peptide pathways 
from cyanobacteria have also been successfully characterized via cloning and heterologous 
expression in E. coli. The successful expression and characterization of the patellamide 
biosynthetic pathway from Prochloron didemnii, a cyanobacterial symbiont of the ascidian 
Lissoclinum patella, revealed the canonical gene cluster organization that enabled the facile 
identification of other cyanobactin gene clusters [175]. Other cyanobactin biosynthetic pathways 
that have been cloned and expressed include those for the piricyclamides[196], microcyclamides 
[197], microviridins [198], trunkamides [184], and anacyclamides [199]. 
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The characterization of these cyanobacterial biosynthetic pathways has predominantly 
relied on traditional (ligation-based) cloning vectors. Two major drawbacks to ligation-based 
cloning strategies include (1) the limited selection of restriction enzymes suitable for cloning and 
(2) the multiple rounds of subcloning steps required to co-assembly multiple genes together. The 
latter is an especially important consideration in the cloning of biosynthetic pathways that are 
large (e.g., NRPS or PKS-containing pathways) or that contain several genes (e.g., the 
cyanobactin pathways typically contain at least five or more). In contrast to ligation-based 
cloning, yeast recombineering has proven to be a promising alternative in the assembly of 
complete biosynthetic gene clusters. Recombineering relies on yeast’s natural mechanism in the 
repair (recombination) of homologous sequences of DNA [200]. Previous yeast recombineering 
methods utilize PCR primer designs to yield linear amplicons and a linearized plasmid with 
homologous end sequences (as few as 30bp in length) that seamlessly recombine to produce the 
final plasmid construct [200-203]. To address these major limitations of currently-utilized 
plasmid vectors in the investigations of cyanobacterial biosynthetic pathways, a new designer 
plasmid based on yeast-recombineering is proposed here. This designer plasmid can be used to 
selectively assemble native biosynthetic pathways from diverse cyanobacterial species in a single 
cloning step. In addition, this designer plasmid can be utilized to re-assemble biochemical 
pathways, to engineer genetic regulatory sequences, and to generate unnatural analogs in 
heterologous hosts. This designer plasmid is shown to be utilized in the systematic investigation 
of various biosynthetic pathways (cyanobactin, NRPS, PKS) of natural products from diverse 
cyanobacterial species and can be used as a tool to facilitate the discovery of novel natural 




5.1 DESIGNER PLASMIDS ARE USED TO STUDY DIVERSE BIOSYNTHETIC 
PATHWAYS FROM VARIOUS CYANOBACTERIAL SPECIES 
Hallmark features of an expression platform for natural products biosynthesis consists of a 
cloning plasmid that can be utilized to rapidly assemble large fragments of DNA and that can be 
introduced into a laboratory amenable heterologous host for expression. This expression system 
utilizes homologous end sequences introduced via PCR primers to assemble complete 
biosynthetic pathways. Homologous end sequences can also be tailored to introduce synthetic 
regulatory elements, such as ribosome binding sites (RBS), and also enable site-directed 
mutagenesis (e.g., for codon optimization). The proposed cyanobacterial expression plasmid 
described herein has been utilized to characterize natural products from a diversity of 
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To illustrate the utility of these designer plasmids, the assembly of the hapalosin (hal) 
biosynthetic gene cluster is discussed here. The construction of the complete hal gene cluster 
incorporated both synthetic RBS sequences and a synthetic, high frequency, ATG start codon in 
place of the native, low frequency TTG start codon. The hal pathway was assembled in two 
sequential cloning steps to afford the halDE and halBCDE expression plasmids (Figure 5.2a). 
PCR primer designs include synthetic RBS or mutant codon sequences to yield amplicons with 
end sequences that were homologous with either an adjacent DNA fragment or with the 
backbone of the cloning plasmid. In Figure 5.2b, halD and halE PCR amplicons include 
synthetic end sequences that are homologous with each other or with the plasmid (indicated by 
corresponding color-coded regions of the gene inserts or the linear plasmid). The resulting 
plasmid simultaneously introduces a new RBS sequence upstream halD and mutates the native 







Figure 5.2 (a) Stepwise assembly of the entire hapalosin biosynthetic pathway was reconstituted 
using two separate yeast-E. coli binary plasmid systems. (b) Homologous sequences (colored in 
purple, green, and blue) were introduced via selective PCR primer design to facilitate yeast-







Cyanobacteria exhibit highly diverse morphological features, which contribute to their 
genetic intractability. Cyanobacteria are taxonomically classified into five subsection (I-V), 
based on similar bacteriological features [204, 205]. For example, species of subsections I and II 
are similar because all are unicellular, yet species of subsection I reproduce via binary fission or 
budding, while those of subsection II reproduce via multiple fission. Members of subsection III 
are filamentous, non-heterocystous cyanobacteria. Subsection IV and V species are all 
filamentous, heterocystous cyanobacteria. Heterocystous species utilize specialized cells to fix 
nitrogen in the absence of ammonia or nitrate [206]. Subsection IV species branch in one plane 
(false branching), while members of subsection V exhibit branching in multiple planes (true 
branching). 
 





Cyanobacterial Species Subsection References 
Aeruginosamide Cyanobactin Microcystis aeruginosa 
strain PCC 9432 
I [177, 207] 
Kawaguchipeptin Cyanobactin Microcystis aeruginosa 
NIES-88 
I [173, 208] 
Microcyclamides Cyanobactin Microcystis aeruginosa 
strain PCC 7608 
I [197, 209] 
Anabaenopeptin NRPS Planktothrix agardhii CYA 
126/8 
III [210] 
Spumigin NRPS Nodularia spumigena AV1 IV [211] 




Given the diversity amongst the cyanobacteria subsections, an important consideration in 
the utility of a universal cyanobacterial expression platform is the scope of this system to clone 
and express biosynthetic pathways from diverse cyanobacterial sources. Therefore, biosynthetic 
pathways of members from all but one (subsection II) were investigated in this study (Table 
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5.1). In addition, pathways containing the major enzymes involved in cyanobacterial secondary 
metabolite biosynthesis—nonribosomal peptide synthetase (NRPS), polyketide synthase (PKS), 
and cyanobactin enzymes—were explored. The ability to clone and express diverse biosynthetic 
pathways from cyanobacterial members of various subsections demonstrates the widespread 
utility of this expression platform in the investigation of cyanobacterial natural products. 
5.2 RAPID ASSEMBLY OF COMPLETE CYANOBACTERIAL GENE CLUSTERS 
The elucidation of novel cyanobacterial natural products and/or the investigation of their 
biosynthetic pathways necessitate the rapid assembly of the entire gene cluster into a plasmid 
suitable for heterologous expression. To demonstrate the utility of the proposed cloning plasmid 
system, the aeruginosamide (age) gene cluster from Microcystis aeruginosa PCC7432 was 
assembled. Aeruginosamides are natural products with potent protease inhibitor activity [207], 
and the recent identification of the age gene cluster illuminated the aeruginosamides as the 
products of a cyanobactin assembly line [177]. This is an unexpected discovery, as most 
cyanobactin products are cyclic, with the aeruginosamides as being only one of two (the other 











Figure 5.3 (a) Aeruginosamide biosynthetic pathway organization from M. aeruginosa 
PCC9432. (b) Heterologous expression of the complete age pathway afforded the production of 
aeruginosamide B.  (c) Heterologous expression of the complete age pathway afforded the 
production of aeruginosamide C. (d) Restriction enzyme digest analysis of the complete age 
pathway to confirm plasmid assembly. 
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The entire age gene cluster was assembled in a single cloning step consisting of four 
~3kb inserts to afford the complete age pathway (Figure 5.3a). The successful assembly of the 
age pathway expression plasmid was verified by restriction enzyme digest analysis (Figure 
5.3d). The aeruginosamides 9 and are both highly modified, including heterocyclization of the 
cysteine residue to afford a thiazole in addition to N-terminus prenylation and C-terminus 
methylation. Prenylation requires the substrate dimethylallyl pyrophosphate (DMAPP); however, 
E. coli cannot produce DMAPP endogenously. Martin and colleagues constructed a mevalonate 
(MEV)-dependent pathway (plasmid pMBI) that can synthesize DMAPP in the presence of the 
precursor MEV for heterologous expression in E. coli [213]. Co-expression of the age gene 
cluster with pMBI afforded the production of both 9 and 10, which were exhibited accurate mass 
values and retention times consistent with the aeruginosamides observed from a crude extract of 
the native producer M. aeruginosa PCC9432 (Figure 5.3b-c). 
5.2.1 Characterization of the Hapalosin Biosynthetic Gene Cluster 
Rapidly correlating uncharacterized gene clusters to their biosynthetic products is a central 
objective of expression systems. To demonstrate the ability of this platform to successfully 
construct and express biosynthetic pathways, a large NRPS biosynthetic pathway was 
investigated: the hapalosin (hal) pathway, which is approximately 25.2 kbp in length. Hapalosin 
is produced by H. welwitschii UTEX B1830 and is a hybrid NRP-PK lipo-depsipeptide that 
exerts multidrug resistance (MDR) reversing activity [212]. Five genes (halABCDE) are 










Figure 5.4 (a) Hapalosin biosynthetic pathway organization from H. welwitschii UTEX1830B. 
(b) Heterologous expression of the complete pathway (halABCDE) afforded the production of 
hapalosin (peak a). (c) Restriction enzyme digest analysis of the complete hal pathway to 
confirm plasmid assembly. 
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The complete hal pathway was reconstituted on two separate plasmids: pMQ131 contains 
the halA and sfp genes, and pMQ123i contains the halBCDE genes (Figure 5.2). The sfp gene is 
a phosphopantetheinyl transferase that is responsible for the essential posttranslational 
modification of acyl and peptidyl carrier proteins. The successful construction of the hal pathway 
expression plasmid was verified by restriction enzyme digest analysis (Figure 5.4c). Expression 
of the halABCDE pathway in E. coli afforded the production of hapalosin, which was verified by 
retention time and accurate mass with hapalosin produced from the native producer H. 
welwitschii UTEX B1830 (Figure 5.4b). Expectedly, the expression of the partial pathway 
construct (halDE) afforded no observable hapalosin. 
5.2.2 Characterization of the Kawaguchipeptin Biosynthetic Gene Cluster 
The kawaguchipeptins are cyclic undecapeptides that are produced via cyanobactin machinery 
(encoded by the kgpABCDEGF gene cluster, Figure 5.5a). They were first isolated from M. 
aeruginosa NIES-88, and while the non-prenylated kawaguchipeptin (kawaguchipeptin B) 
exhibited antibacterial activity against Staphylococcus aureus, interestingly, the diprenylated 
analog (kawaguchipeptin A) does not exhibit such bioactivity [173, 208]. Assembly of the kgp 





Figure 5.5 (a) Kawaguchipeptin biosynthetic pathway organization from M. aeruginosa NIES-
88. (b) Heterologous expression of the complete kgp operon afforded the production of 
kawaguchipeptin A. (c) Heterologous expression of the complete kgp operon afforded the 
production of kawaguchipeptin B. Plasmid pMBI was co-expressed with both the complete and 
partial kgp pathways. Standards 5 and 6 correspond to kawaguchipeptins B and A, respectively, 
obtained from a crude extract of M. aeruginosa NIES-88. (d) Restriction enzyme digest analysis 
of the complete kgp pathway to confirm plasmid assembly. 
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Co-expression of the kgp operon with pMBI yielded both kawaguchipeptins A and B 
(Figure 5.5b and 5.5c). As expected, the expression of the partial kgp operon (kgpAGF) did not 
produce either kawaguchipeptin. Interestingly, the M. aeruginosa NIES-88 native producer of 
the kawaguchipeptins revealed the production of two putative isomers of kawaguchipeptin A 
(Figure 5.5c). However, heterologous expression of the complete kgp operon afforded the 
production of a single peak corresponding to kawaguchipeptin B. It is possible that the 
heterologous expression of the kgp operon preferentially produces the minor conformational 
isomer of the macrocycle. 
5.3 ESTABLISHING GENES ESSENTIAL TO BIOSYNTHETIC PATHWAYS 
Delineating the pathway for natural products biosynthesis enables insight into the enzymatic 
function of the genes involved and affords opportunities to rationally engineer genetic elements 
to enhance the production of these molecules. Traditional approaches rely on the generation of 
biosynthetic pathway mutants and the analysis of product or intermediate accumulation. This 
approach is currently precluded by the morphological complexity of cyanobacteria and the lack 
of available genetic tools for manipulation. The designer plasmids, on the other hand, can 
circumvent these hurdles to understanding the essential genes required for the biosynthesis of 
cyanobacterial products. The utility of this expression system in defining minimal biosynthetic 
pathways is demonstrated in the following two examples. First, the essential genes of the 
spumigin (spu) pathway were explored through selective cloning of the spu pathway. Second, the 
essential genes of the microcyclamide (mca) biosynthetic pathway were explored through the 
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systematic generation of mutant pathway plasmid constructs and their heterologous expression in 
E. coli. 
5.3.1 Selective cloning of the Spumigin pathway provides insight into essential 
biosynthetic genes 
Spumigins are protease inhibitors produced from N. spumigena, which are filamentous nitrogen-
fixing cyanobacterium that form toxic blooms in brackish waters worldwide [211]. The spumigin 
gene cluster from N. spumigena AV1 consists of spuABCDE (Figure 5.6a), and it is predicted 
that only spuAB (NRPS modules) are essential in the biosynthesis of spumigins. The designer 
plasmid platform was utilized to construct spuAB (plasmid pSpuAB in Figure 5.6b), which was 
subsequently co-expressed with sfp. The construction of the spuAB plasmid was verified by 
restriction enzyme digest analysis (Figure 5.6c). Only in the presence of homo-L-tyrosine was 
spumigin D produced via heterologous expression of spuAB in E. coli, as determined by 
retention time and accurate mass comparison to an extract of the native producer N. spumigena 
AV1 (Figure 5.6b). This finding suggests that spuAB are essential in the biosynthesis of the 
spumigins and that SpuC (hypothetical protein), and SpuD (threonine dehydrogenase), and SpuE 







Figure 5.6 (a) Spumigin biosynthetic pathway organization from N. spumigena AV1. (b) 
Heterologous expression of spuAB and sfp afforded the production of spumigin D only in the 
presence of L-homotyrosine. (c) Restriction enzyme digest analysis of the spuAB pathway to 
confirm plasmid assembly. 
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5.3.2 The McaF of the Microcyclamide Biosynthetic Pathway is Essential 
The microcyclamides are a group of related cyclic hexapeptides from the cyanobacterium M. 
aeruginosa and have shown to be cytotoxic [209]. The biosynthetic pathway for the 
microcyclamide (mca) pathway was characterized previously. [197] The native mca operon from 
Microcystis aeruginosa strain PCC 7806 was cloned and assembled to afford mcaABCDEFG. 
The proposed functions of the various genes of the mca pathway are described in Figure 5.7a. 
Additionally, the mca operon was re-organized to yield reduced pathways mcaADEFG and 
mcaADEG. The mcaBC genes are predicted to encode hypothetical proteins but have been 
previously determined to be non-essential to the biosynthesis of cyanobactins [197]. The 
assembly of the complete mca biosynthetic pathway was verified by restriction enzyme digest 
analysis (Figure 5.7c). Expression of mcaADEG resulted in no detection via MS of any 
microcyclamides production, compared to the mcaABCDEFG pathway (Figure 5.7b). However, 
re-introduction of mcaF to mcaADEG to yield mcaADEFG restored microcyclamide 7806B 
production. McaF is a predicted prenyltransferase, and although the microcyclamides are not 
modified with prenyl groups, this observation suggests that McaF is still essential to the 
biosynthesis of microcyclamides, an observation noted previously by Schmidt et al. in the 






Figure 5.7 (a) Microcyclamide biosynthetic pathway organization from M. aeruginosa 
PCC7806. (b) Heterologous expression of either the complete or partial (mcaADEFG) operon 
afforded the production of microcyclamides. Standards 7 and 8 correspond aerucyclamide and 
microcyclamide compounds observed from a crude extract of M. aeruginosa PCC7806. (c) 
Restriction enzyme digest analysis of the complete mca pathway to confirm plasmid assembly. 
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5.3.3 Designer plasmids and their heterologous expression can be used to generate 
analogs 
A desirable feature of heterologous expression systems is the ability to generate novel analogs 
with enhanced bioactivity or with functional groups that can serve as chemical handles for 
subsequent modification. Anabaenopeptins are a group of diverse cyclic peptides that have 
demonstrate protease inhibition and are produced from several different cyanobacterial species, 
including those from Anabaena, Planktothrix, Microcystis and Nodularia [210, 214]. The 
anabaenopeptin (apn) gene cluster from P. agardhii CYA 126/8 was reconstituted as apnABCD 
(Figure 5.8a). Because apnE encodes for an ABC transporter and is not directly involved in the 
biosynthesis of the anabaenopeptins, these were excluded from the biosynthetic gene cluster 
construct. The assembly of the apnABCD pathway was verified by restriction enzyme digest 
analysis (Figure 5.8e). As expected, the co-expression of apnABCD and sfp in the presence of 
homo-L-tyrosine afforded the production of 3 and 4, as verified by both accurate mass and 
retention time, compared to the anabaenopeptins observed from a crude extract of P. agardhii 






Figure 5.8 (a) Anabaenopeptin biosynthetic pathway organization from P. agardhii NIVA-CYA 
126/8. (b) Only heterologous expression of the complete apn operon in the presence of homo-L-
tyrosine afforded the production of 3. (c) Only heterologous expression of the complete apn 
operon in the presence of L-homotyrosine afforded the production of 4. (d) Supplementation of 
the E. coli culture with 4b afforded the production of the chlorinated analog of 3 (4a).  Standards 
3 and 4 correspond to anabaenopeptins from crude extract of P. agardhii NIVA-CYA 126/8. (e) 

















The incorporation of halogenated substrates in the biosynthesis of 4 from P. agardhii 
CYA 126/8 was investigated. Compound 4 contains an exocyclic tyrosine residue that can 
potentially be substituted with a halogenated phenylalanine residue. The incorporation of 
unnatural substrates into the 4 structure was investigated by supplementing the culture media 
with p-chlorophenylalanine or p-fluorophenylalanine in addition to homo-L-tyrosine, which is a 
natural substrate in the biosynthesis of native anabaenopeptins. LCMS analysis of the 
supernatant extract revealed that compounds corresponding to chlorinated and fluorinated 
analogs of 4 were observed from the expression culture, only when supplemented with their 
respective halogenated phenylalanine substrate. The observation of a chlorinated 4 (4a) only in 
the presence of p-chlorophenylalanine is shown in Figure 5.8d. The ratios (based on ion count) 
of halogenated 4 to native 4 was determined to be 1:100 and 1:10 for the fluorinated and 
chlorinated analogs, respectively. This indicates that tyrosine is the preferred substrate for the 
ApnA module and that chlorinated phenylalanine, compared to fluorinated phenylalanine, is 
more readily incorporated into the pathway. The electronegativity of the atom in the para 
position of the phenyl ring of tyrosine or phenylalanine can explain the ease of incorporation of 
these various substrates, whereby the least electronegative (oxygen) is most preferred, followed 
by a moderately electronegative atom (chlorine), and then the most electronegative (fluorine). 
 
5.4 DISCUSSIONS AND CONCLUSIONS 
Cyanobacteria have been known to be a promising source of natural products with diverse 
biological activities, and recent genome sequencing has continued to suggest that these 
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microorganisms are prolific producers of yet characterized secondary metabolites that may be 
useful in the development of new medicines [200]. Despite the prevalence of biosynthetic gene 
clusters for compounds yet to be discovered, few methods exist to access these compounds or to 
investigate their biosynthesis. This study establishes a new designer plasmid platform that 
utilizes yeast recombineering technology to successfully clone and then heterologously express 
diverse types of biosynthetic pathways from cyanobacterial members from four of the five 
subsections of this genera (Table 5.1). 
 
This platform was successfully applied to: 1) rapidly assemble entire biosynthetic 
pathways in a single cloning step (aeruginosamide); 2) correlate cryptic biosynthetic pathways to 
their product (hapalosin, kawaguchipeptin); 3) establish the genes essential for biosynthesis 
(spumigin, microcyclamides); and 4) generate unnatural analogs that may serve as precursors for 
further synthetic modifications or that may exhibit enhanced bioactivity (anabaenopeptins). 
 
In one example from this study, the systematic expression of genes from the 
microcyclamide (mca) pathway defined the essential (minimal) pathway required for the 
biosynthesis of microcyclamides. Deletion of the PatF-like prenyltransferase of the mca operon 
(McaF) resulted in no detectable production of microcyclamide, while re-introduction of McaF 
to the pathway restored microcyclamide production (Figure 5.7b). This is consistent with 
previous studies that observed the essential role of PatF in the complete maturation of the 
patellamides [175]. Rapid access to complete and partial pathways of the mca biosynthetic 
pathway for heterologous expression investigations is expected to facilitate understanding of the 
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role a predicted prenyltransferase in the maturation of natural products lacking prenyl 
modifications. 
 
Another notable feature of the proposed cyanobacterial biosynthetic pathway cloning and 
expression system is the ability to generate unnatural and novel analogs. This was demonstrated 
by the biosynthesis of halogenated analogs of anabaenopeptin via substrate-guided biosynthesis 
(i.e., the introduction of defined unnatural substrates to direct the biosynthesis of novel natural 
products.) The facile access to unnatural analogs of cyanobacterial natural products will enable 
the investigation and development of compounds with enhanced and novel biological activities. 
 
There exists a lack of genetic tools to access the promising reservoir of cyanobacterial 
natural products. This study has established a new designer plasmid founded on a previously 
reported yeast-recombineering based plasmid [203] that can be used to rapidly assemble diverse 
biosynthetic gene clusters from cyanobacteria from members of several subsections of 
cyanobacterial genera. A limitation of this platform is the ability to produce appreciable 
quantities of product that can be useful for characterization, particularly of novel natural 
products. Possible solutions to this challenge include optimization strategies that alter 
transcriptional and translation regulatory elements in addition to methods to enhance substrate 
availabilities and heterologous host suitability. Nonetheless, this platform represents a tool that 




6.0  HAPALOSIN BIOSYNTHESIS IN HAPALOSIPHON WELWITSCHII AND ITS 
COMBINATORIAL GENERATION IN ESCHERICHIA COLI 
Secondary metabolites from cyanobacteria of the order Stigonematales have demonstrated 
promising anticancer, anti-inflammatory, antibiotic, and anti-fungal activities. Prominent 
examples of natural products from Stigonematales include the hapalindoles [215], fischerellins 
[216], hapalosin [212], and ambigols [217] (Figure 6.1). Although their biological activities are 
well-recognized, little is known about their biosyntheses. Investigating their biosynthetic 
pathways can enable access to these structurally complex compounds and also provide insight 
into new chemical transformations [218]. Recent characterizations of sequenced genomes from 
species of the order Stigonematales have shown that a significant portion of their genomes are 
dedicated to polyketide synthase (PKS) and nonribosomal peptide synthetase (NRPS) genes. In 
one study, it was shown that approximately 5% of the Fischerella sp. genome was found to 
consist of PKS and NRPS genes.[171]
 
Therefore, there has been a growing interest in sequencing 
the genomes of cyanobacteria to uncover the gene clusters responsible for the production of 
cyanobacterial natural products. Our research group has recently sequenced the genome of three 
cyanobacterial strains in the order of Stigonematales, including Hapalosiphon welwitschii 
UTEX1830, Fischerella muscicola UTEX1829, and Fischerella ambigua UTEX1903, in an 
effort to investigate the biosyntheses of their natural products. Genome mining of these species 
has elucidated the biosynthetic machinery of valuable natural products, including those of the 
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hapalindole- and ambiguine-type indole alkaloids [219, 220], the multidrug resistance (MDR) 





Figure 6.1 Natural products discovered from species of the cyanobacterial order Stigonematales. 
 
A central challenge in the study of cyanobacterial natural products biosynthesis arises 
from the lack of tools to genetically manipulate these organisms. The extracellular mucilaginous 
sheaths that encase cyanobacterial cells prohibit the introduction of exogenous DNA [192], 
which makes the study of defined cyanobacterial mutants of biosynthetic pathways difficult to 
accomplish. Furthermore, genetic regulatory elements, such as promoters, ribosome binding 
sites, and terminators, have not been well-characterized in cyanobacteria. Other research groups 
have been able to investigate cyanobacterial biosynthetic pathways by cloning and 
heterologously expressing them, such as in the case for the cyanobactins patellin A [185] and 
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trunkamide [221]. However, such approaches rely on ligation-based cloning plasmids and can 
require multiple cloning steps to assemble complete biosynthetic pathways. 
 
To address the shortcoming of current approaches in understanding the enzymatic 
machinery involved in the biosynthesis of cyanobacterial natural products, we developed a 
designer plasmid system that enables the rapid assembly of entire biosynthetic pathways and 
their expression in the heterologous host E. coli. The designer plasmid is a yeast-E. coli shuttle 
vector that enables the concomitant cloning and genetic engineering of large sequences of DNA 
via yeast-assisted homologous recombination. We utilized this system to discover the 
biosynthetic pathway for the MDR-reversing agent hapalosin from H. welwitschii. Expression of 
the hapalosin biosynthetic pathway in E. coli revealed that this hybrid NRPS-PKS assembly line 
exhibits high substrate promiscuity, which affords the generation of a combinatorial library of 
hapalosin analogs. 
 
6.1 IDENTIFICATION OF PUTATIVE HAPALOSIN BIOSYNTHETIC GENE 
CLUSTER IN HAPALOSIPHON WELWITSCHII BY DE NOVO GENOME 
SEQUENCING 
Hapalosin is a 12-membered cyclic depsi-lipopeptide that was originally discovered from H. 
welwitschii UTEX1830B by Moore and coworkers[212]. The unique 12-membered ring, mixed 
lactone and lactam scaffold suggests hapalosin is most likely assembled by a mixed enzymatic 
machinery operated by both PKS and NRPS. However, the sequence of monomer assembly to 
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form the final structure of hapalosin is unclear. Genome mining of H. welwitschii UTEX1830, 
revealed a 26 kbp-long gene cluster that contains five PKS-NRPS genes (Figure 6.2). Domain 
predictions of the NRPS and PKS modules of this gene cluster suggested that it is responsible for 




Figure 6.2 Organization of the hapalosin gene cluster and proposed gene functions and 
PKS/NRPS domain predications. Genes and their respective substrates of the full structure are 
correlated by color. Abbreviations: AL: fatty acid ligase; T: thiolation domain; KS: ketosynthase 
domain; AT: acyltransferase domain; MT: methyltransferase domain; KR: ketoreductase 
domain; T: thiolation domain; C: condensation domain; A: adenylation domain; TE: thioesterase 
domain. 
 
The first gene halA is a didomain NRPS that contains a fatty acid ligase and was 
predicted to incorporate a C8-fatty acid into the structure of the final product. Next, halB, a 
pentadomain PKS, was predicted to include the ability to incorporate a C2 ketide unit via Claisen 
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condensation, followed by either C- or O-methylation by a methyltransferase. halC also 
consisted of a pentadomain NRPS whereby the second adenylation domain was predicted to have 
the capacity to incorporate a ketoacid [222], while the ketoreductase may subsequently reduce 
the ketone to an α-hydroxy acid, analogous to that which has been discovered in the biosynthesis 
of cereulide [223]. halD is a tetradomain NRPS where the A domain is predicated to be able to 
select phenylalanine as well as carry out methylation via a methyltransferase domain. Lastly, 
halE was predicted to be a pentadomain PKS with a similar capacity as halB to incorporate a C2 
ketide unit via Claisen condensation. The C-terminus thioesterase domain of halE was presumed 
to catalyze the final macrolactonization event. 
6.2 ASSEMBLY OF THE HAPALOSIN GENE CLUSTER USING A DESIGNER 
PLASMID 
To establish the biosynthetic function of the hapalosin gene cluster from Hapalosiphon 
welwitschii UTEX1830, the DNA sequences of interest from the hapalosin locus were cloned 
and used to construct the expression plasmids via yeast-assisted homologous recombination 
(yeast recombineering). [74],[224]
 
Both plasmids were constructed to incorporate synthetic 
translational and transcriptional regulatory sequences, including ribosome binding sites (RBS) 
and the isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible Lac (plasmids pHal3 and 4) or 
Tac (plasmid pHal2) promoters (Figure 6.3). Additionally, the low frequency TTG start codon 
of halD was mutated to the high frequency ATG start codon of E. coli to further enhance 
translational efficiency. The ATG start codon was introduced via site-directed mutagenesis of the 
cloning primer for this gene. The sequential plasmid construction to assemble the halBCDE 
 95 
locus enabled the incorporation of the synthetic RBS as well as the ATG codon. The construction 
of expression plasmids pHal2 and pHal4 were verified by restriction enzyme DNA digestion 
analyses. The observed DNA fragments were consistent with the expected DNA products for 




Figure 6.3 Construction of hapalosin expression plasmids pHal2 – 4. Sequential cloning enabled 
the introduction of synthetic translational regulatory element RBS sequences and the site-
directed mutagenesis of the native low frequency TTG codon to the high frequency ATG codon. 
P: Lac (pHal3 and 4) or Tac (pHal2) promoter sequences; T: terminator; ORI: origin of 
replication; Marker: selectable marker. 
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6.3 HETEROLOGOUS EXPRESSION OF HAPALOSIN GENE CLUSTER AND ITS 
DELETION MUTANT IN HETEROLOGOUS EXPRESSION IN E. COLI 
The heterologous expression of the hal gene cluster was assessed in E. coli, and the culture 
supernatant was analyzed for metabolite production. The biosynthesis of hapalosin A from E. 
coli was compared to an extract from the native producer Hapalosiphon welwitschii UTEX1830 
(Figure 6.4). A molecule from the heterologous expression of the entire hal pathway in E. coli 
eluted at the same retention time and nominal mass as that of hapalosin A obtained from H. 
welwitschii. The production of hapalosin A was verified by isolating the compound and by 
comparative 
1
H-NMR and high resolution MS analysis. Furthermore, as expected, the halDE 
partial pathway expression culture did not yield production of hapalosin A. Peaks corresponding 
to hapalosin A from E. coli and Hapalosiphon welwitschii are labeled A in Figure 6.4. 
 
Three other prominent peaks were also discovered in the E. coli expression culture of the 
full hal pathway. These compounds are labeled B,C and D in Figure 6.4 and their nominal 
masses were determined to be 504, 462, and 486 Da, respectively, whereas the nominal mass of 
hapalosin A is 490 Da. The differences in nominal masses suggested the possibility of hapalosin 
analogs varying only in –CH2– (14 Da) and –C2H4– (28 Da) groups. HR-MS
2
 analysis verified 
the presence of hapalosin analogs corresponding to hapalosins B, C and D. The HR-MS
2
 
fingerprint analysis for hapalosin A is shown in Figure 6.5. Hapalosin B had only previously 
been reported to be produced naturally from the cyanobacteria strain Nostoc sp. 4A [225]; 
therefore, this finding represents the first observation of hapalosin B production from 





Figure 6.4 Comparative LC-MS chromatograms of hapalosin biosynthetic pathway production 
from E. coli and cyanobacterial Hapalosiphon welwitschii strain UTEX1830. Hapalosin A is 
denoted in the LC-MS traces as A for both E. coli and cyanobacterial extracts. Three other 
prominent compounds were discovered in the E. coli expression strain containing the hapalosin 
pathway, which are labeled B, C, and D. These will be discussed later in this document. 
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+ 490.31631 490.31546 1.7
B C28H42NO5
+ 472.30575 472.30484 1.9
C C23H38NO5
+ 408.27445 408.27362 2.0
D C17H24NO4
+ 324.18055 324.18059 -0.1
E C17H24NO4
+ 306.16998 306.16925 2.4
F C17H22NO3
+ 288.15942 288.15885 2.0
G C13H16NO4
+ 250.10738 250.10692 1.8
H C12H18NO3
+ 224.12812 224.12772 1.8
I C12H16NO2
+ 206.11756 206.11722 1.6
J C12H14NO
+ 188.10699 188.10669 1.6
K C11H19O
+ 167.14304 167.14286 1.1
 
 
Figure 6.5 The HR-MS
2 
fragmentation of hapalosin A obtained from heterologous expression of 
the biosynthetic pathway in E. coli. Key fragments and structures are labeled from A – J. 
 
 99 
The structural elucidation of hapalosins C and D and consideration of the enzymes 
responsible for each chemical transformation in the biosynthesis of hapalosin suggested substrate 
promiscuity of the fatty acid ligase domain of HalA and differential reactivity at the C-
methyltransferase domain of HalB. Therefore, in addition to substrate promiscuity of the 
adenylation domain of HalC to yield hapalosin B, the production of the three hapalosins B, C, 
and D serves as evidence that at least three points within the biosynthetic pathway result in the 




Figure 6.6 Structures of hapalosins A-D provide insight into the differential biosynthesis of 
hapalosin products within the pathway. Colored atoms are derived from substrates of different 
Hal modules. Green atoms correspond to substrates of HalC, blue to HalA, and red to HalB. 
6.4 DEFINING THE HAL MINIMAL PATHWAY 
To determine the genes essential in the production of hapalosin, E. coli expression strains 
harboring deletion mutant variants of the pathway were assembled and expressed. As discussed 
previously, it was determined that expression of halDE and sfp were insufficient to biosynthesize 
hapalosin. However, expression of the halBCDE partial pathway was observed to produce 
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hapalosin, although yields were comparably modest to that of the full hal pathway (Figure 6.7). 
This unexpected observation suggested that the function of HalA could be provided by an 




Figure 6.7 LC-MS chromatogram comparison of E. coli expression strains harboring the full 
pathway halABCDE or the pathway without the fatty acid ligase, halBCDE. Hapalosin A 
(labeled A) was still produced from the partial pathway strain, although production was 
comparably modest. 
 
Lipoic acid in E. coli serves an essential role as a prosthetic group in key enzymes 




The biosynthesis of lipoic acid is accomplished by two 
enzymes, LipA and B, which function as the lipoate synthase and octanoyltransferase, 
respectively. Biosynthesis initiates with the interaction of LipB with octanoyl-ACP, an 
intermediate of the fatty acid biosynthetic pathway, as only marginal concentrations of freely 
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available octanoic acid are present within the E. coli cell. Next, the octanoyl-LipB complex 
presents the octanoyl substrate to LipA, which functions to introduce the terminal thiolane ring 
to yield lipoic acid. [227] 
 
Given the essential role of lipoic acid within E. coli, it is hypothesized that the thiolation 
domain of LipB interacts with the adenylation domain of HalB to shuttle the octanoyl moiety, the 
first substrate used for hapalosin biosynthesis, to the hapalosin pathway. Therefore, hapalosin 
production from the halBCDE partial pathway expressed in E. coli suggests that a PKS module 
from cyanobacterial (HalB) can interact with a fatty acid ligase from a different species (E. coli). 
If this interaction were to take place, it would be a rare event, as interactions between domains 
are highly specific. [228]
 
This unexpected result, establishes the capacity for enzyme-enzyme 
promiscuity from the Hal pathway. 
6.5 GENERATION OF HAPALOSIN ANALOGS 
Evidence of substrate promiscuity within the hapalosin biosynthetic pathway expressed in E. coli 
consequently prompted the systematic investigation of hapalosin analogs that could be generated 
from other E. coli substrates as well as from unnatural substrates. 
6.5.1 Generation of Hapalosin Libraries in Escherichia coli 
Evidence of biosynthetic divergence at points HalA, HalB, and HalC of the pathway prompted 
an exploration for other hapalosin analogs. Thus far, promiscuity of the adenylation domains of 
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HalA and HalC had been established with the structural identification of hapalosins C and B, 
respectively. Furthermore, variation of the C-methyltransferase domain of HalB was established 
with the identification of hapalosin D. Aside from hapalosin B, none of these hapalosin 
compounds were present from the native cyanobacteria producer Hapalosiphon welwitschii. To 
investigate the scope of substrate promiscuity and enzymatic divergence of the Hal pathway, 
hypothetical hapalosin products were proposed based on alternative substrates and variations of 
the enzymatic machinery for each member of the pathway. Proposed hapalosin analogs from E. 




The production of hapalosin D had demonstrated the capacity of the hapalosin 
intermediate to elude methylation by the C-methyltransferase of HalB. It was logical to inquire 
whether the N-methyltransferase of HalD could also allow hapalosin intermediates to proceed 
through the biosynthetic pathway to yield the non-N-methylated products. Examination of the 
heterologous expression of halABCDE in E.coli revealed the production of the non-N-methylated 
hapalosin compound, confirming that both methyltransferases present within the pathway do not 
proceed with completion (Figures D10 and D11). 
 
Incomplete C-methylation underscores the ability of these domains to accommodate the 
absence of methylation but did not yield direct insight into the substrate promiscuity of the HalB 
adenylation domain itself. Malonyl-CoA serves as the native substrate for the HalB adenylation 
domain, although other malonyl-CoA substrates are also commonly utilized by acyltransferase 
(AT) domains, including methylmalonyl- and ethylmalonyl-CoA. To examine whether other 
malonyl-CoA substrates can be selected by the AT domain of HalB, halABCDE heterologous 
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expression extracts from E. coli were analyzed for the presence of hapalosin compounds 
substituted with methyl- and ethylmalonyl-CoA moieties. Indeed, trace amounts of an α-gem-
dimethyl analog, the hapalosin product of methylmalonyl-CoA incorporation, was discovered, 
validating the promiscuity of HalB, a rare feature of AT domains. [229] 
 
Although the production of C6 and C8 fatty acid analogs of hapalosin (hapalosins A and 
C, respectively) had been confirmed, a C16 fatty acid analog had also been envisioned, due to 
the intracellular abundance of C16 saturated fatty acids within E. coli. [230] Although a C16 
fatty acid hapalosin had not been discovered, screening for analogs of shorter fatty acid chain 
lengths revealed the presence of trace amounts of a C10 fatty acid analog instead. 
 
This discovery suggested a chain length limitation of the fatty acid ligase domain of HalA 
or the association of an E. coli acyltransferase with HalB. The basis of the former hypothesis 
relies on the fact that free C10 fatty acid concentrations are considerably lower than that of other 
long chain fatty acids, such as C16 fatty acid, and transfer of non-native fatty acid substrates 
would preferentially select those in abundance. Instead, the less abundant C10 fatty acid was 
incorporated, evidence that acyl chains between 6 to 10 carbon atoms is likely optimal for the 
substrate binding pocket of the HalA fatty acid ligase. 
 
The final domain of the Hal gene cluster consists of the thioesterase (TE) domain, 
responsible for the cyclization reaction to yield the final product. In the hapalosin biosynthet ic 
pathway, a nucleophilic hydroxyl group, generated from the Claisen condensation with malonyl-
CoA from the HalB domain, attacks the electrophilic carbon of the substrate-enzyme thioester 
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tether. This macrocyclization yields the final cyclized hapalosin product. However, a 
nucleophilic water molecule can compete for the electrophilic carbon of the substrate-enzyme 
thioester tether. This results in premature release to yield linearized products. Examination of the 
halABCDE pathway expression from E. coli demonstrated that six different linear hapalosin 
products can be observed, suggesting that the hapalosin intermediate can be prematurely 
hydrolyzed from the TE domain of HalE. Alternatively, it is possible to explain the observation 
of these linear hapalosin products due to hydrolysis of the mature macrocycle after its complete 
assembly. This mechanism would also suggest that products would arise from the hydrolysis of 
the other lactone moiety. However, examination of the halABCDE pathway expression from E. 
coli did not yield the presence of such alternatively hydrolyzed hapalosin products, which 
supports the hypothesis that these linear hapalosin compounds arise due to the premature 
hydrolysis of the hapalosin intermediate from the TE domain of HalE. 
6.5.2 The Generation of Unnatural Hapalosin Analogs 
The unusual ability of the HalA fatty acid ligase to select longer and shorter acyl chain substrates 
motivated the investigation of unnatural substrate (azido-conjugated) selectivity of this fatty acid 
ligase. Furthermore, the specificity of the adenylation domain of HalD was examined through E. 
coli feeding studies to incorporate halogen-substituted phenylalanine substrates. 
 
Fatty acid substrates containing a terminal azide were synthesized, but the choice of fatty 
acid chain length was carefully considered based on previous findings of fatty acid substrate 
selectivity. It was demonstrated that C8 fatty acids proved to be the preferred substrate, while C6 
and C10 fatty acids appeared to serve as lower and upper limits in chain length. Based on these 
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findings, 6-azidohexanoic, 7-azidoheptanoic, and 8-azidooctanoic acids were synthesized and 
used as feeding substrates to E. coli expression cultures (Figure 6.8). 
 
  
Figure 6.8 Azido-alkanoic acid feeding experiments in E. coli  expression cultures. Hapalosin A 




 analyses indicated that each of the azido-alkanoic acids were 
incorporated into the Hal pathway to yield their corresponding azide-conjugated hapalosin 
products. While the yield of azido-alkanoic acid incorporation was comparable between the 6-
azidohexanoic and 7-azidoheptanoic acids, the yield was markedly decreased for the 8-
azidooctanoic acid incorporation. In fact, to facilitate incorporation of the 8-azidooctanoic acid 
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moiety, the final concentration of this substrate was doubled in the culture medium, compared to 
that of the other azido-alkanoic acid substrates, in order to observe modest incorporation. 
 
This series of unnatural fatty acid feeding experiments serves as further evidence that a 
fatty acid chain length limitation exists for the incorporation of the substrate into the Hal 
pathway. An inspection of the natural and unnatural substrates optimal for incorporation suggests 
that chains of 8 to 9 atoms following the carboxylic acid (i.e., counting from the α carbon to the 
last C–H or N=N bond of the chain) is the optimal upper limit, since octanoic, 6-azidohexanoic, 
and 7-heptanoic acids were all incorporated with comparable efficiency, based on LC-MS 
analysis. On the other hand, a substrate with a chain of 10 atoms following the carboxylic acid 
displayed a negative bias toward incorporation. It would therefore be unsurprising if longer acyl 
chains could not be incorporated at all and also explains why C12, C14, and C16 hapalosin 




Previous attempts to detect natural analogs of hapalosin bearing substitutions of the 
phenylalanine residue with tyrosine or tryptophan were unsuccessful and were attributed to high 
substrate selectivity of the adenylation domain of HalD. To test whether increased concentrations 
of an unnatural phenylalanine substrate could be incorporated instead, 4-fluoro-phenylalanine 
was introduced at concentrations up to 5mM in the growth medium. Trace amounts of the 
fluorinated hapalosin compound was subsequently discovered by HR-MS
2
 in the expression 
culture supernatant (Figure 6.9). 
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+ 508.30689 508.30832 -2.8
B C28H41FNO5
+ 490.29633 490.29791 -2.3
C C17H23FNO4
+ 324.16056 324.16129 -2.2
D C17H21FNO3
+ 306.15000 306.15067 -2.2
E C12H17FNO3
+ 242.1187 242.11938 -2.8
F C12H15FNO2
+ 224.10813 224.10878 -2.9
G C12H13FNO
+ 206.09757 206.09818 -3.0
G C11H19N




 analysis and fragmentation assignments of a fluorinated hapalosin analog. 
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As another example of unnatural amino acid incorporation into the hapalosin structure, 4-
chloro-phenylalanine was also introduced to E. coli expression cultures to generate the 
corresponding chlorinated hapalosin analog, which was also detected by HR-MS
2
. Although 
halogenated amino acids had been successfully incorporated into the hapalosin structure, the 
yields of corresponding halogenated hapalosin analogs were considerably lower than that of the 
azide-modified hapalosin structures. The capacity of the adenylation domain of HalD to select 
for unnatural substrates demonstrates that in total, there exist six points of biosynthetic 
divergence in the Hal pathway. These points of biosynthetic divergence allowed the generation 
of a combinatorial library of hapalosin analogs with multiple substitutions, resulting in the 
generation of a total of 32 hapalosin analogs. 
6.6 CONCLUSIONS 
The present study demonstrates the utility of the demonstrated expression plasmid used to 
investigate biosynthetic pathways of cyanobacterial natural products. This study identified the 
gene cluster responsible for the production of the multidrug-resistance (MDR) reversing agent 
hapalosin from H. welwitschii UTEX1830B. Assembly and heterologous expression of this large 
(26-kbp) gene cluster in E. coli revealed the unexpected generation of hapalosin analogs, owing 
to the unusual plasticity of this pathway. The incorporation of unnatural substrates (azide-
conjugated fatty acids and halogenated amino acids) underscores the potential of this cloning and 
expression system as a platform for generating cyanobacterial natural product analogs via 
precursor-directed biosynthesis. [231]  
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The incorporation of “clickable” functional groups (propargylation or azido-conjugation) 
to afford analogs of natural products is highly desired and has been demonstrated in polyketides 
[232] and nonribosomal peptides [233] through mutagenesis studies of acyltransferase and 
adenylation domains, respectively. The incorporation of click functional groups can enable the 
facile synthesis of novel structures with enhanced bioactivities. These analogs can also serve as 
small-molecule probes via bioorthogonal conjugation to investigate the biochemical mechanisms 
of these therapeutic compounds, accelerating drug development [234]. Likewise, the introduction 
of carbon-halogen bonds into natural products can expand the potential of native scaffolds. For 
example, the introduction of a carbon-fluorine bond confers bioactivity for some drugs (reviewed 
in [235]). The carbon-chlorine bond is similarly important because it can serve as a chemical 
handle to selectively introduce new functional groups. An approach to generate analogs of the 
peptide antibiotic pacidamycin was recently demonstrated through the biosynthesis of the 
chlorinated product, followed by selective cross-coupling various moieties [236]. 
 
Recent genome sequencing efforts of several cyanobacteria species have revealed that 
these organisms are capable of producing numerous cryptic secondary metabolites with potential 
anticancer, anti-inflammatory, antibiotic, and anti-fungal activities. However, due to the lack of 
genetic tools and to difficulties in their genetic manipulation, investigating their biosynthesis has 
been elusive. This study has established a designer plasmid that can rapidly assemble and 
introduce engineered regulatory elements to link cyanobacterial biosynthetic pathways to their 
natural products. This plasmid has been used to characterize the biosynthetic pathway for the 
MDR reversing agent hapalosin and the generation of a library of unnatural (azide-conjugated 
and halogenated) analogs via heterologous expression in host E. coli. This system represents a 
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promising approach to discover new cyanobacterial natural products and to produce analogs with 




7.0  THE HAPALOSIN BIOSYNTHETIC GENE CLUSTER FROM 
HAPALOSIPHON WELWITSCHII UTEX1830 REVEALS A NOVEL SUBSTRATE 
RECYCLING MECHANISM 
Hapalosin is a cyclic depsi-lipopeptide from the stigonematalean cyanobacterium Hapalosiphon 
welwitschii UTEX1830B and exerts multidrug resistance reversing activity via P-glycoprotein 
inhibition [212]. The biosynthesis of hapalosin proceeds via a hybrid nonribosomal peptide 
synthetase (NRPS) and polyketide synthase (PKS) enzymatic assembly line. The general 
biosyntheses of depsipeptides proceed through NRPS enzymatic machinery, condensing α-
hydroxy acid substrates to elongate the growing peptide chain. Recent investigations of 
biosynthetic pathways of depsipeptides have revealed that two distinct mechanisms exist to 
incorporate α-hydroxy acids. In one scenario, the α-keto acid substrate is selected and activated 
by its corresponding adenylation domain and is then reduced by a subsequent reductase domain 
to yield the α-hydroxylacyl-S-pantetheinyl carrier protein intermediate. This has been shown in 
the biosynthesis of the ionophore cereulide from Bacillus cereus [223]. In the other scenario, the 
α-hydroxy acid substrate is selected directly for activation and then incorporated into the 
growing peptide chain. This mechanism exists in the biosynthesis of fungal cyclodepsipeptides, 
including the anthelmintic PF1022A from Rosellinia sp. PF1022 [237] as well as the enniatins, 
ionophores from Fusarium sp. [238]. Noteworthy from both mechanisms of depsipeptide 
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biosynthesis is the high selectivity of the adenylation domain for either its cognate α-hydroxy or 







Figure 7.1 (a) Hapalosin biosynthetic gene cluster organization from H. welwitschii 
UTEX1830B. (b) Structures of hapalosin A and B. 
 
Recent genome sequencing of the H. welwitschii UTEX 1830B genome [219] revealed 
that hapalosin is biosynthesized via a hybrid pathway containing NRPS and PKS enzymes 
(Refer to Hapalosin Gene Cluster, Chapter 6). The hapalosin (hal) biosynthetic pathway 
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consists of five genes, halABCDE, corresponding to a fatty acid ligase, NRPS, PKS, NRPS, and 
NRPS, respectively (Figure 7.1a). Interestingly, HalC contains tandem adenylation domains 
followed by a ketoreductase domain. Canonical NRPS modules contain just a single adenylation 
domain for the activation and incorporation of a single amino or keto acid substrate. Therefore, 
the presence of tandem adenylation domains is an unusual feature of this NRPS enzyme. Based 
on bioinformatic analysis, the adenylation domain(s) of the HalC module are predicted to be 
responsible for the activations of the α-ketoisovaleric acid (1) and α-keto-β-methylvaleric acid 
(3), which are subsequently reduced to the corresponding hydroxy acids by a downstream 
ketoreductase domain of the HalC domain. The incorporation of activated substrates 1 and 3 lead 
to the biosynthesis of hapalosin A and B, respectively (Figure 7.1b). In this study, the unusual 
tandem adenylation domains and ketoreductase domain of HalC of the hapalosin biosynthetic 
pathway are characterized in vitro and in vivo via heterologous expression in E. coli. Insights 
into this pathway revealed a novel mechanism for the incorporation of the α-keto(hydroxy) acid 
substrates into the hapalosin structure. 
7.1 HALC-A2 DOMAIN EXHIBITS SUBSTRATE ACTIVATION PROMISCUITY 
To determine the function of both adenylation domains (A1 and A2) present in the HalC module 
of the hal pathway, the sequences corresponding to each domain were individually cloned and 
expressed to afford purified proteins of each stand alone domain. The HalC adenylation domains 
were screened against a panel of substrates including 1 and 3, as well as their reduced, α-hydroxy 
acid analogs 2 and 4, respectively (Figure 7.2). Sequence analysis of the HalC A1 domain 
revealed two point mutations within the amino acid sequence of the HalC module, R922S and 
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K1011Q, predicted to be essential for substrate adenylation (Figure E1). Indeed, in vitro activity 
screening of the HalC A1 domain against substrates 1 – 4 did not exhibit any appreciable ATP 




Figure 7.2 HalC_A2 domain adenylation activity towards four substrates. 
 
The HalC A2 domain was therefore expected to be responsible for the activation of 
substrates 1 and 3 for final biosynthesis of hapalosins A and B, respectively. The in vitro 
adenylation activity of the HalC A2 domain revealed comparable enzyme activity for substrates 
1 and 3 (Figure 7.2). Reduced native substrate analogs 2 and 4 were also screened for HalC A2 
enzymatic activity, and unexpectedly, substrate 2 showed comparable enzyme activity as that of 
1 and 3. 
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7.2 HALC A2 ENZYMATIC ACTIVITY AGAINST Α-KETO AND –HYDROXY 
ACID SUBSTRATES 
The Michaelis-Menten kinetic parameters for the HalC A2 domain against substrates 1 and 2 
were determined (Figure 7.3). While the turnover number for substrates 1 and 2 were 
comparable (0.95 ± 0.07 min
-1
 and 1.11 ± 0.16 min
-1
, respectively), the Km values for 1 and 2 
were determined to be 32.10 ± 5.45 μM and 125.8 ± 34.47 μM, respectively. The catalytic 













). The smaller Km value and greater catalytic efficiency 
for the activation of 1 over 2 is consistent with the hypothesis that 1 is the native substrate for the 




Figure 7.3 HalC_A2 domain kinetic profiles in the activation of α-ketoisovaleric acid and α-
hydroxy isovaleric acid. 
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7.3 CHEMICAL COMPLEMENTATION OF THE HAL MUTANT PATHWAY 
The unexpected adenylation domain activity of HalC A2 against substrate 2 suggested that the α-
hydroxy acid substrate can be activated and circumvent the ketoreductase domain of the HalC 
module. To confirm that the biosynthesis of hapalosin A can proceed in absence of HalC 
ketoreductase activity and with the introduction of 2, mutations S2071A and Y2086F were 
introduced into active site of the HalC domain amino acid sequence. The mutant HalC sequence 
was then used to assembly the remainder of the hal pathway for heterologous expression in E. 
coli. Expression of the mutant pathway afforded the production of hapalosin A only with the 
introduction of 2 (Figure 7.4). The absence of hapalosin A production from the expression of the 
mutant pathway without 2 suggests that the HalC A2 domain can activate both 1 and 2 to afford 




Figure 7.4 Hapalosin production in E. coli is abolished by introducing HalC_KR active site 
mutations S2071A and Y2086F. The mutant pathway can be complemented by the addition of 2. 
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7.4 A NOVEL MECHANISM FOR RECYCLING Α-KETO AND -HYDROXY ACID 
SUBSTRATES 
Substrate activation of the adenylation domains of the HalC module in vitro has revealed 
that the A1 adenylation domain is not responsible for the activation of either α-keto or -hydroxy 
acid substrates, which is consistent with predicted inactivity of this domain based on sequence 
analysis. On the other hand, the A2 adenylation domain was observed to be responsible for the 
activation of the α-keto acid substrates 1 and 3, which incorporated into the final structures of 
hapalosins A and B, respectively (Figure 7.2). Unexpectedly, the α-hydroxy acid substrate 
analog 2 was also activated by the HalC A2 domain. Comparable catalytic efficiency for both 
substrates (Figure 7.3) suggests that the biosynthetic machinery from the native producer H. 
welwitschii UTEX1830B utilizes either substrate in the maturation of hapalosin. Chemical 
complementation of the HalC ketoreductase mutant of the hapalosin pathway expressed 
heterologous and in the presence of α-hydroxy acid substrate 2 confirms this finding (Figure 
7.4). Collectively, these observations led to the proposition of a novel recycling mechanism of 




Figure 7.5 Proposed recycling mechanism of α-hydroxy isovaleric acid by HalC module. 
 
Activation and subsequent reduction of the α-keto acid substrate affords the 
corresponding α-hydroxylacyl-S-pantetheinyl carrier protein intermediate. This intermediate can 
subsequently undergo one of two pathways: 1) it is utilized in elongation to produce the final 
hapalosin structure or 2) it is hydrolyzed from the thioester tether to yield the corresponding α-
hydroxy keto acid. The latter (minor pathway) will then undergo (re)activation to regenerate the 
α-hydroxylacyl-S-pantetheinyl carrier protein intermediate, which would bypass ketoreductase 
activity to proceed with the subsequent biosynthetic steps in the hapalosin pathway. 
7.5 CONCLUSIONS 
The hapalosin biosynthetic pathway from cyanobacterial species H. welwitschii UTEX1830B 
presents uncommon evolutionary features. The HalC module contains unusual tandem 
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adenylation domains, presumably as the result of a gene duplication event; however, the first of 
these domains (HalC A1) contains active site point mutations that render this adenylation domain 
inactive. On the other hand, the second domain (HalC A2) unexpectedly displayed substrate 
promiscuity for both the α-keto and -hydroxy valeric acid substrates, which demonstrated a novel 
substrate recycling mechanism. The proposed α-hydroxy acid substrate recycling mechanism is 
the first of such to be characterized. Adenylation domain activation of previously characterized 
NRPS pathways [212, 223, 237, 238] has demonstrated that these domains are only capable of 
activating either the α-keto or -hydroxy acid, not both. This finding is especially unusual as 
adenylation domains are well established to be highly selective in substrate activation [239]. It is 
conceivable that the ability of the HalC A2 adenylation domain to accept both α-keto and -
hydroxy acid substrates is an evolved strategy to utilize the α-hydroxy acid monomer in order to 
mitigate the energy cost incurred in the re-activation and reduction of α-keto acid substrates that 
were released prematurely from the biosynthetic assembly line. This novel observation 
represents an additional mechanism by which microorganisms can utilize substrates in the 




8.0  HIDDEN OXIDATIVE DIVERSITY OF MICROCYCLAMIDE REVEALED BY 
PATHWAY REFRACTORING IN E. COLI: IMPLICATION THAT LATE-STAGE 
OXIDATIVE MATURATION OF THIAZOLE AND OXAZOLE IN CYANOBACTIN 
BIOGENESIS IS DIRECTIONAL AND PROCESSIVE 
Cyanobactins are ribosomally synthesized peptides from cyanobacteria that exhibit bioactivities, 
including antiviral, antimalarial, and anticancer properties [172, 173, 240]. Cyanobactin 
secondary metabolites are ubiquitous, as an estimated 30% of all cyanobacterial species produce 
these molecules [171, 240], evidence to their physiological and ecological significance. The 
mechanisms of their biosynthesis are of special interest because the machinery to produce 
compounds of this class of natural products is highly amenable to molecular engineering to 
generate combinatorial libraries with the potential for novel and enhanced bioactivities [185, 
221]. 
 
The microcyclamides and aerucyclamides are cyclic hexapeptidic cyanobactins from the 
cyanobacterium Microcystis aeruginosa [174, 209, 241] that have demonstrated cytotoxic 
activity [174, 209]. The biosynthetic pathway for microcyclamides and aerucyclamides (the mca 
operon) was previously characterized [197] and revealed this operon to share marked sequence 
similarity to the patellamide biosynthetic gene cluster, demonstrating that the microcyclamides 
and aerucyclamides are members of the cyanobactin family of secondary metabolites. 
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Recent genome sequencing of dozens of cyanobacterial strains have revealed that these 
microorganisms are capable of producing numerous secondary metabolites, most of which are 
cryptic but may serve as promising scaffolds for therapeutic compounds [171]. However, major 
challenges in accessing and investigating these molecules arise due to the genetic intractability of 
these organisms and the lack of genetic tools for their manipulation. To address the shortcoming 
toward the rapid characterization of biosynthetic pathways of cyanobacterial natural products, 
our research group has recently developed a designer plasmid that can rapidly assemble complete 
biosynthetic pathways (Refer to Plasmid Tools, Chapter 5). In this study, the mca biosynthetic 
pathway from M. aeruginosa PCC7806 was assembled and heterologously expressed. The 
systematic generation and expression of mca pathway mutants allowed for the determination of 
the genes essential in the biosynthesis of the microcyclamides. Furthermore, the heterologous 
expression of the mca operon revealed the generation of an unexpected diversity of oxidative 
patterns throughout the microcyclamide structures. The pattern of oxidation revealed that a 
directionality mechanism exists in the oxidation of azoline groups around the microcyclamide 
macrocycle. The findings of this study demonstrate that the heterologous expression and 
investigation of the mca gene cluster can reveal biosynthetic mechanisms that are significant in 
the maturation of azol(in)e-containing cyanobactins. 
8.1 MICROCYCLAMIDES GENE CLUSTER ORGANIZATION 
The microcyclamide biosynthetic pathway (mca) has been previously identified 
bioinformatically in two strains of M. aeruginosa, NIES298 and PCC7806 [197], and resembles 
the canonical cyanobactin biosynthetic pathway of the patellamides (Figure 8.1a). The mca 
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biosynthetic pathway affords three distinct precursor peptides that are encoded for by a single 
gene mcaE. Interestingly, there exists a duplicate copy for the peptide sequence for 
aerucyclamide A and B. The McaE precursor peptide (Figure 8.1b) is predicted to cleave at the 
N-terminus by McaA. McaG is then expected to both cleave the precursor peptide at the C-
terminus and macrocyclize the peptide. McaF shares sequence homology to PatF, a putative 
prenyltransferase, but its role is unclear in the biosynthesis of the microcyclamides. 







Figure 8.1 (a) Microcyclamide (mca) operon organization from M. aeruginosa PCC7806. (b) 
McaE precursor peptide sequences with residues presented in the microcyclamide or 
aerucyclamide structures highlighted; sequences highlighted in blue, green, and red correspond 
to structures 1/2, 3/5, and 4, respectively. (c) Microcyclamide and aerucyclamide structures 





Similar to the patellamides, the microcyclamides include serine, threonine, and cysteine 
residues that undergo heterocyclization via the PatD-like heterocyclase McaD to afford the 
corresponding azoline [197]. Following azoline formation, heterocycles undergo further 
oxidation by the PatG-like oxidase McaG to afford the azole. The directional sequence of azoline 
oxidation to the corresponding azole throughout the microcyclamide structure is still an 
unexplored aspect of cyanobactin maturation. 
8.2 SYSTEMATIC CLONING AND HETEROLOGOUS EXPRESSION OF THE 
MCA GENE CLUSTER 
The mca gene cluster was cloned from PCC7806 using a designer plasmid based on yeast 
recombineering, as described previously (Refer to Plasmid Tools, Chapter 5). Three expression 
plasmid constructs were generated (Figure 8.2a), containing the complete pathway (mcaA to G) 
or partial pathways (mcaADEGF and mcaADEG). As expected, expression of a plasmid 
containing the mcaA to mcaG operon resulted in the production of microcyclamides and 
aerucyclamides that have been previously characterized from M. aeruginosa PCC7806 (Figure 
8.2b). This observation also validates the utility of this designer plasmid and expression platform 
to rapidly assemble and characterize biosynthetic pathways. In addition to expression of the 
complete mca pathway, re-organized pathways consisting of the mcaADEG and the mcaADEFG 
pathways were explored to determine the genes essential for biosynthesis. Genes mcaB and C 
were deleted from the plasmid containing the wild type operon, as these homologs of unknown 
function were discovered to be non-essential for the maturation of cyanobactins [197, 221]. The 
restoration of microcyclamides production only after the introduction of mcaF to mcaADEG to 
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afford the mcaADEFG pathway (Figure 8.2b) demonstrates that mcaF is an essential gene in the 
mca biosynthetic pathway. McaF shares sequence homology to the prenyltransferase PatF. 
Although the function of the PatF-like protein in the maturation of cyanobactins is unclear [175], 
it has been shown to be essential in their biosynthesis. The restoration of microcyclamides 
production by introduction of mcaF, therefore, appears to be consistent with previous 




Figure 8.2 (a) Expression plasmid constructs of the mca operon to afford the complete pathway 
(mcaA to G) or partial pathways (mcaADEGF and mcaADEG). (b) Comparative LCMS analysis 
between the native producer M. aeruginosa PCC7806 and the heterologous expression of the 
mca constructs in E. coli. 
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8.3 UNEXPECTED DISCOVERY OF OXIDATIVE ANALOGS OF 
MICROCYCLAMIDES 
MS analysis of the microcyclamides revealed that these structures readily undergo fragmentation 
to yield MSMS spectra that further validated the characterization of the microcyclamides and 
aerucyclamides from the heterologous host E. coli compared to those from the native producer 
M. aeruginosa PCC7806. Characteristic (“fingerprint”) fragmentation ions were identified for 
each of the known microcyclamides. The fingerprint fragmentation ions for aerucyclamide A are 
highlighted in Figure 8.3a. Furthermore, LCMS data of the mcaABCDEFG metabolite 
expression profile revealed the co-elution of known microcyclamides in addition to compounds 
with nominal masses that differ by two Daltons. As an example, the high resolution MS for 
aerucyclamide A (nominal m/z value of 535) revealed the presence of an unknown compound 
with a nominal m/z value of 537 (Figure 8.3b). In addition, the predicted molecular formula 
from the high resolution accurate mass values for this putatively related compound suggested 
that it could contain two additional hydrogen atoms. As oxidation of the azoline groups is a 
major and shared feature amongst the microcyclamides, this led to the hypothesis that these 
unknown compounds may correspond to oxidative analogs that feature azoles in place of 
azolines or vice versa. To determine the structure of these compounds and their potential relation 
to the microcyclamides, the MSMS fragmentation patterns were characterized for known 
microcyclamides. Comparative MSMS fragmentation analysis between aerucyclamide A and the 
ion with m/z value of 537 revealed that this compound was an oxidative analog of aerucyclamide 
A containing two thiazoline groups instead of one thiazoline and one thiazole, as in the structure 





Figure 8.3 (a) MSMS spectrum of 3 with fingerprint ions enabled the structural characterization 
of the microcyclamide and aerucyclamide compounds. (b) MS spectrum of 3 revealed the 
presence of an ion corresponding to an analog with two additional Daltons. (c) MSMS of a 
chromatographic peak corresponding to both 3 and 3a revealed the preferential production of 3. 
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8.4 MCAG OXIDATION IS A DIRECTIONAL AND LATE-STAGE 
TRANSFORMATION 
Hypothetically, a microcyclamide structure containing one azole and one azoline ring could be 
arranged in one of two ways to afford analogs with identical molecular formulae. For example, 
the thiazole of aerucyclamide A could be situated in the position of the thiazoline ring and vice 
versa to afford two distinct oxidative analogs with identical molecular formulae. To determine 
the exact oxidative position of the azol(in)e rings around the microcyclamides macrocycles, 
these structures were characterized via comparative MSMS fragmentation using fingerprint ions 
determined for known structures. It was observed that indeed positional oxidative analogs (i.e., 
two analogs that contain an azole in one position and an azoline in the other) exist for each of the 
microcyclamides and aerucyclamides. It was further determined that the relative yields of each 
analog were not equivalent, suggesting that directional preference exists for oxidation around the 
macrocycle. To determine the oxidative preference, an average MSMS spectrum was obtained 
for the two analogs of interest, which co-elute via LCMS and present identical molecular 
formulae. Distinct fingerprint ions corresponding to their respective analogs were quantified 
from these average MSMS spectra, and the relative yield of each analog was estimated based on 
the ion counts of these fingerprint ions. A characteristic fingerprint ion for the average MSMS 
spectrum of aerucyclamide A and its oxidative analog are shown in Figure 8.3c. Based on ion 
counts, it was determined that there was approximately 6.5% of fragment A compared to 93.5% 
of fragment B, which correspond to the aerucyclamide A oxidative analog and aerucyclamide A, 
respectively. This suggests that oxidative preference exists for heterocycle adjacent to the 
glycine residues compared to that flanked by the two isoleucine residues of aerucyclamide A. 
 129 
The oxidative analogs of the other microcyclamide and aerucyclamide structures were also 




























Figure 8.4 (a) Oxidative directional analogs and the relative yields observed from heterologous 
expression of the mca operon in E. coli. (b) Proposed mechanism for the directionality of azoline 




Collectively, there are two trends that can be ascertained from the oxidative diversity of 
these microcyclamide and aerucyclamide analogs (Figure 8.5). First, oxidation of the thiazoline 
is preferred over that of the oxazoline, such as in the case of the microcyclamide 7806B analogs. 
Second, in structures containing two thiazol(in)e rings, the thiazoline adjacent to the glycine 




Figure 8.5 Proportion of oxidized analog pair 3 and 3b observed from heterologous expression 
of the mca operon over a period of 4 days. 
 
The generation of oxidative analogs of microcyclamide and aerucyclamide from the 
heterologous expression of the mca operon suggested that azoline oxidation is a late-stage 
transformation. Additional support for this claim arises from the observation of an aerucyclamide 
D analog that contains two thiazoline rings, which represents the reduced precursor to McaG 
oxidase activity to afford aerucyclamide D. To further support the hypothesis that McaG oxidase 
activity is a late-stage transformation, the relative production of aerucyclamide A and its reduced 
analog was analyzed from the heterologous mca operon expression over 2, 3, and 4 days (Figure 
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8.5). The quantity of aerucyclamide A relative to its reduced precursor was determined to be 
6.12% ± 0.54, 10.40% ± 0.89, and 18.67% ± 3.34 after 2, 3, and 4 days, respectively. The 
increased amount of aerucyclamide A detected from culture extracts over time is evidence that 
McaG-mediate oxidation is a late-stage transformation. 
8.5 DISCUSSION AND CONCLUSIONS 
Cyanobactins are a promising class of natural products that have the potential to be developed 
into medicines. They are a continuously growing class of molecules, with nearly 30% of all 
sequenced strains of cyanobacteria harboring gene clusters that encode the biosynthetic 
machinery for their production [171, 240]. Understanding the mechanisms of their biosynthesis 
is important, as previous research findings have shown that these pathways are highly amenable 
to genetic engineering to generate novel combinatorial products [185, 221]. However, there 
exists a major challenge in investigating these molecules, as techniques to genetically manipulate 
cyanobacteria are lacking. To address this gap in technology, a designer plasmid and expression 
platform has been established. This study has utilized this platform to rapidly assemble and 
express the microcyclamide (mca) gene cluster from M. aeruginosa PCC 7806. In addition, 
selective and systematic assembly of mca genes has enabled the identification of the minimal 
pathway essential to the biosynthesis of the microcyclamides and aerucyclamides. 
 
An unexpected discovery from the biosynthesis of the mca pathway was the generation of 
oxidatively diverse microcyclamides and aerucyclamides. Specifically, positional diversity of 
azoline ring oxidation to afford the azole was observed. Furthermore, two trends emerged from 
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the oxidative diversity of these microcyclamide and aerucyclamide analogs (Figure 8.4). First, 
oxidation of the thiazoline is preferred over that of the oxazoline, and second, in structures 
containing two thiazol(in)e rings, the thiazoline adjacent to the glycine residue is preferentially 
oxidized. The latter observation could arise from the structure of the active site being more 
accommodative to smaller amino acid side chains flanking the site of thiazoline oxidation. The 
preference for McaG-mediated oxidation of thiazoline over oxazoline could be a consequence of 
enhanced affinity of McaG to the thiazoline group over oxazoline. This is supported by the 
prevalence of cysteine residues presented in the hexapeptide sequences of the microcyclamides 
and aerucyclamides (ATVSIC, FTGCMC, ITGCIC). There is only one oxazole-forming residue 
(serine) of the six total azole-forming residues presented from the three distinct hexapeptides. 
There are also duplicate copies of the peptide sequence (ITGCIC) encoded in the mcaE gene that 
give rise to aerucyclamides A and B. If the predominance of thiazole-forming amino acids in the 
precursor peptide is an indication of enzymatic substrate selectivity, then the thiazoline group is 
likely the preferred substrate for the McaG oxidase. Schneider et al. demonstrated in vitro the 
capacity of a single oxidase domain from either the bleomycin or epothilone biosynthetic 
pathway to catalyze the formation of both oxazoline and thiazoline into their respective azoles 
[242]. While oxidase affinity was comparable for each azoline substrate, thiazole formation was 
nearly 10-fold faster over oxazoline formation. This was explained by the exclusive presence of 
thiazole moieties within the major congeners of bleomycin and epothilone biosynthesis, 
suggesting that thiazoline is the native substrate of these oxidases. In addition, thiazole formation 
is more thermodynamically favorable than oxazole formation [243], which may contribute to the 
increased presence of thiazole moieties in microcyclamide and aerucyclamide structures. 
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In addition to the directionality of azoline oxidation around the macrocycle, McaG-
mediated azoline oxidation was determined to be a late-stage process. McaG is a PatG-like 
homolog, and PatG is composed of two distinct domains with the N-terminus domain responsible 
for oxidoreductase function, while the C-terminus domain is responsible for proteolysis of the 
precursor peptide [175, 221]. The sequence of PatG-mediated azoline oxidation and precursor 
peptide proteolysis is unclear. Time course experiments of the heterologous expression of the 
mca biosynthetic pathway revealed a relative increase in the production of aerucyclamide A, 
compared to its reduced precursor (Figure 8.5), over time. This suggests that azoline oxidation is 
a late-stage transformation that follows McaG-mediated proteolysis of the precursor peptide. 
 
This investigation has demonstrated the utility of a novel designer plasmid to rapidly 
assemble and investigate cyanobacterial biosynthetic pathways. The biosynthetic gene cluster for 
the cyanobactin microcyclamide from M. aeruginosa PCC 7806 was studied using this platform. 
Heterologous expression of complete and mutant pathways established the genes essential for 
microcyclamides biosynthesis and also identified the McaG-mediated oxidation of azolines to 
azoles in microcyclamide structures to be a directional and late-stage transformation. This 
platform represents a genetic tool that can be utilized to characterize the biochemical 
mechanisms of other biosynthetic pathways from cyanobacteria. 
8.6 PART II: OUTLOOK AND FUTURE DIRECTIONS 
Traditional approaches to the discovery of natural products in the development of new drugs 
have proven limited in recent years. Notably, natural products discovery has hinged on the 
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development of compounds isolated via bioassay-guided techniques. The major drawback of this 
approach in microbial natural products discovery is the high rate of replication (i.e., 
“rediscovery” of known compounds)—in part, a result of horizontal gene transfer events that 
propagate secondary metabolite biosynthetic gene clusters amongst various microbial species. 
The consequence of this approach is the rapid decline in the rate of novel natural products 
discovered each year. A promising alternative relies on the utilization of genome sequencing 
information to identify orphan biosynthetic pathways predicted to produce novel natural products 
that may serve as scaffolds for next generation therapeutics. 
 
Cyanobacteria are a promising source of natural products and emerging genomic 
sequencing data reveals that these organisms dedicate a significant portion of their genome in the 
biosynthesis of secondary metabolites; however, platforms to investigate their biosyntheses are 
limited. The advances from Chapters 5 through 8 have established a cloning and heterologous 
expression system that can rapidly assemble entire gene clusters to correlate biosynthetic operons 
to their chemical products. A hallmark feature of this platform is its ability to rapidly generate re-
organized and mutant pathways. In this way, details into the investigation of biosynthetic 
mechanisms of cyanobacterial natural products could be explored, particularly in the case of the 
hapalosins and micro(aeru)cyclamides biosynthesis. 
 
A major step forward in advancing this platform will entail efforts to optimize the 
expression and production of such secondary metabolites. This would facilitate the discovery of 
novel secondary metabolites from orphan gene clusters of cyanobacteria and accelerate current 
understanding of the biological and ecological significance of these molecules and how they can 
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be developed into medicines and other useful chemicals. However, it is worth noting that 
expression optimization can be a complex and challenging task, requiring precise control of 
numerous parameters (e.g., substrate availability, gene expression, growth conditions). 
Nonetheless, the significance of this source of natural products justifies the need to explore this 





SUPPORTING INFORMATION FOR CHAPTER 2 
A.1.1 Materials and General Procedures 
Synthetic oligonucleotides for gene amplification by PCR were purchased from Life 
Technologies or Integrated DNA Technology. Kapa HiFi DNA polymerase was obtained from 
Kapa Biosystems. Restriction endonucleases and Antarctic phosphatase were purchased from 
New England BioLabs. LB broth and agar used for bacteria culture were obtained from Teknova. 
Antibiotics were obtained from Gold Biotechnology and Chem-Impex International. DNA 
sequencing was performed by Elim BioPharm Inc. 
A.1.2 Bacteria strains and culture conditions 
All plasmid cloning steps were implemented using E. coli TOP10 (Invitrogen) and XL1-Blue 
(Stratagene) strains. Yeast recombineering experiments were implemented using the yeast 
recombineering strain VL6-48N. A. baumannii strain ATCC17978 were used for all mutant 
generation and phenotypic analysis experiments. All bacteria strains were grown at 37°C in LB 
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broth with gentle shaking for aeration. Yeast were grown at 30°C in YPD media with gentle 
shaking. When needed, gentamicin and kanamycin were used at concentrations of 10µg/mL and 
50µg/mL for E. coli, respectively, and at concentrations of 50µg/mL for A. baumannii. 
A.1.3 General procedures for plasmid construction via yeast recombineering 
The protocol for yeast-assisted recombination to generate plasmid constructs was adapted from a 
previously reported procedure. [74] DNA fragments of interest were introduced together with 
SmaI-digested parent plasmid (either pMQ30 for the suicide vector plasmid or the pAB1 for 
expression plasmids), the PCR amplicons were transformed into yeast strain VL6-48N. 
Following transformation, the yeast were plated in uracil-deficient SC agar plates and allowed to 
grow for 3 to 4 days. Following the growth period, all yeast colonies were collected and 
combined, then plasmid was isolated and transformed into E. coli TOP10 (Invitrogen). 
Transformed E. coli TOP10 were then selected on LB agar plates containing gentamicin. 
Individual colonies were grown in liquid culture and plasmid was isolated and subsequently 
analyzed via restriction enzyme digest analysis to obtain the desired plasmid construct. 
A.1.4 Mutant Generation 
The protocol used for kanamycin disruption mutant generation was adapted from a previously 
reported procedure. [73] The kanamycin resistance cassette was amplified from pCR®-Blunt II-
TOPO® vector (Thermo Fisher Scientific). Briefly, primers catAUpFw and KMupintRV were 
used to amplify approximately the first 500bp of gene catA, and primer pair catADwnRV and 
KMdwintFW were used to amplify the last 500bp of gene catA. Additionally, primer pair 
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catAUpFw and catADwnRV were used to amplify the kanamycin resistance cassette from pCR-
BluntII-TOPO vector (Invitrogen) as template. Primers FWnest and DWnest were used for 
nested OE-PCR using the following condition: 94°C for 15 s, 40°C for 1 min, 72°C for 2 min (10 
cycles); 94°C for 15 s, 55°C for 1 min, 72°C for 3 min (20 cycles), and a final extension at 68°C 
for 10 min. 5µg of the overlap-extended PCR product was purified using isopropanol 
precipitation and subsequently transformed into electrocompetent A. baumannii ATCC17978. 
Transformed cells were recovered in SOC for 1hr at 37°C and plated on LB agar containing 
kanamycin. The following day, kanamycin-resistant clones were verified for correct allele-
exchange by PCR using primers catAUpFW and KmRV as well as catADwnRV and KmFW. 
Clones generating PCR products consistent with the correct kanamycin mutant allele were 
further verified by DNA sequencing. 
 
The protocol used to generate markerless in-frame deletion mutants was adapted from a 
previously reported procedure. [244]
 
The suicide plasmid vector to delete the catA gene was 
constructed using the yeast-assisted recombination protocol described above.
 
Primers 
catAKO1FW and catAKO1RV were used to amplify approximately 500bp upstream of gene 
catA, and primers catAKO2FW and catAKO2RV were used to amplify approximately 500bp 
downstream of gene catA. These were introduced into the SmaI restriction site of pMQ30 and 
introduced to yeast. The resulting mixture of plasmid constructs was isolated from yeast and 
introduced to E. coli TOP10. Desired plasmid constructs were screened from E. coli TOP10 
clones via restriction enzyme digest analysis. The desired plasmid construct to delete the catA 
gene was transformed into electrocompetent wildtype A. baumannii ATCC17978 cells, allowed 
to recover in SOC media at 37°C for 1hr, and plated on LB agar plates containing gentamicin. 
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The following day, single colonies were re-streaked on LB agar plates containing gentamicin to 
ensure stable integration of the suicide vector. Stable gentamicin-resistant clones were then 
allowed to grow on LB agar plates without antibiotic at 25°C for 2 days to allow loss of the 
suicide plasmid. Single clones were then streaked on LB agar plate containing sucrose (5% 
(w/v)) and no NaCl. Sucrose-resistant clones were screened by PCR (using primers 
catAKOValidationFW and catAKOValidationRV) for the desired in-frame deletion of catA. 
A.1.5 Construction of A. baumannii Expression Plasmids 
The A. baumannii-E. coli-S. cerevisiae shuttle vector and derivatives thereof were constructed 
via yeast recombineering.
 
Primers WH1266ORIFW and WH1266ORIRV were used to clone the 
origin of replication sequence from an A. baumannii replicable plasmid pWH1266 [245]. The 
PCR amplicon containing the A. baumannii replicon was introduced into the AatII and SfiI site 
of plasmid pMQ124, yeast recombineered, and the desired plasmid pXLAB1 was obtained as 
described above. 
 
The LacZ reporter plasmid was constructed via yeast recombineering. The full length 
lacZ gene was cloned via PCR using primers LacZFW and LacZRV from a pMQ131-derived 
plasmid containing the full length lacZ gene [203]. The amplicon was introduced into the SmaI 
site of plasmid pXLAB1 and the desired construct pXLAB2 was obtained by screening via 
restriction enzyme digest analysis. 
 
The abaR, catA, and catABCDEFGH with sfp expression plasmids were all constructed 
via yeast recombineering. The desired amplicons were all introduced into the SmaI site of 
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plasmid pXLAB1 to generate their corresponding construct. Primers abaRFW and abaRRV were 
used for amplification of abaR. catAFW and catARV were used for amplification of gene catA. 
The full cat pathway was assembled by amplifying five 3.5kb fragments with approximately 
500bp overlapping regions between each adjacent fragment. The sfp gene was also PCR 
amplified and co-introduced immediately downstream of the PBAD promoter. Primers 
sfp_RBS_FW and sfp_RBS_RV were used to clone the sfp gene. Fragments 1 through 5 were 
PCR amplified using the following pairs of primers, respectively: catFULL1FW/catFULL1RV, 
catFULL2FW/catFULL2RV, catFULL3FW/catFULL3RV, catFULL4FW/catFULL4RV, 
catFULL5FW/catFULL5RV. 
A.1.6 LacZ reporter assays 
A. baumannii overnight liquid culture (0.1mL)  supplemented with arabinose (1% (w/v)) was 
added to buffer Z (0.9mL of 113mM Na2HPO4, 40mM NaH2PO4-H2O, 10mM KCl, 1mM 
MgSO4-7H2O, 0.0028% (v/v) β-mercaptoethanol, pH 7.0 per 500mL H2O), sodium dodecyl 
sulfate (20µL, 0.1% (w/v)), and chloroform (50µL). After adding all components, the mixture 
was vortexed at room temperature (2 min). Following vortexing, o-nitrophenyl-β-D-galactoside 
(0.2mL, 4 mg/mL in water) was added and allowed to incubate at room temperature (30 min). 
After incubation, Na2CO3 (0.5mL, 1M) was added. The reaction mixture was vortexed briefly, 
left at room temperature (5min), and diluted with an equal volume of buffer Z. The absorbance 
of the reaction mixture was then measured at 420nm. β-galactosidase activity (A420nm) was 
normalized to the OD600 measured from the A. baumannii overnight liquid culture. 
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A.1.7 Motility Assays 
The procedure for executing motility assays was adapted from a previously reported protocol. 
[65] Briefly, agar plates were prepared using BD Difco Nobel agar (Sparks, M.D., U.S.) at 0.3% 
(w/v) concentration in water containing 1% (w/v) tryptone. When necessary, gentamicin 
(25µg/mL), arabinose (1% (w/v/)), and 3-OH C12-HSL (250nM) were supplemented. Plates were 
inoculated by dipping a flat-ended wooden stick into a culture grown overnight and gently placed 
on the surface of the agar. Plates were incubated for 24 to 48hr at 37°C and observed for 
motility. 
A.1.8 Horse blood agar hemolysis and colony morphology 
5% (v/v) of defibrinated horse blood agar plates were obtained pre-prepared from Benton-
Dickinson (BD) company (Franklin Lakes, N.J., U.S.). To assess hemolysis, 3µL of overnight 
liquid culture of A. baumannii was pipetted onto horse blood agar plates and incubated at 37°C 
for 48 to 72hr. Both horse blood hemolysis and colony morphology were observed following 
incubation. 
A.1.9 Desiccation Resistance 
This assay was adapted from a previously reported procedure. [246] Overnight liquid cultures of 
A. baumannii were diluted 100-fold and allowed to grow to OD600 = 0.5. This liquid culture was 
diluted further 10- for the desiccation assay. 1µL of each diluted culture was spotted onto filter 
paper in a sterile petri dish, then incubated at 37°C for 24hrs. Desiccated A. baumannii inoculum 
 143 
were then recovered on tryptic soy agar plates and allowed to grow overnight. Desiccation 
resistance and sensitivity phenotypes were then observed after overnight growth. 
A.1.10 Wax Moth G. mellonella Cytotoxicity 
A. baumannii virulence against the wax moth larvae G. mellonella was executed using a 
procedure previously reported. [89]
 
In this procedure, overnight liquid culture of A. baumannii 
were serially diluted by 10-fold and resuspended in PBS buffer. 10μL volume inoculum of each 
diluent was introduced to the wax worm larvae and allowed to incubate at 37°C for up to 96hr. 
After each 24hr period, the number of surviving larvae was quantified to assess virulence of each 
A. baumannii strain against G. mellonella. The percent survival was calculated against a negative 
control G. mellonella group subjected to PBS buffer only. 
A.1.11 Heat Shock Viability 
A previously reported procedure was adapted for these experiments. [246] Overnight liquid 
culture of A. baumannii strains were diluted 100-fold in LB media and allowed to grow to OD600 
= 1.0. When the appropriate cell density was reached, A. baumannii liquid culture was heated to 
55°C in a heat block for 10 minutes; the number of viability cells was counted before heating and 
after heating for 10 minutes. Viable cells were counted by serial dilution of the heated culture by 
10-fold increments and plating the dilutions onto tryptic soy agar plates. The percent viability 
was normalized to the initial number of viable cells (i.e., without heating). 
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A.1.12 Reverse Transcriptase (RT) PCR Analysis 
To obtain cells for RNA extraction, cultures were first inoculated into 3 mL of LB medium.  The 
cultures were grown overnight in LB medium, subcultured to OD600 = 0.05, grown to OD600 = 
0.6.  RNA was isolated from A. baumannii cells using an RNeasy kit (Qiagen).  RNA was 
treated first with an on column DNase I treatment (Qiagen), followed by 2 U of RQ1 DNase 
(Promega) for 30 min at 37°C, followed by a second purification using a Zymo RNA cleanup kit. 
RNA was normalized to 100 ng/µl using DNase-free water and 5 µl was used in each reverse 
transcriptase (RT) reaction to generate cDNA using Superscript III RT (Invitrogen) following the 
manufacturers specifications. A PCR reaction with a 94°C hold for 5 minutes, followed by 28 
cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 30 seconds at 72°C, followed by a 72°C 
hold for 7 minutes was used to detect the amount of transcript. The 16S rRNA gene was used as 
a control. 
A.1.13 Generation and Verification of ∆catA::Km and ∆catA mutants 
To verify the correct generation of mutants, colony PCR was implemented to yield PCR products 
consistent with the expected mutant region. To screen for correct ∆catA::Km mutants, two sets 
of primers were designed. For each pair, one anneals to the kanamycin resistance cassette and the 
other anneals to the chromosome of the A. baumannii strain, yielding two PCR products of 
approximately 1.5kb in size. The relative locations of these primers are denoted by the blue and 
red arrows in Figure A1. Therefore, the wildtype locus does not yield any PCR products with 
this primer design, while two PCR products can be obtained from the mutant. 
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The in-frame deletion mutant was screened using PCR primers complementary to regions 
flanking the deleted gene. The relative location of these primers are indicated by the purple 
arrows in Figure A2. Therefore, the wild type locus yields a larger PCR product of 
approximately 2.5kb, while the in-frame deleted gene yields a PCR product of approximately 
1.0kb. All mutants  
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Figure A1 Disruption mutant ∆catA::Km was generated by introduction of a kanamycin 





















Figure A2 Markerless in-frame deletion mutant ∆catA. The suicide plasmid vector contains an 
origin of replication for E. coli (ColE1), a counterselectable sacB gene which confers toxicity to 






Figure A3 PCR products obtained from colony PCR of ∆catA::Km and ∆catA mutants. The 
expected PCR products for each mutant are listed on the left. Lanes “L” contained the reference 
DNA ladder. 
 
 L      1     2     3      4 L       5     6 




1 ATCC17978 WT None 
2 ATCC17978 WT None 
3 ∆catA::Km 1548 bp 
4 ∆catA::Km 1376 bp 
5 ATCC17978 WT 2525 bp 



















Figure A4 RT-PCR analysis of wildtype and mutants ∆catA and ∆catA::Km. Transcription of 
genes catA, catB, catD, catE, catF, catH, and the housekeeping (control) 16S rRNA gene were 
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Table A1 Plasmids used in this study 
Plasmid Major features Reference 
pMQ124 oriColE1/pRO1600, aacC1, PBAD-lacZα, CEN6
 [74] 
pXLAB1 pMQ124[74] derivative containing ori from A. calcoaceticus This work, [245] 
pXLAB2 pAB1 containing full length LacZ gene under PBAD control This work 
pXLAB3 Suicide vector; contains approx. 500bp flanking regions of catA gene. This work 
pXLAB4 pAB1 containing catA gene at SmaI position This work 
pXLAB5 pAB1 containing abaR gene at SmaI position This work 
pXLAB6 pAB1 containing sfp and catABCDEFGH This work 
 
 
Table A2 Primers used in this study 
Primer name Sequence Application 




5’ primer to clone kanamycin resistance 
cassette for OE-PCR 




3’ primer to clone kanamycin resistance 
cassette for OE-PCR 
FWnest TCGTTCTTTGCCTGTCTGAA 5’ primer for nested OE-PCR 
DWnest ACCGTTCTACGGTTTGGATG 3’ primer for nested OE-PCR 
KmFW CCGGAATTGCCAGCTGGG 5’ primer to clone kanamycin resistance 
KmRV TTCAGAAGAACTCGTCAAG 3’ primer to clone kanamycin resistance 
catAKO1FW TTGCATGCCTGCAGGTCGACTCTAGA 5’ primer to clone 500bp upstream catA 
catAKO1RV 
TGATCATTGAGTTTTCGAACAGCAAT




5’ primer to clone 500bp downstream 
catA 
catAKO2RV AGCTATGACCATGATTACGAATTCGA 






























ATTAC 3’ primer to clone abaR 
catAKOValidationFW TGCGCGTATCTAAATTAAG 
5’ primer to validate in-frame deletion of 
catA 
catAKOValidationRV TCACAGACCAAGCATTCGT 





5’ primer to clone sfp gene and introduce 
RBS 
sfp_RBS_RV TTATATCCTCCTACGGGTATGGAGAAT 





5’ primer to clone first 3.5kb fragment of 
the full cat gene cluster 
catFULL1RV CGGCATAGTCACGGGCGA 
3’ primer to clone first 3.5kb fragment of 
the full cat gene cluster 
catFULL2FW TCGCTTGCCAAAATCACATCC 
5’ primer to clone second 3.5kb fragment 
of the full cat gene cluster 
catFULL2RV TTCGCCAGTGGTTCACCTAAA 
3’ primer to clone second 3.5kb fragment 
of the full cat gene cluster 
catFULL3FW ATGATAGATTGCAAGTAACGAC 
3’ primer to clone third 3.5kb fragment of 
the full cat gene cluster 
catFULL3RV ACACCATAACCGGACCCACACG 
3’ primer to clone third 3.5kb fragment of 
the full cat gene cluster 
catFULL4FW CGTAGAAAGCGAACAATCTAA 
3’ primer to clone fourth 3.5kb fragment 
of the full cat gene cluster 
catFULL4RV TACACGCCTACTAAACTCAGC 
3’ primer to clone fourth 3.5kb fragment 
of the full cat gene cluster 
catFULL5FW GATTCCATTGCGTCAGATTGCT 3’ primer to clone fifth 3.5kb fragment of 
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3’ primer to clone fifth 3.5kb fragment of 








TCAG 3’ primer to clone catA 
RTcatAFW GTGCGTGTGCTGTTTAATG 5’ primer for RT-PCR of catA 
RTcatARV CTTCATTAAGGATCGTTGCTTC 3’ primer for RT-PCR of catA 
RTcatBFW AGTACATGGTCACCAATCGTCAA 5’ primer for RT-PCR of catB 
RTcatBRV TCAGCCATGCACCATTCTGTAAA 3’ primer for RT-PCR of catB 
RTcatDFW ATTTCCTGAGCCGATCTTTGA 5’ primer for RT-PCR of catD 
RTcatDRV CTTCAGGTACATTTTCTGGAATT 3’ primer for RT-PCR of catD 
RTcatEFW AGTGTATTTGCAACCTTAATTATG 5’ primer for RT-PCR of catE 
RTcatERV AGTATGCACATACGACGTTTG 3’ primer for RT-PCR of catE 
RTcatFFW CGCGTAGTCGTTCAGATGTGATTCC 5’ primer for RT-PCR of catF 
RTcatFRV CGATCTCCGCCTGCATTCAACT 3’ primer for RT-PCR of catF 
RTcatHFW AAGATGGGCATCACAGACCTG 5’ primer for RT-PCR of catH 
RTcatHRV GCTTAGACACTGACATGCGGC 3’ primer for RT-PCR of catH 
RT16SFW ATGAAGTCTGTTTTATCAGATAAG 5’ primer for RT-PCR of 16S rRNA 




SUPPORTING INFORMATION FOR CHAPTER 3 
B.1.1 General Materials 
Synthetic oligonucleotides for gene amplification by PCR were purchased from Life 
Technologies or Integrated DNA Technology. Kapa Robust 2G DNA polymerase was obtained 
from Kapa Biosystems. Restriction endonucleases and Antarctic phosphatase were purchased 
from New England BioLabs. LB broth and agar used for bacteria culture were obtained from 
Teknova. Antibiotics were obtained from Gold Biotechnology and Chem-Impex International. 
Polyvinyl chloride plastic 96-well plates were purchased from Corning. DNA sequencing was 
performed by Elim BioPharm Inc. P. aeruginosa PAO1 laboratry strain and plasmids pMQ124 
and pMQ30 were generously donated by the research laboratory of Professor Robert Shanks of 
the Ear and Eye Institute at the University of Pittsburgh Medical Center. 
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B.1.2 Bacteria strains and culture conditions 
All plasmid cloning steps were implemented using E. coli TOP10 (Invitrogen). Yeast 
recombineering experiments were implemented using the yeast recombineering strain VL6-48N. 
The common laboratory strain P. aeruginosa PAO1 was used for all mutant generation and 
phenotypic analysis experiments. All bacteria strains were grown at 37°C in LB broth with 
gentle shaking for aeration. Yeast were grown at 30°C in YPD media with gentle shaking. When 
needed, gentamicin was used at concentrations of 10µg/mL for E. coli and at concentrations of 
50µg/mL for P. aeruginosa. 
 
B.1.3 General procedures for plasmid construction via yeast recombineering 
DNA fragments of interest (generated by PCR amplification) were introduced together with 
SmaI-digested parent plasmid (either pMQ30 for the suicide vector plasmid or pMQ124 for 
expression plasmids), the PCR amplicons were transformed into yeast strain VL6-48N. 
Following transformation, the yeast were plated in uracil-deficient SC agar plates and allowed to 
grow for 3 to 4 days. Following the growth period, all yeast colonies were collected in 1mL of 
TE buffer, then plasmid was isolated and transformed into E. coli TOP10. Transformed E. coli 
TOP10 were then selected on LB agar plates containing gentamicin. Individual colonies were 
grown in liquid culture and plasmid was isolated and subsequently analyzed via restriction 
enzyme digest analysis to obtain the desired plasmid construct. 
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B.1.4 ΔcptAB mutant generation 
The suicide plasmid vector to delete the cptAB genes was constructed using the yeast-assisted 
recombination protocol described above. Primers cptABKO1FW and cptABKO1RV were used 
to amplify approximately 500bp upstream of genes cptAB, and primers cptABKO2FW and 
cptABKO2RV were used to amplify approximately 500bp downstream of genes cptAB. These 
were introduced into the SmaI restriction site of pMQ30 and transformed into yeast. The 
resulting mixture of plasmid constructs was isolated from yeast and introduced to E. coli TOP10. 
Desired plasmid constructs were screened from E. coli TOP10 clones via restriction enzyme 
digest analysis. 
 
To prepare electrocompetent cells, 6mL of wildtype PAO1 was grown in LB overnight at 
37°C. The following day, the overnight culture was washed three times with sterile sucrose 
solution (500mM) at room temperature. Approximately 1μg of the suicide vector was mixed with 
the electrocompetent cells and allowed to recover in LB media at 37°C for 1hr. The transformed 
cells were plated on LB agar plates containing gentamicin and allowed to grow overnight at 
37°C. 
 
The following day, stable gentamicin-resistant clones were then allowed to grow on LB 
agar plates without antibiotic at 25°C for 2 days to allow loss of the suicide plasmid. Single 
clones were then streaked on LB agar plate containing sucrose (5% (w/v)) and no NaCl. Sucrose-
resistant clones were screened by PCR (using primers cptABKOValidationFW and 
cptABKOValidationRV) for the desired in-frame deletion of catA. The wildtype PAO1 yielded 
an amplicon that was 4780bp in size, and the ΔcptAB mutant yielded an amplicon that was 
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1912bp in size (Figure B1). Mutant clones identified by colony PCR were sequence verified 
using primers cptABKOValidationFW / cptABKOValidationRV and cptABKOValidation2FW / 
cptABKOValidation2RV. 
B.1.5 Construction of the cptAB complementation plasmid 
The cptAB complementation plasmid was constructed via yeast recombineering, as described 
above. Primers cptAB1into124_FW / cptAB1into124_RV and cptAB2into124_FW / 
cptAB2into124_RV were used to amplify the two fragments that contained the entire cptAB 
locus. Primers were designed such that fragments recombining with the backbone of the plasmid 
overlap by approximately 60 nucleotides. PCR amplicons that recombine with each other overlap 
with one another by approximately 100 nucleotides. Restriction enzyme digest verification of 
this plasmid is shown in Figure B2. 
B.1.6 Twitching motility 
The bacteria were stabbed through an agar layer of LB (1% agar) to the bottom of the Petri dish 
and incubated for 48hr at 37°C and then left at 25°C for 24hr. Following incubation, the agar was 
carefully cut around the edges of the plate and removed. After removal of the agar, crystal violet 
(1% (w/v), ethanol solution) was used to stain attached cells and the radius was determined for 
the wildtype and mutant strains. All motility assays were performed in triplicate. 
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B.1.7 Colony Morphology 
The colony morphology of P. aeruginosa strains were observed from the twitching motility LB 
agar plates that were prepared above. After incubation of the stab-inoculated LB agar plates at 
37°C for 48hr, the colony morphologies were observed for autolysis. 
B.1.8 Abiotic Biofilm Formation 
Overnight cultures of P. aeruginosa were diluted 1000-fold in LB media containing the 
appropriate antibiotics. 100μL volume aliquots of the diluted inoculum were pipetted into wells 
of a polyvinyl chloride 96-well plate. The plate was then covered with a sterile Kimwipe and 
placed in a sealed bag containing a damp paper towel. The plates were then incubated at 30°C for 
18hr under static conditions. 
 
The following day, bacterial growth was assessed by measuring the optical density (OD) 
at 600nm using a plate reader (Molecular Devices SpectraMax 340). The overnight bacteria 
cultures from the 96-well plate were decanted and washed 10 times with nanopure water to 
ensure all planktonic bacteria were discarded from the wells. Then, 125μL of 1% (w/v) crystal 
violet in ethanol solution was introduced into each well and allowed to incubate for 20-30 
minutes at room temperature under static conditions. Following the CV stain, the wells were 
decanted of all stain and washed 10 times with nanopure water to ensure all CV not associated 
with biofilm was removed from the wells. Following the post-CV stain wash, 100μL of aqueous 
1% (w/v) SDS was pipetted into each well and allowed to shake gently for 20-30 minutes at 
room temperature, until all biofilm-associated CV was solubilized. CV concentration was then 
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assessed by measuring the absorbance of each well at 540nm. Biofilm formation was compared 
between each P. aeruginosa sample by normalizing the CV response (A540nm) by bacteria 
growth (OD600nm). 
 
Table B1 Primers used in this study 




Clone ~500bp flanking sequence 




Clone ~500bp flanking sequence 




Clone ~500bp flanking sequence 




Clone ~500bp flanking sequence 




Clone fragment #1 of cptAB into 
pMQ124 
cptAB1into124_RV acaatgcaggtcggcctc 
Clone fragment #1 of cptAB into 
pMQ124 
cptAB2into124_FW atttcagccgccccacgg 





Clone fragment #2 of cptAB into 
pMQ124 
cptABKOValidationFW tccgccatagtcgtattcccag Validate mutant generation 
cptABKOValidationRV tattgccggatgccctgacg Validate mutant generation 
cptABKOValidation2FW ccccgctcgatacgctgaaaaac Validate mutant generation 




Figure B1 Colony PCR screening of identified ΔcptAB mutant (left lane), compared to PAO1 
wildtype. Primers used for colony PCR: cptABKOValidationFW and cptABKOValidationRV 
 
Figure B2 Restriction enzyme digest analysis for cptAB plasmid. Either PvuII (left) or NotI and 
NcoI (right) were used to verify the assembly of these expression plasmids. 
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APPENDIX C 
SUPPORTING INFORMATION FOR CHAPTER 5 
C.1.1 General methods and materials 
PCRs were executed using a C1000 thermal cycler (Bio-Rad). HRMS analysis was conducted 
using a Q Exactive Benchtop Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific) 
equipped with a Luna® 5 µm C18(2), 100 Å, 250 x 4.6 mm LC Column (Phenomenex). All MS 
experiments utilized electrospray ionization modes for analysis. Synthetic oligonucleotides for 
gene amplification by PCR were purchased from Life Technologies or Integrated DNA 
Technology. Kapa HiFi DNA polymerase was obtained from Kapa Biosystems. Plasmid DNA 
purification was executed using column purification kits obtained from either SydLabs or 
Qiagen. Restriction endonucleases and Antarctic phosphatase were purchased from New 
England BioLabs. LB broth and agar used for culturing E. coli were obtained from Teknova. All 
E. coli strains were cultured in LB media supplemented with antibiotics kanamycin (50 µg/mL), 
gentamicin (10 µg/mL), and tetracycline (10 µg/mL), when necessary. Biosynthetic precursor 
substrates were introduced to cultures at the time of induction at the following final 
concentrations (when necessary): 5mM for halogenated phenylalanine substrates, 1mM for 
homo-L-tyrosine, and 1mM mevalonate. Homo-L-tyrosine was purchased from Combi-Blocks. 
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p-Chlorophenylalanine and p-fluorophenylalanine were purchased from Chem-Impex 
International. All cyanobacterial genomic DNA were acquired from Professor David Fewer’s 
research laboratory (University of Helsinki). Plasmid pMBI was acquired from Professor Jay 
Keasling’s research laboratory (University of California, Berkeley). LaserGene SeqBuilder 
(DNAStar) software was used for all in silico plasmid DNA sequence manipulation. 
 
Table C1 Primers used in this study 
Primer name Sequence Purpose 
age_frag1_5'_toMQ123i cgagctcggtacccggggaaggagatatacatatgctagatagattac
atac 
1-step cloning of age pathway 
(fragment #1) 
age_frag1_3' ctgtttattaatcttggcg 1-step cloning of age pathway 
(fragment #1) 
age_frag2_5' ctttacggcagcctgtaacc 1-step cloning of age pathway 
(fragment #2) 
age_frag2_3' gagggctggcattgtcatc 1-step cloning of age pathway 
(fragment #2) 
age_frag3_5' ctctatatatcacaggtctttttg 1-step cloning of age pathway 
(fragment #3) 
age_frag3_3' gttcactgagttgttctatg 1-step cloning of age pathway 
(fragment #3) 
age_frag4_5' ttgaacagtggtctgactttcc 1-step cloning of age pathway 
(fragment #4) 




1-step cloning of kaw pathway 
(fragment #1) 
kaw_frag1_3' TTACTTCAGCAAAGAGCCACG 1-step cloning of kaw pathway 
(fragment #1) 
kaw_frag2_5' CTGGCGGTCGATGTAGTTC 1-step cloning of kaw pathway 
(fragment #2) 
kaw_frag2_3' CTGTTCGGGGATGCACAC 1-step cloning of kaw pathway 
(fragment #2) 








1-step cloning of spu pathway 
(fragment #1) 
123i_spu_Fg1_RV atcatcccacatactccaac 1-step cloning of spu pathway 
(fragment #1) 
123i_spu_Fg2_FW CATCAATTAGCAAAAGAAAATCAG 1-step cloning of spu pathway 
(fragment #2) 
123i_spu_Fg2_RV CAGCAGTAGTTTCGGGACG 1-step cloning of spu pathway 
(fragment #2) 
123i_spu_Fg3_FW aatccacggtgacggctac 1-step cloning of spu pathway 
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(fragment #3) 
123i_spu_Fg3_RV catcaaatcggctaatatcatag 1-step cloning of spu pathway 
(fragment #3) 
123i_spu_Fg4_FW ccagaggaacgtctttatttg 1-step cloning of spu pathway 
(fragment #4) 
123i_spu_Fg4_RV ctcgatggtgctatggtc 1-step cloning of spu pathway 
(fragment #4) 
123i_spu_Fg5_FW cctctattccaagtcatgtttaac 1-step cloning of spu pathway 
(fragment #5) 





2-step cloning of apn pathway 
(2nd step) 
apnA_fg1_RV ttgacttgttcttcaaagag 
2-step cloning of apn pathway 
(2nd step) 
apnA_fg2_FW gaaggaattacgatggtttg 
2-step cloning of apn pathway 
(2nd step) 
apnA_fg2_RV tgactgaccatttgcagagg 
2-step cloning of apn pathway 
(2nd step) 
apnB_FW gaagatatttattctctctc 
2-step cloning of apn pathway 
(2nd step) 
apnB_RV_into_apnC atgtatatctccttccccgggtaccgagtcataaaaataattgttgtg 





2-step cloning of apn pathway 
(1st step) 
apnCD_fg1_RV 
3'  AAGTTATCCCGACGACCCAC 2-step cloning of apn pathway 
(1st step) 
apnCD_fg2_FW 
CATGATTCCAAGTCAGATTATGATC 2-step cloning of apn pathway 
(1st step) 
apnCD_fg2_RV 
ACTGGGAACAATATAGGCGAC 2-step cloning of apn pathway 
(1st step) 
apnCD_fg3_FW 
AGGAGACTTAGCTAAATGGCGAAC 2-step cloning of apn pathway 
(1st step) 
apnCD_fg3_RV 
CTTCTAAACAAGTTTGACGAGTTTGC 2-step cloning of apn pathway 
(1st step) 
apnCD_fg4_FW 










C.1.2 Plasmid construction 
Cyanobacterial biosynthetic constructs were either assembled in a single cloning step or 
stepwise. PCR amplicons were generated using cyanobacterial genomic DNA as template, unless 
otherwise specified. The following biosynthetic pathways contained in pMQ123i were 
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constructed in a single step: ageABCDEFG, kawABCDEFG, mcaABCDEFG, mcaADEFG and 
spuAB. Details for the construction of the mcaABCDEFG, mcaADEFG, and mcaADEG 
pathways are described in Microcyclamide Chapter 8. The kaw pathway was assembled as 
three separate fragments that were amplified using the following primers, respectively: kaw_ 
frag1_5'_toMQ123i / kaw_ frag1_3', kaw_ frag2_5 '/ kaw_ frag2_3', kaw_ frag3_5'/kaw_ 
frag3_3'. The spu pathway was assembled as five separate fragments that were amplified using 
the following primers, respectively: 123i_spu_ Fg1_FW / 123i_spu_ Fg1_RV, 123i_spu_ 
Fg2_FW / 123i_spu_ Fg2_RV, 123i_spu_ Fg3_FW / 123i_spu_ Fg3_RV, 123i_spu_ Fg4_FW / 
123i_spu_ Fg4_RV, 123i_spu_ Fg5_FW / 123i_spu_ Fg5_RV. 
 
The following biosynthetic pathways contained in pMQ123i were constructed in two 
steps: mcaADEF, mcaADEFG, apnABCD, and halABCDE. Details for the construction of the 
complete hal pathway are described in Hapalosin Chapter 6. Details for the construction of the 
mca pathways are described in Microcyclamide Chapter 8. The apnABCD pathway was 
constructed by first generating the apnCD construct in pMQ123i. Four fragments corresponding 
to genes apnCD were generated via PCR using the following primers to recombineer at the 
HindIII and SpeI sites of pMQ123i: apnCD_fg1_FW_into_123i/apnCD_fg1_RV, 
apnCD_fg2_FW / apnCD_fg2_RV, apnCD_fg3_FW / apnCD_fg3_RV, apnCD_fg4_FW / 
apnCD_fg4_RV_into123i. The apnAB genes were subsequently cloned using primers 
apnA_fg1_FW_into_123i/apnA_fg1_RV and apnA_fg2_FW/apnA_fg2_RV, generating three 
fragments, which were cloned at the Eco53kI restriction site of the apnCD plasmid construct. 
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PCR amplification of fragments was performed using an annealing temperature gradient 
that ranged from 55°C to 65°C. PCR conditions were as follows: 95°C initial denaturation for 
3:00min, 98°C denaturation for 20sec, 55°C to 65°C annealing for 15sec, 72°C extension for 1 
min per 1kbp, and 72°C final extension for 5:00min. The denaturation, annealing, and extension 
steps were performed a total of 35 times. Volume per PCR reaction was 10µL. The PCR 
reactions were stored at 4°C or -20°C thereafter. Approximately 10ng of purified genomic DNA 
was utilized per reaction tube. PCR amplification was verified by agarose gel (1% (w/v)) 
electrophoresis, followed by ethidium bromide staining and visualization under UV illumination. 
When the desired amplicon was generated as a mixture, the amplicon of interested was excised 
from the agarose gel following electrophoresis. 
 
PCR primers were designed such that recombineering fragments overlap by at least 30bp 
between each insert or with the plasmid backbone. Non-native and synthetic E. coli ribosome 
binding site (RBS) sequences were introduced within the pathway and upstream of genes by 
incorporating these sequences into the middle of a 3’ primer sequence of one recombineering 
fragment and also into the middle of a 5’ primer sequence of a downstream recombineering 
fragment. 
 
The procedures for yeast-assisted homologous recombination to construct cyanobacterial 
biosynthetic pathways was adopted from procedures previously report [74, 203]. An overnight 
culture (1.0mL) of Saccharomyces cerevisiae cloning strain VL6-48N grown in yeast-peptone 
dextrose media was washed twice with equal volumes of sterile TE (pH 7.4) buffer. After 
washing, 0.5mL of Lazy Bones solution (40% (w/v) PEG MW 3350, 100mM lithium acetate, 
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10mM Tris-HCl pH 7.5, 1mM EDTA) was added to the yeast cells. Then, 20µL salmon sperm 
DNA (2mg/mL) denatured at 98°C for 10min and cooled at 4°C was added to the yeast cells. 
Lastly, 1µg of pMQ123i plasmid (linearized via restriction enzyme and dephosphorylated) and 
all biosynthetic pathway fragments were added to the transformation mixture. The mixture was 
then vortexed for 2 minutes and then allowed to incubate at approximately 25° overnight. The 
following day, the yeast transformation mixture was heated to 42°C for approximately 12 
minutes and then washed three times with equal volumes of sterile TE prior to a final 
resuspension of the yeast cells in 200μL, which were plated on synthetic complete minus uracil 
(SC-URA) selection agar plates. The yeast were allowed to grow on selection plates incubate at 
30°C for three to four days. 
 
Yeast recombineered plasmids were isolated from yeast as follows. Following growth on 
SC-URA selective plates, approximately 50μL yeast cells were resuspended in sterile TE 
(200μL), then an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) and 
approximately 100μL of glass disruption beads (0.5mm diameter) were added to the yeast 
suspension. This mixture was vortexed for 2 minutes and then centrifuged at 21.1 × 10
3 
g for 5 
minutes at room temperature. 150μL of the aqueous phase from the centrifuged mixture is then 
added to 105μL of  isopropanol, which is mixed by gently inverting the tube and allowed to sit at 
room temperature for 5 minutes to allow precipitation of plasmid DNA. Following precipitation, 
the mixture was centrifuged at 21.1 × 10
3 
g for 5 minutes and the supernatant was carefully 
decanted with gentle aspiration. To wash the resultant DNA precipitate, 1mL of ethanol (70% 
(v/v)) is added to the tube to wash, and then the tube is centrifuged at 21.1 × 10
3 
g for 5 minutes. 
The DNA precipitate was washed a total of two times before completely drying the DNA under 
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gentle heating (37°C). The plasmid DNA was dissolved in sterile TE (30μL) and between 2 to 
5μL of DNA was used for transformation into E. coli. 
C.1.3 Heterologous expression of cyanobacterial biosynthetic pathways 
Electrocompetent E. coli TOP10 cells were transformed with pMQ131 (containing the sfp gene 
and only used when necessary) or pMBI (when necessary) and pMQ123i constructs and allowed 
to recover in SOC media for 1hr at 37°C before plating on LB agar plates containing kanamycin 
(50 µg/mL), gentamicin (10 µg/mL), and/or tetracycline (10 µg/mL). A single colony of the 
transformant was used to inoculate 1mL of LB containing the appropriate antibiotics and allowed 
to grow at 37°C overnight. 500µL of the seed culture was subsequently used to inoculate fresh 
LB media (50mL) containing the appropriate antibiotics and allowed to grow at 37°C with 
shaking (200 rpm). When the culture reached mid-log phase exponential growth (OD600 = 0.6), 
the flask was cooled to 25°C and IPTG (1mM) was introduced. At the time of IPTG induction, 
substrates including mevalonolactone (1mM final concentration), homo-L-tyrosine (1mM final 
concentration), p-chlorophenylalanine (5mM final concentration), or p-fluorophenylalanine 
(5mM final concentration) were introduced to the culture media, when necessary. After 48hr of 
induction at 25°C, the culture was centrifuged (4696 g, 30min) and the supernatant was extracted 
with ethyl acetate (2×50mL). The ethyl acetate layers were combined and dried over Na2SO4 and 
the organic solvent was evaporated in vacuo under gentle heating (37°C). 
 
The ethyl acetate-supernatant crude extract was dissolved in methanol to a concentration 
of approximately 10 mg/mL and centrifuged (21.1×10
3
 g, 5min). The crude extract was dissolved 
in methanol to a concentration of approximately 10 mg/mL and centrifuged (21.1×10
3
 g, 5min). 
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The organic supernatant was then used for subsequent high resolution liquid chromatography 
mass spectrometric (HR-LC-MS) analysis. MeOH-dissolved supernatant extract (2 µL) was 
separated by passing through a reverse phase HPLC column (Phenomenex Jupiter® C18, 370Å, 
3µm, 2×150mm) using a Dionex® Ultimate3000 HPLC and analyzed on a Thermo Scientific
TM
 





software was used for MS data analysis. LC method used for analysis (0.2 mL/min flow rate): 
5% (v/v) MeCN in H2O (including 0.1% (v/v) formic acid) for 3 min, ramp to 95% (v/v) MeCN 
in H2O (including 0.1% (v/v) formic acid) over 45 min, and then a final wash with 95% MeCN 
in H2O (including 0.1% (v/v) formic acid) for 15 min. 
C.1.4 High resolution mass spectrometry analysis of heterologous expression constructs 
MS analysis for heterologous expression of mca (microcyclamide) and hal (hapalosin) gene 
cluster constructs can be found within the Appendices of Chapter 8, Microcyclamide and 
Chapter 6, Hapalosin, respectively. 
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72256LCMSP #6391-6461 RT: 34.34-34.70 AV: 71 NL: 9.70E6
T: FTMS + p ESI Full ms [150.00-2000.00]



































72256LCMSP#6391-6461 RT: 34.34-34.70 AV: 71
T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 575.00-576.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  575.26944  9985890.0   100.00   575.26865     0.79 C 32 H 39 O 4 N 4 S
 
Figure C1 Accurate mass for 9 obtained from heterologous expression of age gene cluster in E. 
coli TOP10. 
 
72256LCMSP #6573-6613 RT: 35.29-35.50 AV: 41 NL: 3.74E6
T: FTMS + p ESI Full ms [150.00-2000.00]





























72256LCMSP#6574-6614 RT: 35.29-35.50 AV: 41
T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 674.00-675.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  674.33844  3766890.5   100.00   674.33707     1.37 C 37 H 48 O 5 N 5 S
 
Figure C2 Accurate mass for 10 obtained from heterologous expression of age gene cluster in E. 
coli TOP10. 
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72594LCMSP #5080 RT: 23.42 AV: 1 SB: 80 22.82-23.24 , 24.03-24.76 NL: 2.35E4
T: FTMS + p ESI Full ms [1000.00-1600.00]































T: FTMS + p ESI Full ms [1000.00-1600.00]
m/z= 1285.00000-1286.00000
m/z Intensity Relative Theo. Mass Delta Composition
(ppm)
 1285.56653   25466.6   100.00  1285.55963     5.37 C 58 H 77 O 18 N 16
 
Figure C3 Accurate mass for 5 obtained from heterologous expression of apn gene cluster in E. 
coli TOP10. 
 
72594LCMSP #6959-6984 RT: 30.41-30.49 AV: 6 NL: 4.21E4
T: FTMS + p ESI Full ms [1000.00-1600.00]
































1419.56551 1425.89073 1431.554861430.394271415.38205 1440.068621434.974101420.50888 1426.89258 1434.241891428.519761417.605081414.39160 1438.35097 1440.901751437.03375
1423.78306
72594LCMSP#6962-6984 RT: 30.41-30.49 AV: 6
T: FTMS + p ESI Full ms [1000.00-1600.00]
m/z= 1421.00000-1422.00000
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
 1421.69106   43352.1   100.00  1421.68483     4.38 C 68 H 93 O 18 N 16
 
Figure C4 Accurate mass for 6 obtained from heterologous expression of apn gene cluster in E. 
coli TOP10. 
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73603LCMSP #5011 RT: 31.82 AV: 1 NL: 3.30E5
T: FTMS + p ESI Full ms [150.00-2000.00]


































T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 599.00-600.00





  599.32  336170.5   100.00   599.32     1.72 C 30 H 43 O 7 N 6
 




73374lcmsp #5219 RT: 32.68 AV: 1 NL: 1.78E7
T: FTMS + p ESI Full ms [150.00-2000.00]
































967.26288 1021.25629982.50598 993.53192969.93542 980.38452 1008.52405
73374lcmsp#5217 RT: 32.67
T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 909.00-910.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  909.52246  14946783.0   100.00   909.51926     3.20 C 45 H 69 O 10 N 10
 
Figure C6 Accurate mass for 3 obtained from heterologous expression of apn gene cluster in E. 
coli TOP10. 
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73374lcmsp #6409 RT: 40.07 AV: 1 NL: 8.99E7
T: FTMS + p ESI Full ms [150.00-2000.00]



































935.95978 954.44189941.47437925.45593875.23334 889.48822 980.48047882.23816 948.47583 975.38715 984.48932 993.60156957.91669898.48444871.37244860.80426 915.48132 971.34229
 
73374lcmsp#6409 RT: 40.07
T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 916.00-917.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  916.48535  93307496.0   100.00   916.48148     3.87 C 48 H 66 O 11 N 7
 
Figure C7 Accurate mass for 4 obtained from heterologous expression of apn gene cluster in E. 
coli TOP10. 
 
73376lcmsp #7137 RT: 44.65 AV: 1 NL: 4.14E7
T: FTMS + p ESI Full ms [150.00-2000.00]



































T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 934.00-935.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  934.45221  37466812.0   100.00   934.44760     4.61 C 48 H 65 O 10 N 7 Cl
 
Figure C8 Accurate mass for 4a obtained from heterologous expression of apn gene cluster in E. 
coli TOP10. 
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73652LCMSP (apn F-Phe feeding) #4904-4987 RT: 43.03-43.75 AV: 42 NL: 4.28E5
T: FTMS + p ESI Full ms [150.00-2000.00]


































73652LCMSP (apn F-Phe feeding)#4905-4987 RT: 43.03-43.75 AV: 42
T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 918.00-919.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  918.47955  432929.6   100.00   918.47715     2.40 C 48 H 65 O 10 N 7 F
 
Figure C9 Accurate mass for fluorinated 4 obtained from heterologous expression of apn gene 





SUPPORTING INFORMATION FOR CHAPTER 6 
D.1.1 General methods and materials 
PCRs were executed using a C1000 thermal cycler (Bio-Rad). DNA sequencing was performed 
by Elim BioPharm Inc. Preparative-scale reverse-phase HPLC was performed using a Dionex 
instrument equipped with a 21 × 250 mm Luna C18 column (Phenomenex). LRMS analysis was 
conducted using a Shimadzu LCMS-2020 instrument equipped with an Acclaim® C18 column 
(Dionex, 120Å, 3µm, 2.1 × 150mm). HRMS analysis was conducted using a Q Exactive 
Benchtop Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with a 
Jupiter® C18, 370Å, 3µm, 2×150mm column (Phenomenex). All MS experiments utilized 
electrospray ionization modes for analysis. The NMR spectrum was recorded on a Bruker 
Avance III 700 MHz spectrometer equipped with a 1H/13C/15N triple-resonance inverse probe 
(1.7 mm 'microprobe'). 
 
Synthetic oligonucleotides for gene amplification by PCR were purchased from Life 
Technologies or Integrated DNA Technology. Kapa HiFi DNA polymerase was obtained from 
Kapa Biosystems. Restriction endonucleases, Antarctic phosphatase was purchased from New 
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England BioLabs. LB broth and agar used for culturing E. coli were obtained from Teknova. 6-
bromohexanoic and 8-bromooctanoic acids were both obtained from Sigma. 7-bromoheptanoic 
acid was obtained from Matrix Scientific. Sodium azide was obtained from Fisher Scientific.  
D.1.2 Plasmid construction 
To reconstruct the entire hapalosin biosynthetic pathway, genes halA and sfp were cloned by 
PCR and yeast recombineered into parent vector pMQ131 to yield daughter plasmid pXL2. 
These genes were located downstream of the isopropyl β-D-1-thiogalactopyranoside (IPTG)-
inducible Lac promoter. Included within the design of the PCR primers were sequences to 
synthetically insert an E. coli ribosome binding site (RBS) immediately upstream of gene halA.  
 
A sequential cloning procedure was implemented to yeast recombineer genes halBCDE 
into parent vector pMQ123i to yield the final daughter plasmid pXL4. Sequential construction of 
the final expression plasmid enabled the genetic engineering of an E. coli RBS sequence 
immediately upstream of genes halDE as well as a site-directed mutation of the native TTG start 
codon of halD to the high frequency start codon ATG of E. coli. This was accomplished by first 
recombineering genes halDE into pMQ123i, yielding the partial expression plasmid pXL3. 
Similar to the construction of plasmid pXL2, PCR primers were designed to introduce the RBS 
sequences upstream of the halDE genes. Following successful construction of the halDE initial 
plasmid, known as pXL3, halBC were introduced to afford the halBCDE expression plasmid, 
pXL4. These genes were situated downstream of the IPTG-inducible Tac promoter. A summary 
of the plasmids used in this study are listed in Table D2. 
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D.1.3 Heterologous expression of the hapalosin biosynthetic pathway 
Electrocompetent E. coli XL1-Blue cells were transformed with pMQ131 and pMQ123i 
constructs and allowed to recover in SOC media for 1hr at 37°C before plating on LB agar plates 
containing kanamycin (50 µg/mL) and gentamicin (10 µg/mL). A single colony of the 
transformant was used to inoculate 1mL of LB containing the appropriate antibiotics and allowed 
to grow at 37°C overnight. 500µL of the seed culture was subsequently used to inoculate fresh 
LB media (50mL) containing the appropriate antibiotics and allowed to grow at 37°C with 
shaking (200 rpm). When the culture reached mid-log phase exponential growth (OD600 = 0.6), 
the flask was cooled to 25°C and IPTG (1mM) was introduced. After 48hr of induction at 25°C, 
the culture was centrifuged (5000 g, 30min) and the supernatant was extracted with ethyl acetate 
(2×50mL). The ethyl acetate layers were combined and dried over Na2SO4 and the organic 
solvent was evaporated in vacuo under gentle heating (37°C). 
D.1.4 LC-MS analysis of hapalosin expression in E. coli and LC-HR-MS2 
The ethyl acetate-supernatant crude extract was dissolved in methanol to a concentration of 
approximately 10 mg/mL and centrifuged (21.1×10
3
 g, 5min). The organic supernatant was then 
used for subsequent LR-LCMS analysis. 2µL of MeOH-dissolved supernatant extract was 
separated by R-HPLC prior to LR-LCMS analysis. LC method used for analysis (0.2 mL/min 
flow rate): 5% (v/v) MeCN in H2O (including 0.1% (v/v) formic acid) for 5 min, ramp to 95% 
(v/v) MeCN in H2O (including 0.1% (v/v) formic acid) over 45 min, and then a final wash with 
95% MeCN in H2O (including 0.1% (v/v) formic acid) for 5 min. 
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D.1.5 High resolution tandem-MS analysis of hapalosin analog production in E. coli 







method used for analysis (0.2 mL/min flow rate): 5% (v/v) MeCN in H2O (including 0.1% (v/v) 
formic acid) ramp to 90% (v/v) MeCN in H2O (including 0.1% (v/v) formic acid) over 55 min, 
and then a final wash with 90% MeCN in H2O (including 0.1% (v/v) formic acid) for 5 min.  
 
A precursor ion screening method analogous to ones reported previously [247, 248] was 
implemented to identify novel hapalosin compounds. Hypothesized structures of hapalosin 
compounds based on their chemical formulae were initially identified by their expected precursor 
ion accurate mass within an error of 5 ppm. Accurate masses were subsequently analyzed for 
fingerprint fragmentation peaks.  Characteristic fragment ions frequently consisted of two sets of 
ions: 188, 206, 224 m/z and 288, 306, 324 m/z, which differ by the number of dehydrations. 
Additionally, fragment ions were correlated structurally by their accurate masses.  
D.1.6  Large scale purification of hapalosin from E. coli extracts 
Large scale (3×1.0L) liquid cultures of E. coli XL1-Blue strains containing the hapalosin 
pathway were grown and induced as discussed previously for small scale (50mL) expression 
cultures. Following induction, liquid cultures were centrifuged (7000 g, 30min) and supernatant 
was discarded. Cell pellets obtained from centrifugation were then extracted by adding acetone 
including 0.1% (v/v) formic acid (300mL) to the cell pellet. The cell-acetone mixture was then 
vortexed thoroughly and mixed at 25°C overnight. After mixing, the organic supernatant was 
filtered through Celite®545 (Acros Organics) under reduced pressure and the organic extract 
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was evaporated in vacuo under gentle heating (37°C), yielding between 200-250mg of crude 
extract. The crude was then re-dissolved in 2mL of 4:1 MeOH/DCM, centrifuged (21.1×10
3
 g, 
5min), and the organic supernatant was applied to a size exclusion column (Sephadex LH-20, 
Fluka, 120 cm × 1.5 cm diameter, flow rate 48 mL/hr, 4:1 MeOH/DCM mobile phase). Fractions 
were screened by LC-MS. Hapalosin-containing fractions were found to elute between 160-
180mL of mobile phase. 
 
All hapalosin-containing fractions from size-exclusion purification were combined, 
yielding between 5 to 10mg of enriched crude. The combined fractions were dissolved in 1.2mL 
of MeOH, centrifuged (21.1 × 10
3
 g, 5min), and the organic supernatant was used for preparative 
HPLC. Method used for purification (10.620 mL/min flow rate, 208nm wavelength monitoring): 
50% (v/v) MeOH in H2O (including 0.1% (v/v) formic acid) for 4 min, ramp to 100% (v/v) 
MeOH in H2O (including 0.1% (v/v) formic acid) over 100 min, and then a final wash with 
100% MeOH in H2O (including 0.1% (v/v) formic acid) for 5 min. Hapalosin eluted at 
approximately 84 min retention time under these conditions. Approximately 100µg of pure 
hapalosin was obtained using this procedure. 
D.1.7 Cultivation of Hapalosiphon welwitschii UTEX 1830 and metabolite analysis 
UTEX B1830 was cultured as described previously. Briefly, 1L volume cultures were grown in 
BG-11 media adjusted to pH = 7.8. Cyanobacteria were separated via filtration and the cells were 
lyophilized to yield a dry, filamentous green mass. To 5.0g of lyophilized cells, 400mL of 1:1 
MeOH/DCM was added and stirred overnight at room temperature. The organic solvent was 
separated from the cell mass via filtration and evaporated in vacuo under gentle heating (37°C) 
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to yield the dried crude extract. The crude extract was redissolved in MeOH and analyzed via 
LC-MS and HR-MS
2 
using the same protocol as described above for hapalosin obtained from E. 
coli. 
D.1.8 NMR experiments 
Purified hapalosin was analyzed by 
1




H correlation spectroscopy 






N triple-resonance inverse probe (1.7mm microprobe) was used for analysis. 
D.1.9 Azido-alkanoic acid synthesis 
The procedure to synthesize azido-alkanoic acid substrates for feeding experiments was adapted 
from a protocol previously reported. [234]
 
Briefly, the corresponding 6-, 7-, or 8-bromo-alkanoic 
acid (4mmol) was dissolved in DMF (20mL) and sodium azide (0.82g, 12.6mmol) was added 
and allowed to stir overnight at room temperature. Upon completion of the reaction as monitored 
by TLC, the reaction was diluted with DCM (100mL) and washed with ice cold 1N HCl 
(7×100mL), followed by brine (2×100mL) washing. The organic layer was dried over Na2SO4 
and evaporated in vacuo under gentle heating (37°) to yield yellow viscous oil. See below 
Appendix figures for 
1
H NMR of azidoalkanoic acid products. 
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D.1.10 Azido-alkanoic acid feeding experiments 
Overnight cultures of E. coli XL1-Blue strains containing the hapalosin biosynthetic genes were 
diluted 100-fold in fresh LB media (50mL), supplemented with the corresponding azido-alkanoic 
acid (500µM for 6- and 7-azido-alkanoic acids and 1mM for 8-azidooctanoic acid; 500mM 
azido-alkanoic acid stock solutions were prepared in DMSO), incubated at 37°C with shaking 
(200 rpm), to allow growth to cell density OD600 = 0.6. At mid-log phase exponential growth, 
cultures were cooled to 25°C and induced with IPTG (1mM). After 48hr of induction, the culture 
supernatant was extracted and analyzed as described previously for the analysis of native 
hapalosin. 
 
Table D1 Function annotation of individual gene product in hal biosynthetic gene cluster 
Gene Size, aa Deduced role Protein Homolog Number
Identity/positivity
%/%
halA 708 Fatty acid-CoA ligase (AL-T) acyl-CoA synthetase [Rivularia sp. PCC 7116] YP_007059074.1 56/71
halB 1981
Polyketide synthase                           
(KS-AT-MT-KR-T)





HctF [Lyngbya majuscula] AAY42398.1 47/63
halD 1526
Non-ribosomal peptide synthetase 
(A-A-MT-T)
anabaenopeptilide synthetase ApdB [Anabaena sp. 90] YP_006996377.1 64/77
halE 1818
Polyketide synthase                         
(KS-AT-KR-T-TE)
beta-ketoacyl synthase [Nostoc punctiforme PCC 73102] YP_001866779.1 57/73
 
Table D2 Plasmids used in this study 
Plasmid name Features References 
pMQ131 oriColE1/pC194, aphA-3, Plac-lacZα, CEN6 Reference [74] 
pHal2 Derived from pMQ131; contains halA and sfp This work 
pMQ123i oriColE1/pRK2, aacC1, Ptac-lacZα, 2μm Reference [74] 
pHal3 Derived from pMQ123i; contains halDE This work 




Table D3 Primers used in this study 













TTTATTTTCAG 5’ primer to clone halA 
HapARV 
CTGTTTTATCAGACCGCTTCTGCGTTCTGATGGGCCCT




5’ primer to clone fragment 
1 of halDE 
HalDE_Frag1_RV TTCTTCTTCGGCGGCTACACTAGAG 
3’ primer to clone fragment 
1 of halDE 
HalDE_Frag2_FW GCGTTGAGTATTTGTTGCAGG 
5’ primer to clone fragment 
2 of halDE 
HalDE_Frag2_RV CCTTGTTCTAGTAGCTTCGAG 
3’ primer to clone fragment 
2 of halDE 
HalDE_Frag3_FW GTCAATTGATGCAGCAATTGC 
5’ primer to clone fragment 




3’ primer to clone fragment 




5’ primer to clone fragment 
1 of halBC 
HalBC_Frag1_RV CTTGTGCTAAATTTGACCCAC 
3’ primer to clone fragment 
1 of halBC 
HalBC_Frag2_FW CACTCGCGGCTAATGCATCGTC 
5’ primer to clone fragment 
2 of halBC 
HalBC_Frag2_RV GTTTGGGGTGGGAGTGCTACC 
3’ primer to clone fragment 
2 of halBC 
HalBC_Frag3_FW gagcaacgaacccgtaatacgc 
5’ primer to clone fragment 
3 of halBC 
HalBC_Frag3_RV gtaaaattattggcttgagcggtagcag 
3’ primer to clone fragment 
3 of halBC 
HalBC_Frag4_FW ggtcaaagagattgaagaaacaaaac 




3’ primer to clone fragment 




Figure D1 The successful construction of expression plasmids containing the genes of the 
hapalosin biosynthetic pathway were verified by restriction enzyme digest analysis. sfp-halA 
plasmid construct pHal2 (lane 2) was verified by restriction enzyme digest analysis. 
Additionally, the initial, empty plasmid with no genes, pMQ131, was also analyzed for 
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comparison (lane 1). The expression plasmid containing the partial pathway halDE in plasmid 
pMQ123i (lane 4) was compared to the expression plasmid containing the full biosynthetic 
pathway (lane 5). The empty plasmid pMQ123i was also analyzed as a control (lane 3). 
 
 
Figure D2 Comparative 1H-NMR with hapalosin standard from Moore et al. 
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Figure D3 Comparative 1H-NMR with hapalosin standard derived via synthetic methods. 
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Figure D4 1H-1H COSY NMR analysis of hapalosin isolated from E. coli in this study. 
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Figure D5 Low resolution LC-MS analysis of hapalosin observed from native producer H. 
welwitschii UTEX1830B (black), E. coli heterologous expression (pink). E. coli containing no 
genes of the hapalosin pathway in pMQ123i was used as a negative control (blue). 
 
 





Figure D7 1H NMR spectrum of 7-azidoheptanoic acid (400MHz, CDCl3). 
 
 
Figure D8 1H NMR spectrum of 8-azidooctanoic acid (400MHz, CDCl3). 
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70642MSM_490 #3687-3765 RT: 17.32-17.68 AV: 79 NL: 2.01E6
T: FTMS + p ESI Full ms2 490.30@hcd35.00 [50.00-1020.00]

















































































+ 490.31631 490.31562 1.4
B C28H42NO5
+ 472.30575 472.30501 1.6
C C17H24NO4
+ 306.16998 306.16929 2.3
D C17H24NO4
+ 324.18055 324.17997 1.8
E C17H22NO3
+ 288.15942 288.15886 1.9
F C13H16NO4
+ 250.10738 250.10698 1.6
G C12H18NO3
+ 224.12812 224.12776 1.6
H C12H16NO2
+ 206.11756 206.11726 1.5
I C12H14NO
+ 188.10699 188.10674 1.3
J C11H19O
+ 167.14304 167.14291 0.8
 
Figure D9 HR-MS-MS of compound 1a. 
 187 
71001lcmsp #13898-14022 RT: 44.66-44.83 AV: 2 NL: 4.52E5
F: FTMS + p ESI d Full ms2 476.20@hcd33.00 [50.00-505.00]
















































































+ 476.30066 476.29983 1.7
B C27H40NO5
+ 458.29010 458.29094 -1.8
C C17H24NO4
+ 306.16998 306.1707 -2.4
D C17H22NO3
+ 288.15942 288.15997 -1.9
E C13H16NO4
+ 250.10738 250.10758 -0.8
F C12H18NO3
+ 224.12812 224.12866 -2.4
G C12H16NO2
+ 206.11756 206.11815 -2.9
H C12H14NO
+ 188.10699 188.10754 -2.9
I C10H17O
+ 153.12739 153.12777 -2.5
 
Figure D10 HR-MS-MS of compound 1aa. 
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71001lcmsp #14217 RT: 45.50 AV: 1 NL: 1.66E6
F: FTMS + p ESI d Full ms2 476.20@hcd33.00 [50.00-505.00]










































































+ 476.30066 476.30164 -2.1
B C16H24NO5
+ 310.16490 310.16568 -2.5
C C16H22NO4
+ 292.15433 292.15494 -2.1
D C16H20NO3
+ 274.14377 274.14438 -2.2
E C11H14NO2
+ 192.10191 192.10239 -2.5
F C11H12NO
+ 174.09134 174.09187 -3.0
G C11H19O
+ 167.14304 167.14355 -3.1
 
Figure D11 HR-MS-MS of compound 1ab. 
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71001lcmsp #15617 RT: 49.91 AV: 1 NL: 1.88E5
F: FTMS + p ESI d Full ms2 504.21@hcd33.00 [50.00-530.00]















































































+ 504.33196 504.33307 -2.2
B C29H44NO5
+ 486.32140 486.32288 -3.0
C C17H24NO4
+ 306.16998 306.17078 -2.6
D C17H22NO3
+ 288.15942 288.16019 -2.7
E C12H18NO3
+ 224.12812 224.12868 -2.5
F C12H16NO2
+ 206.11756 206.11826 -3.4
G C12H14NO
+ 188.10699 188.10756 -3.0
H C12H21O
+ 181.15869 181.15915 -2.5
 
Figure D12 HR-MS-MS of compound 1ac. 
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71050lcms_130906184659 #13827 RT: 47.45 AV: 1 NL: 9.29E4
F: FTMS + p ESI d Full ms2 508.20@hcd35.00 [50.00-535.00]












































































+ 508.32688 508.33323 -12.5
B C28H44NO6
+ 490.31631 490.31470 3.3
C C17H26NO5
+ 324.18055 324.18002 1.6
D C17H24NO4
+ 306.16998 306.16959 1.3
E C17H22NO3
+ 288.15942 288.15915 0.9
F C12H16NO2
+ 206.11756 206.11745 0.5
G C12H14NO
+ 188.10699 188.10670 1.5
H C11H19NO
+ 167.14304 167.14299 0.3
 
Figure D13 HR-MS-MS of compound 2a. 
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71050LCMS_130906184659 #12291 RT: 42.39 AV: 1 NL: 1.77E4
F: FTMS + p ESI d Full ms2 494.17@hcd35.00 [50.00-520.00]









































































+ 494.31123 494.31052 1.4
B C27H42NO6
+ 476.30066 476.30121 -1.2
C C17H24NO4
+ 306.16998 306.16946 1.7
D C16H22NO4
+ 292.15433 292.15390 1.5
E C16H20NO3
+ 274.14377 274.14441 -2.3
F C12H18NO3
+ 224.12812 224.12842 -1.3
G C12H16NO2
+ 206.11756 206.11720 1.7
H C12H14NO
+ 188.10699 188.10684 0.8
I C10H17O
+ 153.12739 153.12674 4.2
 
Figure D14 HR-MS-MS of compound 2aa. 
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71005lcmsp #11602 RT: 37.77 AV: 1 NL: 1.51E5
F: FTMS + p ESI d Full ms2 494.12@hcd33.00 [50.00-520.00]








































































+ 494.31123 494.30954 3.4
B C27H42NO6
+ 476.30066 476.30167 -2.1
C C16H24NO5
+ 310.16490 310.16610 -3.9
D C16H22NO4
+ 292.15433 292.15512 -2.7
E C16H20NO3
+ 274.14377 274.14432 -2.0
F C11H14NO2
+ 192.10191 192.10254 -3.3
G C11H12NO
+ 174.09134 174.09196 -3.6
H C11H19O
+ 167.14304 167.14384 -4.8
 
Figure D15 HR-MS-MS of compound 2ab. 
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70931lcmsp_130726163836 #8850-8933 RT: 43.45-43.84 AV: 14 NL: 4.13E6
F: FTMS + p ESI Full ms2 504.20@hcd32.00 [50.00-1045.00]

















































































+ 504.33196 504.32888 6.1
B C29H44NO5
+ 486.3214 486.31805 6.9
C C23H38NO5
+ 408.27445 408.2717 6.7
D C18H28NO5
+ 338.1962 338.19368 7.5
E C18H26NO4
+ 320.18563 320.18326 7.4
F C18H24NO3
+ 302.17507 302.17277 7.6
G C13H16NO4
+ 250.10738 250.10556 7.3
H C12H18NO3
+ 224.12812 224.12657 6.9
I C12H16NO2
+ 206.11756 206.11617 6.7
J C12H14NO
+ 188.10699 188.10573 6.7
K C11H19O
+ 167.14304 167.14198 6.3
 
Figure D16 HR-MS-MS of compound 1b. 
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71001LCMSP #14673 RT: 46.95 AV: 1 NL: 2.29E5
F: FTMS + p ESI d Full ms2 490.20@hcd33.00 [50.00-520.00]














































































+ 490.31631 490.31720 1.8
B C28H42NO5
+ 472.30575 472.30692 2.5
C C18H26NO4
+ 320.18563 320.18616 1.7
D C18H24NO3
+ 302.17507 302.17560 1.8
E C12H18NO3
+ 224.12812 224.12872 2.7
F C12H16NO2
+ 206.11756 206.11810 2.6
G C12H14NO
+ 188.10699 188.10745 2.5
H C10H17O
+ 153.12739 153.12769 2.0
 
Figure D17 HR-MS-MS of compound 1ba. 
 195 
71005lcmsp #13914 RT: 45.14 AV: 1 NL: 3.19E5
F: FTMS + p ESI d Full ms2 522.20@hcd33.00 [50.00-550.00]













































































+ 522.34253 522.34363 -2.1
B C29H46NO6
+ 504.33196 504.33362 -3.3
C C29H44NO5
+ 486.32140 486.32364 -4.6
D C18H26NO4
+ 320.18563 320.1864 -2.4
E C18H24NO3
+ 302.17507 302.17596 -2.9
F C12H18NO3
+ 224.12812 224.12872 -2.7
G C12H16NO2
+ 206.11756 206.11826 -3.4
H C11H19O
+ 167.14304 167.1436 -3.4
 
Figure D18 HR-MS-MS of compound 2b. 
 196 
70931lcmsp_130726163836 #7062-7427 RT: 34.69-36.46 AV: 61 NL: 3.84E5
F: FTMS + p ESI Full ms2 462.20@hcd32.00 [50.00-960.00]













































































+ 462.28501 462.28207 6.4
B C26H38NO5
+ 444.27445 444.27131 7.1
C C17H24NO4
+ 306.16998 306.16778 7.2
D C17H22NO3
+ 288.15942 288.15727 7.5
E C13H16NO4
+ 250.10738 250.10561 7.1
F C12H18NO3
+ 224.12812 224.1266 6.8
G C12H16NO2
+ 206.11756 206.11619 6.6
H C12H14NO
+ 188.10699 188.10574 6.6
I C9H15O
+ 139.11174 139.11075 7.1
 
Figure D19 HR-MS-MS of compound 1c. 
 197 
71051lcms_130906195318 #12637 RT: 43.07 AV: 1 NL: 1.03E5
F: FTMS + p ESI d Full ms2 448.33@hcd35.00 [50.00-475.00]









































































+ 448.26936 448.26855 1.8
B C25H36NO5
+ 430.25880 430.25873 0.2
C C17H24NO4
+ 306.16998 306.16937 2.0
D C17H22NO3
+ 288.15942 288.15912 1.0
E C12H18NO3
+ 224.12812 224.12775 1.7
F C12H16NO2
+ 206.11756 206.11751 0.2
G C12H14NO
+ 188.10699 188.10683 0.9
H C8H13O
+ 125.09609 125.09619 -0.8
 
Figure D20 HR-MS-MS of compound 1ca. 
 198 
71050lcms_130906184659 #11396 RT: 39.36 AV: 1 NL: 1.33E5
F: FTMS + p ESI d Full ms2 480.16@hcd35.00 [50.00-510.00]












































































+ 480.29558 480.29583 -0.5
B C26H38NO5
+ 444.27445 444.27448 -0.1
C C17H24NO4
+ 306.16998 306.16943 1.8
D C17H22NO3
+ 288.15942 288.15884 2.0
E C16H20NO3
+ 274.14377 274.14282 3.5
F C12H18NO3
+ 224.12812 224.12793 0.8
G C12H16NO2
+ 206.11756 206.11732 1.2
H C12H14NO
+ 188.10699 188.10695 0.2
I C9H15O
+ 139.11174 139.11169 0.4
 
Figure D21 HR-MS-MS of compound 2c. 
 199 
71005lcmsp #11364 RT: 37.00 AV: 1 NL: 3.49E4
F: FTMS + p ESI d Full ms2 466.32@hcd33.00 [50.00-495.00]





































































+ 466.27993 466.28102 -2.3
B C16H22NO4
+ 292.15433 292.15582 -5.1
C C11H14NO2
+ 192.10191 192.10237 -2.4
D C11H12NO
+ 174.09134 174.0919 -3.2
E C9H15O
+ 139.11174 139.11209 -2.5
F C8H15
+ 111.11683 111.11752 -6.2
 
Figure D22 HR-MS-MS of compound 2cb. 
 200 
71001LCMSP #13763 RT: 44.22 AV: 1 NL: 1.57E5
F: FTMS + p ESI d Full ms2 476.20@hcd33.00 [50.00-505.00]












































































+ 476.30066 476.29483 12.2
B C27H40NO5
+ 458.29010 458.29141 -2.9
C C18H26NO4
+ 320.18563 320.18628 -2.0
D C18H24NO3
+ 302.17507 302.17572 -2.2
E C12H18NO3
+ 224.12812 224.12878 -2.9
F C12H16NO2
+ 206.11756 206.11819 -3.1
G C12H14NO
+ 188.10699 188.10753 -2.9
H C9H15O
+ 139.11174 139.11215 -2.9
 
Figure D23 HR-MS-MS of compound 1d. 
 201 
71005lcmsp #12093 RT: 39.36 AV: 1 NL: 7.07E4
F: FTMS + p ESI d Full ms2 494.12@hcd33.00 [50.00-520.00]














































































+ 494.31123 494.31237 -2.3
B C27H42NO6
+ 476.30066 476.30203 -2.9
C C27H40NO5
+ 458.29010 458.28940 1.5
D C18H26NO4
+ 320.18563 320.18646 -2.6
E C18H24NO3
+ 302.17507 302.17542 -1.2
F C12H18NO3
+ 224.12812 224.12871 -2.6
G C12H16NO2
+ 206.11756 206.11848 -4.5
H C12H14NO
+ 188.10699 188.10770 -3.8
I C9H15O
+ 139.11174 139.11221 -3.4
 
Figure D24 HR-MS-MS of compound 2d. 
 202 
71001lcmsp #16426 RT: 52.45 AV: 1 NL: 2.30E4
F: FTMS + p ESI d Full ms2 518.20@hcd33.00 [50.00-545.00]










































































+ 518.34761 518.34895 -2.6
B C30H46NO5
+ 500.33705 500.33777 -1.4
C C17H24NO4
+ 306.16998 306.17041 -1.4
D C17H22NO3
+ 288.15942 288.16028 -3.0
E C12H16NO2
+ 206.11756 206.11829 -3.5
F C12H14NO
+ 195.17343 195.17487 -7.4
G C13H23O
+ 188.10699 188.1076 -3.2
 
Figure D25 HR-MS-MS of compound 1e. 
 203 
71005LCMSP #14466 RT: 46.89 AV: 1 NL: 1.55E5
F: FTMS + p ESI d Full ms2 508.15@hcd33.00 [50.00-535.00]












































































+ 508.30689 508.30832 -2.8
B C28H41FNO5
+ 490.29633 490.29791 -2.3
C C17H23FNO4
+ 324.16056 324.16129 -2.2
D C17H21FNO3
+ 306.15000 306.15067 -2.2
E C12H17FNO3
+ 242.1187 242.11938 -2.8
F C12H15FNO2
+ 224.10813 224.10878 -2.9
G C12H13FNO
+ 206.09757 206.09818 -3.0
G C11H19N
+ 167.14304 167.14355 -3.1
 
Figure D26 HR-MS-MS of compound 1f. 
 204 
71086lcmsp #15854 RT: 53.31 AV: 1 NL: 1.29E4
F: FTMS + p ESI d Full ms2 524.28@hcd35.00 [50.00-555.00]




































































+ 524.27734 524.27698 0.7
B C17H23ClNO4
+ 340.13101 340.13040 1.8
C C17H21ClNO3
+ 322.12045 322.11957 2.7
D C12H15ClNO2
+ 240.07858 240.07854 0.2
E C11H19O
+ 167.14304 167.14282 1.3
 
Figure D27 HR-MS-MS of compound 1g. 
 205 
71001lcmsp #12332-12475 RT: 39.72-39.90 AV: 2 NL: 1.39E7
F: FTMS + p ESI d Full ms2 503.36@hcd33.00 [50.00-530.00]










































































+ 503.28641 503.28539 2.0
B C26H37N4O5
+ 485.27585 485.27644 -1.2
C C17H24NO4
+ 306.16998 306.17058 -2.0
D C17H22NO3
+ 288.15942 288.15996 -1.9
E C12H18NO3
+ 224.12812 224.12861 -2.2
F C12H16NO2
+ 206.11756 206.11802 -2.2
G C12H14NO
+ 188.10699 188.10742 -2.3
H C8H14N
+ 124.11208 124.11251 -3.5
 
Figure D28 HR-MS-MS of compound 1h. 
 206 
71051lcms_130906195318 #12037 RT: 41.11 AV: 1 NL: 3.08E4
F: FTMS + p ESI d Full ms2 489.16@hcd35.00 [50.00-515.00]




































































+ 489.27076 489.26993 1.7
B C17H24NO4
+ 306.16998 306.16956 1.4
C C17H22NO3
+ 288.15942 288.15930 0.4
D C12H16NO2
+ 206.11756 206.11742 0.7
E C12H14NO
+ 188.10699 188.10674 1.3
F C7H12N
+ 110.09643 110.09695 -4.7
 
Figure D29 HR-MS-MS of compound 1ha. 
 207 
71001lcmsp #11732 RT: 37.69 AV: 1 NL: 8.57E4
F: FTMS + p ESI d Full ms2 489.12@hcd33.00 [50.00-515.00]











































































+ 489.27076 489.2716 -1.7
B C16H22NO4
+ 292.15433 292.15012 14.4
C C16H20NO3
+ 274.14377 274.14468 -3.3
D C11H14NO2
+ 192.10191 192.10234 -2.2
E C11H12NO
+ 174.09134 174.09187 -3.0
F C8H14N
+ 124.11208 124.11261 -4.3
 
Figure D30 HR-MS-MS of compound 1hb. 
 208 
71001lcmsp #11613 RT: 37.31 AV: 1 NL: 5.50E5
F: FTMS + p ESI d Full ms2 521.30@hcd33.00 [50.00-550.00]












































































+ 521.29698 521.29705 -0.1
B C17H26NO5
+ 324.18055 324.18152 -3.0
C C17H24NO4
+ 306.16998 306.17059 -2.0
D C17H22NO3
+ 288.15942 288.16019 -2.7
E C12H18NO3
+ 224.12812 224.12868 -2.5
F C12H16NO2
+ 206.11756 206.11824 -3.3
G C11H12NO
+ 174.09134 174.09187 -3.0
H C8H14N
+ 124.11208 124.11253 -3.6
 
Figure D31 HR-MS-MS of compound 2h. 
 209 
71001LCMSP #10857 RT: 34.86 AV: 1 NL: 1.87E5
F: FTMS + p ESI d Full ms2 507.15@hcd33.00 [50.00-535.00]










































































+ 521.29698 521.29705 -0.1
B C17H26NO5
+ 324.18055 324.18152 -3.0
C C17H24NO4
+ 306.16998 306.17059 -2.0
D C17H22NO3
+ 288.15942 288.16019 -2.7
E C12H18NO3
+ 224.12812 224.12868 -2.5
F C12H16NO2
+ 206.11756 206.11824 -3.3
G C11H12NO
+ 174.09134 174.09187 -3.0
H C8H14N
+ 124.11208 124.11253 -3.6
 
Figure D32 HR-MS-MS of compound 2hb. 
 210 
71001LCMSP #13262 RT: 42.50 AV: 1 NL: 3.12E5
F: FTMS + p ESI d Full ms2 517.17@hcd33.00 [50.00-545.00]















































































+ 517.30206 517.29895 6.0
B C27H39N4O5
+ 499.29150 499.29013 2.7
C C18H26NO4
+ 320.18563 320.18634 -2.2
D C18H24NO3
+ 302.17507 302.17588 -2.7
E C12H18NO3
+ 224.12812 224.12864 -2.3
F C12H16NO2
+ 206.11756 206.11816 -2.9
G C12H14NO
+ 188.10699 188.10753 -2.9
H C8H14N
+ 124.11208 124.11255 -3.8
 
Figure D33 HR-MS-MS of compound 1i. 
 211 
70963lcmsp #10204-10323 RT: 39.27-39.72 AV: 30 NL: 1.72E7
F: FTMS + p ESI Full ms2 517.30@hcd32.00 [50.00-1075.00]
















































































+ 517.30206 517.29895 6.0
B C27H39N4O5
+ 499.29150 499.29171 -0.4
C C27H39N2O5
+ 471.28535 471.28544 -0.2
D C22H35N4O5
+ 435.26020 435.2599 0.7
E C17H26NO5
+ 324.18055 324.18033 0.7
F C17H24NO4
+ 306.16998 306.16972 0.8
G C17H22NO3
+ 288.16998 288.16925 2.5
H C13H16NO4
+ 250.10738 250.1072 0.7
I C12H18NO3
+ 224.12812 224.12808 0.2
J C12H16NO2
+ 206.11756 206.11761 -0.2
K C12H14NO
+ 188.10699 188.10693 0.3
L C9H16N
+ 138.12776 138.1276 1.2
 
Figure D34 HR-MS-MS of compound 1j. 
 212 
71050lcms_130906184659 #12757 RT: 44.06 AV: 1 NL: 3.44E4
F: FTMS + p ESI d Full ms2 503.20@hcd35.00 [50.00-530.00]






































































+ 503.28641 503.28592 1.0
B C17H24NO4
+ 306.16998 306.16949 1.6
C C17H22NO3
+ 288.15942 288.15845 3.4
D C12H16NO2
+ 206.11756 206.11736 1.0
E C12H14NO
+ 188.10699 188.10678 1.1
F C8H14N
+ 124.11208 124.11221 -1.0
 
Figure D35 HR-MS-MS of compound 1ja. 
 213 
71050lcms_130906184659 #12699 RT: 43.68 AV: 1 NL: 2.91E5
F: FTMS + p ESI d Full ms2 503.20@hcd35.00 [50.00-530.00]










































































+ 503.28641 503.28503 2.7
B C16H24NO5
+ 310.16490 310.16443 1.5
C C16H22NO4
+ 292.15433 292.15375 2.0
D C16H20NO3
+ 274.14377 274.14328 1.8
E C11H14NO2
+ 192.10191 192.10165 1.4
F C11H12NO
+ 174.09134 174.0912 0.8
G C12H14NO
+ 138.12773 138.12761 0.9
 
Figure D36 HR-MS-MS of compound 1jb. 
 214 
71050lcms_130906184659 #11428 RT: 39.47 AV: 1 NL: 1.83E6
F: FTMS + p ESI d Full ms2 535.28@hcd35.00 [50.00-565.00]










































































+ 535.31263 535.31213 0.9
B C27H41N4O6
+ 517.30206 517.30109 1.9
C C17H26NO5
+ 324.18055 324.17966 2.7
D C17H24NO4
+ 306.16998 306.16934 2.1
E C17H22NO3
+ 288.15942 288.15887 1.9
F C12H18NO3
+ 224.12812 224.12778 1.5
G C12H16NO2
+ 206.11756 206.11736 1.0
H C12H14NO
+ 188.10699 188.10677 1.2
I C12H14NO
+ 138.12773 138.12761 0.9
 
Figure D37 HR-MS-MS of compound 2j. 
 215 
70963lcmsp #10634-10738 RT: 40.93-41.31 AV: 26 NL: 2.50E6
F: FTMS + p ESI Full ms2 531.30@hcd32.00 [50.00-1100.00]


















































































+ 531.31826 531.31793 -0.6
B C28H41N4O5
+ 513.30715 513.30732 -0.3
C C28H41N2O5
+ 485.30100 485.30117 -0.4
D C22H35N4O5
+ 435.26020 435.2601 0.2
E C18H28NO5
+ 338.19620 338.19580 0.7
F C18H26NO4
+ 320.18563 320.18540 0.8
G C18H24NO3
+ 302.17507 302.17484 0.8
H C13H16NO4
+ 250.10738 250.10719 0.1
I C12H18NO3
+ 224.12812 224.12809 -0.3
J C12H16NO2
+ 206.11756 206.11763 0.4
K C12H14NO
+ 188.10699 188.10691 0.4
L C9H16N
+ 138.12776 138.12773 0.2
 
Figure D38 HR-MS-MS of compound 1k. 
 216 
71026lcmsp #7507-7585 RT: 24.36-24.59 AV: 8 NL: 3.92E5
F: FTMS + p ESI Full ms2 532.00@hcd35.00 [73.67-1105.00]













































































+ 531.31826 531.31723 1.9
B C28H41N4O5
+ 513.30715 513.30642 1.4
C C28H41N2O5
+ 485.30100 485.30067 0.7
D C17H24NO4
+ 306.16998 306.16957 1.3
E C17H22NO3
+ 288.15942 288.15891 1.8
F C12H18NO3
+ 224.12812 224.12774 1.7
G C12H16NO2
+ 206.11756 206.11728 1.4
H C12H14NO
+ 188.10699 188.10674 1.3
I C10H18N
+ 152.14338 152.14322 1.1
 
Figure D39 HR-MS-MS of compound 1l. 
 217 
71049LCMS_130906174037 #14848 RT: 50.19 AV: 1 NL: 5.82E4
F: FTMS + p ESI d Full ms2 545.17@hcd35.00 [50.00-575.00]








































































+ 545.33336 545.32727 11.2
B C18H26NO4
+ 320.18563 320.18472 2.2
C C18H24NO3
+ 302.17507 302.17441 0.4
D C12H18NO3
+ 224.12812 224.12804 0.4
E C12H16NO2
+ 206.11756 206.11714 2.0
F C12H14NO
+ 188.10699 188.10672 1.4
G C10H18N
+ 152.14338 152.14314 1.6
 




SUPPORTING INFORMATION FOR CHAPTER 7 
E.1.1 General methods and materials 
PCRs were executed using a C1000 thermal cycler (Bio-Rad). DNA sequencing was performed 
by Elim BioPharm Inc. Low resolution MS analysis was conducted using a Shimadzu LCMS-
2020 instrument equipped with an Acclaim® C18 column (Dionex, 120Å, 3µm, 2.1 × 150mm). 
All MS experiments utilized electrospray ionization modes for analysis. 
 
Synthetic oligonucleotides for gene amplification by PCR were purchased from Life 
Technologies or Integrated DNA Technology. Kapa HiFi DNA polymerase was obtained from 
Kapa Biosystems. Restriction endonucleases, T4 DNA ligase and Antarctic phosphatase were 
purchased from New England BioLabs. LB broth and agar used for culturing E. coli were 
obtained from Teknova. 
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E.1.2 Protein cloning, expression and purification 
HalC adenylation domains A1 and A2 were independently cloned into the NotI and BamHI sites 
of the expression plasmid pQTev to yield pQTev-HalCA1 and pQTev-HalCA2, respectively. An 
overnight culture of the expression strain E. coli BL21(DE) star containing either plasmid was 
inoculated by 1000-fold dilution into fresh media (1.0L scale, LB media, 37°C, 200rpm). The 
culture was then grown to an OD600nm of approximately 0.6, cooled (16°C), and induced with 
isopropyl β-D-1-thiogalactopyranoside (IPTG, 1mM final concentration, overnight). The 
following day, protein expression cultures were centrifuged (5000g, 30min, 4°C), and the 
resulting cell pellet was resuspended in lysis buffer (10% (v/v) glycerol, 0.1% (v/v) Tween-20, 
500mM NaCl, 50mM Tris-HCl, pH 7.5). The resuspended cells were placed on ice and then 
sonicated (Fisher Scientific Sonic Dismembrator 550) in 5 second pulses, followed by 20 second 
cool down periods, for a time totaling 5 minutes. The disrupted cell pellet was then centrifuged 
(20000g, 30min, 4°C), and the soluble lysate was applied to NTA nickel beads (Ni-NTA 
Agarose, MCLAB) and allowed to mix gently (1hr, 4°C). The protein-bound NTA nickel beads 
were then washed (20mL of 20mM imidazole, 10% (v/v) glycerol, 500mM NaCl, 50mM Tris-
HCl, 10mM β-mercaptoethanol, pH 7.5). Following the washing step, protein was eluted from 
the NTA nickel beads with elution buffer (wash buffer containing 125mM imidazole). Eluted 
fractions were analyzed via SDS-PAGE on a 12.5% (w/v) polyacrylamide gel, using a constant 
voltage of 100V (Bio-Rad Mini-PROTEAN® Tetra Cell and PowerPac Basic). Protein-
containing fractions were combined together and dialyzed overnight (2×500mL, 100mM Tris-
HCl, 1mM MgCl2, 10% (v/v) glycerol, pH 7.5, 4°C). The dialyzed protein solution was then 
concentrated via centrifugal filtration (Spin-X® UF Concentrator 30k MWCO PES, Corning®, 
4696g, 5min, 4°C). 
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E.1.3 Enzyme kinetics and substrate activity assays 
A pyrophosphate detection assay reported previously [249] was modified to investigate 
adenylation domain enzyme kinetics and substrate selectivity. Briefly, pyrophosphate reactions 
(100μL) contained 100mM HEPES pH 8.0, 10mM MgCl2, 0.04 U pyrophosphatase, 0.1 U purine 
nucleoside phosphorylase, 250μM 7-methylthioguanosine, 1mM tris(2-carboxyethyl)phosphine, 
150mM hydroxylamine, 2.5mM ATP, and varying concentrations of substrate. Adenylation 
enzyme (5μM final concentration) was added to initiate the reaction, which was monitored at 
360nm at room temperature over 5 minutes. GraphPad Prism® 5 was used for curve fitting to 
extrapolate Michaelis-Menten enzyme kinetics parameters. To determine substrate activity, the 
absorbance at 360nm of the pyrophosphate reactions was measured after 5 minutes of incubation 
at room temperature. For these assays, 250μM of substrate or disodium pyrophosphate (Na2PPi) 
was tested. Substrate activities of various substrates were normalized to Na2PPi (positive control) 
or sterile dH2O (negative control) responses. 
E.1.4 Hapalosin Gene Cluster Plasmid construction 
For details for the assembly of the complete hapalosin biosynthetic gene cluster, refer to 
Chapters 4 and 5. A brief summary of the procedures is outlined here. To reconstruct the entire 
hapalosin biosynthetic pathway, genes halA and sfp were cloned by PCR (using genomic DNA 
isolated from Hapalosiphon welwitschii UTEX1830B) and yeast recombineered into parent 
vector pMQ131 to yield daughter plasmid pXL2. Primers used to amplify the sfp and halA genes 
are as follows, respectively: sfpRBSFW/sfpRBSRV and HapAFW/HapARV. These genes were 
located downstream of the isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible Lac 
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promoter. Included within the design of the PCR primers were sequences to synthetically insert 
an E. coli ribosome binding site (RBS) immediately upstream of gene halA. This genetically 
engineered feature, therefore, enabled the enhanced translation of halA mRNA transcripts to 
yield the functional enzyme in vivo. 
 
A sequential cloning procedure was implemented to yeast recombineer genes halBCDE 
into parent vector pMQ123i to yield the final daughter plasmid pXL4. Sequential construction of 
the final expression plasmid enabled the genetic engineering of an E. coli RBS sequence 
immediately upstream of genes halDE as well as a site-directed mutation of the native TTG start 
codon of halD to the high frequency start codon ATG of the E. coli, ATG. This was 
accomplished by first recombineering genes halDE into pMQ123i, yielding the partial 
expression plasmid pXL3. Similar to the construction of plasmid pXL2, PCR primers were 
designed to introduce the RBS sequences upstream of the halDE genes. The halDE genes were 
cloned as three separate fragments using the following primers: HalDE_Frag1_FW / 
HalDE_Frag1_RV, HalDE_Frag2_FW / HalDE_Frag2_RV, and HalDE_Frag3_FW / 
HalDE_Frag3_RV. Following successful construction of the halDE initial plasmid, known as 
pXL3, halBC were introduced to afford the halBCDE expression plasmid, pXL4. The halBC 
genes were cloned as four separate fragments and introduced into the Eco53kI site of pXL3; 
primers used for halBC cloning are as follows: HalBC_Frag1_FW / HalBC_Frag1_RV, 
HalBC_Frag2_FW / HalBC_Frag2_RV, HalBC_Frag3_FW / HalBC_Frag3_RV, and HalBC_ 
Frag4_FW / HalBC_Frag4_RV. These genes were situated downstream of the IPTG-inducible 
Tac promoter. A summary of the plasmids used in this study are listed in Table E1. 
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To introduce the mutant halC_KR sequence into the hal pathway, two amplicons were 
generated using primers HalC-KRmut1_FW/HalC-KRmut1_RV and HalC-KRmut2_FW/HalC-
KRmut2_RV (Table E2; point mutations underlined). Primers were designed to introduce 
S2071A and Y2086F point mutations within the active site of HalC-KR. Once this mutant locus 
was generated and sequenced, it was used as a template to PCR amplify and recombine into the 
complete Hal pathway containing the mutant halC_KR sequence using the yeast recombineering 
procedures described above. 
 
Construction of the stand-alone adenylation domains HalC_A1 and HalC_A2 were 
constructed via ligation-based cloning methods into the NotI and BamHI restriction enzyme sites 
of the pQTev expression plasmid. Primers HalCA1_BamHI_5’/HalCA1_BamHI_3’ and 
HalCA2_BamHI_5’/HalCA2_BamHI_3’ were used for cloning of the HalC_A1 and HalC_A2 
adenylation domains (respectively) into pQTev. 
E.1.5 Heterologous expression of the hapalosin biosynthetic pathway 
Electrocompetent E. coli XL1-Blue cells were transformed with pHal2 and pHal3 or pHal4 
constructs and allowed to recover in SOC media for 1hr at 37°C before plating on LB agar plates 
containing kanamycin (50 µg/mL) and gentamicin (10 µg/mL). A single colony of the 
transformant was used to inoculate 1mL of LB containing the appropriate antibiotics and allowed 
to grow at 37°C overnight. 500µL of the seed culture was subsequently used to inoculate fresh 
LB media (50mL) containing the appropriate antibiotics and allowed to grow at 37°C with 
shaking (200 rpm). When the culture reached mid-log phase exponential growth (OD600 = 0.6), 
the flask was cooled to 25°C and IPTG (1mM) was introduced. After 48hr of induction at 25°C, 
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the culture was centrifuged (5000 g, 30min) and the supernatant was extracted with ethyl acetate 
(2×50mL). The ethyl acetate layers were combined and dried over Na2SO4 and the organic 
solvent was evaporated in vacuo under gentle heating (37°C). When necessary, 2-hydroxy-3-
methylbutyric acid (1mM) was added to the E. coli culture at the time of induction. 
E.1.6 LC-MS analysis of hapalosin expression in E. coli 
The ethyl acetate-supernatant crude extract was dissolved in methanol to a concentration of 
approximately 10 mg/mL and centrifuged (21.1×10
3
 g, 5min). The organic supernatant was then 
used for subsequent LR-liquid chromatography-mass spectrometric (LC-MS) analysis. 2µL of 
MeOH-dissolved supernatant extract was separated by reverse phase high performance liquid 
chromatography, R-HPLC prior to LR-LCMS analysis, (Dionex Acclaim® C18, 120Å, 3µm, 2.1 
× 150mm) and analyzed on a Shimadzu LCMS-2020 instrument using both ESI positive and 
negative and APCI ionizations. LC method used for analysis (0.2 mL/min flow rate): 5% (v/v) 
MeCN in H2O (including 0.1% (v/v) formic acid) for 5 min, ramp to 95% (v/v) MeCN in H2O 
(including 0.1% (v/v) formic acid) over 45 min, and then a final wash with 95% MeCN in H2O 
(including 0.1% (v/v) formic acid) for 5 min. 
E.1.7 Cultivation of Hapalosiphon welwitschii UTEX 1830 and metabolite analysis 
UTEX B1830 was cultured as described previously. Briefly, 1L volume cultures were grown in 
BG-11 media adjusted to pH = 7.8. Cyanobacteria were separated via filtration and the cells were 
lyophilized to yield a dry, filamentous green mass. To 5.0g of lyophilized cells, 400mL of 1:1 
MeOH/DCM was added and stirred overnight at room temperature. The organic solvent was 
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separated from the cell mass via filtration and evaporated in vacuo under gentle heating (37°C) 
to yield the dried crude extract. The crude extract was redissolved in MeOH and analyzed via 






















Figure E1 BLAST analysis and sequence alignments for Hal-A2 domain. 
HalC-A1 domain homologs GenBank Accession # Full Length Size (aa) Organism Proposed function
gi 111019388 YP_702360 4903 Rhodococcus jostii RHA1 non-ribosomal peptide synthetase
gi 18034623 AAL57600 3316 Xenorhabdus bovienii peptide synthetase XpsB
gi 83768440 BAE58579 1021 Aspergillus oryzae RIB40 unnamed protein product
gi 163939760 YP_001644644 1476 Bacillus weihenstephanensis KBAB4 amino acid adenylation domain-containing protein
gi 87121795 ZP_01077681 NZ_AANE01000000 1558 Marinomonas sp. MED121 Amino acid adenylation, partial
gi 26248307 NP_754347 1120 Escherichia coli CFT073 peptide synthetase
gi 160944390 ZP_02091618 NZ_ABED02000000 491 Faecalibacterium prausnitzii M21/2 hypothetical protein FAEPRAM212_01900
gi 68845342 P0C063 4451 Aneurinibacillus migulanus Gramicidin S synthase II
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Figure E2 BLAST analysis and sequence alignments for Hal-A1 domain. 
HalC-A2 domain homologs GenBank Accession # Full Length Size (aa) Organism Proposed function
gi 254763406 P40806 5043 Bacillus subtilis subsp. subtilis str. 168 Polyketide synthase PksJ
gi 17549638 NP_522978 937 Ralstonia solanacearum GMI1000 peptide synthetase
gi 116584634 ABK00751 3374 Bacillus cereus cereulide synthetase A, CesA
gi 157691118 YP_001485580 2731 Bacillus pumilus SAFR-032 nonribosomal peptide synthetase subunit
gi 126347649 CAJ89363 2873 Streptomyces ambofaciens ATCC 23877 putative peptide synthetase
gi 133917244 CAM59601 1416 Planktothrix agardhii NIVA-CYA 126 non-ribosomal peptide synthetase/polyketide synthase hybrid enzyme
gi 156141035 ABU51602 970 Aspergillus nidulans nonribosomal peptide synthetase TdiA
gi 157429065 ABV56587 1273 Kutzneria sp. 744 nonribosomal peptide synthetases KtzG
gi 159898935 YP_001545182 1818 Herpetosiphon aurantiacus DSM 785 AMP-dependent synthetase/ligase
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Table E1 Plasmids used in this study 
Plasmid name Features References 
pMQ131 oriColE1/pC194, aphA-3, Plac-lacZα, CEN6 Reference [74] 
pHal2 Derived from pMQ131; contains halA and sfp This work 
pMQ123i oriColE1/pRK2, aacC1, Ptac-lacZα, 2μm Reference [74] 
pHal3 Derived from pMQ123i; contains halDE This work 
pHal4 Derived from pHal3; contains halBC This work 
pHal4mutant Derived from pHal4; contains mutant halC_KR This work 
pQTev-HalCA1 Sequences for halC_A1 domain cloned into NotI 
& BamHI sites of pQTev 
This work 
pQTev-HalCA2 Sequences for halC_A2 domain cloned into NotI 
& BamHI sites of pQTev 
This work 
 
Table E2 Primers used in this study 
Primer name Sequence Application 
HalC-KRmut1_FW gaattggatcctctagattctccatacggtcaaagagattgaagaaacaaaa
c 




Construction of HalC mutant KR 
template 
HalC-KRmut2_FW GcagtaaatagtgtatttggaggagctacctttagtgcatTttctgctg Construction of HalC mutant KR 
template 












5’ primer to clone sfp and RBS 
sfpRBSRV TTATATCCTCCTACGGGTATGGAGAATTATAA
AAGCTCTTCGTACGAG 
3’ primer to clone sfp and RBS 
HapAFW TTCTCCATACCCGTAGGAGGATATAAATGAAC
AACAATTTATTTTCAG 
5’ primer to clone halA 
HapARV CTGTTTTATCAGACCGCTTCTGCGTTCTGATG
GGCCCTTAAACACTAACTGAAGAGG 




5’ primer to clone fragment 1 of 
halDE 
HalDE_Frag1_RV TTCTTCTTCGGCGGCTACACTAGAG 3’ primer to clone fragment 1 of 
halDE 
HalDE_Frag2_FW GCGTTGAGTATTTGTTGCAGG 5’ primer to clone fragment 2 of 
halDE 
HalDE_Frag2_RV CCTTGTTCTAGTAGCTTCGAG 3’ primer to clone fragment 2 of 
halDE 








5’ primer to clone fragment 1 of 
halBC 
HalBC_Frag1_RV CTTGTGCTAAATTTGACCCAC 3’ primer to clone fragment 1 of 
halBC 
HalBC_Frag2_FW CACTCGCGGCTAATGCATCGTC 5’ primer to clone fragment 2 of 
halBC 
HalBC_Frag2_RV GTTTGGGGTGGGAGTGCTACC 3’ primer to clone fragment 2 of 
halBC 
HalBC_Frag3_FW gagcaacgaacccgtaatacgc 5’ primer to clone fragment 3 of 
halBC 
HalBC_Frag3_RV gtaaaattattggcttgagcggtagcag 3’ primer to clone fragment 3 of 
halBC 
HalBC_Frag4_FW ggtcaaagagattgaagaaacaaaac 5’ primer to clone fragment 4 of 
halBC containing mutant halC KR 
HalBC_Frag4_RV catatgtatatctccttccccgggtaccgagtcaagtattttcggcttttagc 3’ primer to clone fragment 4 of 
halBC containing mutant halC KR 
HalCA1_BamHI_5
’ 
GATCGGATCCcccgacgcggtagcagtggtg Clone HalC_A1 into pQTEV 
HalCA1_BamHI_3
’ 
GATCGCGGCCGCctccttttaaaactacgtaag Clone HalC_A1 into pQTEV 
HalCA2_BamHI_5
’ 
GATCGGATCCctacttcgacttcctgctg Clone HalC_A2 into pQTEV 
HalCA2_BamHI_3
’ 




SUPPORTING INFORMATION FOR CHAPTER 8 
F.1.1 General methods and materials 
Refer to Chapter 5, Plasmid Tools Expression for detailed information regarding general 
methods and materials utilized for the following experiments. Heterologous gene expression and 
MS analysis procedures are also detailed there. 
 
Table F1 Primers used in this study 
Primer Sequence Purpose 
mca_frag1_5'_toMQ123i cgagctcggtacccggggaaggagatatacatATGCTAGATAGATT
ACATACCATC 
Assembly of mca WT 
operon 
mca_frag1_3' TCTCTAGTGCCTGTTTATTAATC Assembly of mca WT 
operon 
mca_frag2_5' GCAGCTTTACGGCAGCCTG Assembly of mca WT 
operon 
mca_frag2_3' CATATTGTTCTCCCGGAGCAAG Assembly of mca WT 
operon 
mca_frag3_5' GTATGTCTGCATCTTGGCTCAG Assembly of mca WT 
operon 
mca_frag3_3' AACCAATCTTCTGCGGAAAG Assembly of mca WT 
operon 
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organized mca pathway 
McaE-5'-insert-to-
123iMcaADG 
gcggataacaatttcacacaggaaacagaattatgaggattactccaatggataag Assembly of re-














organized mca pathway 
mcaF_into_123i_RV ggcaaattctgttttatcagaccgcttctgcgttctgatttactaactaaaatcttctcg Assembly of re-
organized mca pathway 
 
F.1.2 Microcyclamide biosynthetic pathway plasmid construction 
The wildtype mca pathway was assembled as four separate fragments that were amplified using 
the following primers, respectively: mca_frag1_5'_toMQ123i / mca_frag1_3', mca_frag2_5' / 
mca_frag2_3', mca_frag3_5'/mca_frag3_3', mca_frag4_5'/mca_frag4_3'_toMQ123i. In order to 
construct the mcaADEG, the mcaADG expression plasmid was first cloned at the SmaI site of 
pMQ123i using three fragments using primers: mca_frag1_5'_toMQ123i/mcaA-123i-3', mcaD-
123i-5'/mcaD-123i-3', mcaG-123i-5'/mca_frag4_3'_toMQ123i. The mcaE gene was then cloned 
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into the mcaADG construct at the Eco53kI restriction site. Primers McaE-5'-insert-to-
123iMcaADG/McaE-3'-insert-to-123iMcaADG were used to clone the mcaE gene as a single 
fragment to yield the mcaADEG construct. Primers (McaE-5'-insert-to-123iMcaADG/mcaA-
123i-3', mcaD-123i-5' / mcaD-123i-3', mcaG-123i-5' / mcaG_into_mcaF_RV, mcaF_into_ 
mcaG_FW / mcaF_into_123i_RV) were used to generate four fragments to assemble the 
mcaADEFG construct at the SmaI site of pMQ123i in a single cloning step. The mcaADEG 
plasmid was used as a PCR template to amplify the mcaEA fragments necessary to assemble the 
mcaADEFG pathway. The WT mca plasmid was used as PCR template to amplify the remaining 













F.1.3 Mass Spectrometry Analysis of Microcyclamide Structures from Heterologous 
Expression Experiments 
73562lcmsp #6506 RT: 34.40 AV: 1 NL: 3.94E5
T: FTMS + p ESI Full ms2 535.00@hcd35.00 [50.00-1110.00]















































110.06052 292.16602 421.15451 499.21289
363.14932 446.18579389.16470
































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H35N6O6S 535.23333 535.2348 2.7
B C21H31N6O54S 463.2122 463.21295 1.6
C C21H28N5O4S 446.18565 446.18579 0.3
D C19H28N5O3S 406.19074 406.19141 1.6
E C17H26N5O3S 380.17509 380.17551 1.1
F C17H23N4O3S 363.14854 363.14932 2.1
G C13H17N4O3S 309.10159 309.10236 2.5
H C12H19N4O3 267.14517 267.14581 2.4
I C12H15N2O2S 251.08487 251.08522 1.4
J C11H15N2OS 223.08996 223.09026 1.3
K C9H13N2OS 197.07431 197.0746 1.5
L C8H14N3O2 184.10805 184.10846 2.2
M C8H11N2O2 167.0815 167.08177 1.6
73562lcmsp #6505 RT: 34.40 AV: 1 NL: 3.34E6
T: FTMS + p ESI Full ms [150.00-2000.00]




























T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 535.00-536.00
m/z Intensity Relative Theo. Mass Delta Composition
(ppm)
  535.23480  4491735.5   100.00   535.23333     1.47 C 24 H 35 O 6 N 6 S
E. coli mca wildtype pathway
Accurate mass for microcyclamide 7806B
 
Figure F1 MS and MSMS analysis of microcyclamide 7806B from E. coli heterologous 
expression. 
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73562lcmsp #6598 RT: 34.97 AV: 1 NL: 4.49E6
T: FTMS + p ESI Full ms2 537.00@hcd35.00 [50.00-1115.00]




























































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H35N6O6S 535.23333 535.2348 2.7
B C21H31N6O54S 463.2122 463.21295 1.6
C C21H28N5O4S 446.18565 446.18579 0.3
D C19H28N5O3S 406.19074 406.19141 1.6
E C17H26N5O3S 380.17509 380.17551 1.1
F C17H23N4O3S 363.14854 363.14932 2.1
G C13H17N4O3S 309.10159 309.10236 2.5
H C12H19N4O3 267.14517 267.14581 2.4
I C12H15N2O2S 251.08487 251.08522 1.4
J C11H15N2OS 223.08996 223.09026 1.3
K C9H13N2OS 197.07431 197.0746 1.5
L C8H14N3O2 184.10805 184.10846 2.2
M C8H11N2O2 167.0815 167.08177 1.6
 




E. coli mca wildtype pathway
73562lcmsp #7534 RT: 40.85 AV: 1 NL: 3.55E5
T: FTMS + p ESI Full ms2 537.00@hcd35.00 [50.00-1115.00]

























































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H37N6O6S 537.24898 537.25 1.9
B C21H33N6O4S 465.22785 465.2287 1.8
C C21H30N5O4S 448.2013 448.20181 1.1
D C19H30N5O3S 408.20639 408.20709 1.7
E C17H28N5O3S 382.19074 382.19141 1.8
F C15H21N4O3S 337.13289 337.13351 1.8
G C13H19N4O3S 311.11724 311.11774 1.6
H C12H21N4O3 269.16082 269.16141 2.2
I C12H15N2O2S 251.08487 251.08524 1.5
J C11H15N2OS 223.08996 223.09032 1.6
K C9H13N2OS 197.07431 197.07466 1.8
L C8H16N3OS 186.1237 186.12408 2.0
 
Figure F3 MS and MSMS analysis of microcyclamide 7806B analog from E. coli heterologous 
expression. 
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73562lcmsp #9548 RT: 53.59 AV: 1 NL: 5.35E7
T: FTMS + p ESI Full ms2 535.00@hcd35.00 [50.00-1110.00]




















































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H35N6O4S2 535.21557 535.21649 1.7
B C23H35N6O3S2 507.22066 507.22165 2.0
C C19H30N5O2S2 424.18354 424.18423 1.6
D C18H24N5O3S2 422.13151 422.13242 2.2
E C14H22N5O2S2 356.12094 356.12152 1.6
F C14H19N4O2S2 339.09439 339.09543 3.1
G C14H23N2OS 267.15256 267.15295 1.5
H C9H13N4O2S 241.07537 241.07579 1.7
I C9H15N2OS 199.08996 199.09035 2.0
J C5H8N3OS 158.03826 158.03859 2.1
 
E. coli mca wildtype pathway
Accurate mass for aerucyclamide A
73562lcmsp #9547 RT: 53.59 AV: 1 NL: 1.46E9
T: FTMS + p ESI Full ms [150.00-2000.00]
































T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 535.00-536.00
m/z Intensity Relative Theo. Mass Delta Composition
(ppm)
  535.21674  1464180736.0   100.00   535.21557     1.16 C 24 H 35 O 4 N 6 S 2
 
Figure F4 MS and MSMS analysis of aerucyclamide A from E. coli heterologous 
expression. 
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E. coli mca wildtype pathway
Accurate mass for aerucyclamide B
73562lcmsp #9953 RT: 56.12 AV: 1 NL: 2.01E7
T: FTMS + p ESI Full ms [150.00-2000.00]




























T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 533.00-534.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  533.20160  20263240.0   100.00   533.19992     1.68 C 24 H 33 O 4 N 6 S 2
 
Figure F5 MS analysis of aerucyclamide B from E. coli heterologous expression. 
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E. coli mca wildtype pathway
73562lcmsp #9686 RT: 54.45 AV: 1 NL: 1.81E7
T: FTMS + p ESI Full ms2 517.00@hcd35.00 [50.00-1075.00]















































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H33N6O5S 517.22277 517.22351 1.4
B C21H28N5O4S 446.18565 446.1864 1.7
C C19H28N5O3S 406.19074 406.19141 1.6
D C17H26N5O3S 380.17509 380.1756 1.3
E C17H23N4O3S 363.14854 363.14905 1.4
F C15H19N4O3S 335.11724 335.11819 2.8
G C13H17N4O3S 309.10159 309.10226 2.2
H C12H19N4O3 267.14517 267.14569 1.9
I C12H15N2O2S 251.08487 251.08528 1.6
J C11H15N2OS 223.08996 223.0903 1.5
K C9H13N2OS 197.07431 197.07463 1.6
L C8H14N3O2 184.10805 184.10832 1.5
M C8H11N2O2 167.0815 167.0818 1.8
 
E. coli mca wildtype pathway
Accurate mass for aerucyclamide C
73562lcmsp #9679 RT: 54.40 AV: 1 NL: 1.23E8
T: FTMS + p ESI Full ms [150.00-2000.00]

































T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 517.00-518.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  517.22498  124788712.0   100.00   517.22277     2.21 C 24 H 33 O 5 N 6 S
 
 
Figure F6 MS and MSMS analysis of aerucyclamide C from E. coli heterologous 
expression. 
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E. coli mca wildtype pathway
73562lcmsp #9508 RT: 53.34 AV: 1 NL: 2.89E6
T: FTMS + p ESI Full ms2 519.00@hcd35.00 [50.00-1075.00]




















































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H35N6O5S 519.23842 519.23944 2.0
B C21H30N5O4S 448.2013 448.20221 2.0
C C19H30N5O3S 408.20639 408.20715 1.9
D C17H28N5O3S 382.19074 382.19159 2.2
E C15H21N4O3S 337.13289 337.13358 2.0
F C13H19N4O3S 311.11724 311.11786 2.0
G C12H21N4O3 269.16082 269.16122 1.5
H C12H15N2O2S 251.08487 251.08528 1.6
I C11H15N2OS 223.08996 223.09036 1.8
J C9H13N2OS 197.07431 197.07474 2.2
K C8H16N3O2 186.1237 186.12407 2.0
 
Figure F7 MS and MSMS analysis of aerucyclamide C analog from E. coli heterologous 
expression. 
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E. coli mca wildtype pathway
73562lcmsp #9688 RT: 54.46 AV: 1 NL: 1.93E7
T: FTMS + p ESI Full ms2 519.00@hcd35.00 [50.00-1075.00]
















































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C24H35N6O6S 519.23842 519.23926 1.6
B C21H30N6O4S 448.2013 448.20215 1.9
C C19H30N6O3S 408.20639 408.20709 1.7
D C17H28N6O3S 382.19074 382.19183 2.9
E C17H25N4O3S 365.16419 365.16486 1.8
F C15H21N4O3S 337.13289 337.13367 2.3
G C13H19N4O3S 311.11724 311.11771 1.5
H C12H19N4O3 267.14517 267.14575 2.2
I C8H14N3O2 184.10805 184.10817 0.7
J C8H11N2O2 167.0815 167.0818 1.8
 
Figure F8 MS and MSMS analysis of aerucyclamide C analog from E. coli heterologous 
expression. 
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E. coli mca wildtype pathway
73562lcmsp #8834 RT: 49.08 AV: 1 NL: 1.23E7
T: FTMS + p ESI Full ms2 587.00@hcd35.00 [50.00-1215.00]















































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C26H31N6O4S3 587.15634 587.15717 1.4
B C21H26N5O2S3 476.12431 476.12512 1.7
C C17H22N5O3S3 440.08793 440.08835 1.0
D C13H20N5O2S3 374.07736 374.0769 -1.2
E C13H17N4O2S3 357.05081 357.05182 2.8
F C16H19N2OS2 319.09333 319.09381 1.5
G C8H13N2OS2 217.04638 217.04681 2.0
 
E. coli mca wildtype pathway
Accurate mass for aerucyclamide D
73562lcmsp #8833 RT: 49.08 AV: 1 NL: 4.01E8
T: FTMS + p ESI Full ms [150.00-2000.00]































T: FTMS + p ESI Full ms [150.00-2000.00]
m/z= 587.00-588.00
m/z Intensity Relative Theo. Mass Delta 
(ppm)
Composition
  587.15784  403404960.0   100.00   587.15634     1.49 C 26 H 31 O 4 N 6 S 3
 
Figure F9 MS and MSMS analysis of aerucyclamide D from E. coli heterologous 
expression. 
 241 
E. coli mcaEADGF pathway
73499lcmsp #7772 RT: 49.22 AV: 1 NL: 2.23E5
T: FTMS + p ESI Full ms2 587.00@hcd35.00 [50.00-1215.00]























































































Peak Molecular Formula Accurate Mass Observed Mass Error (ppm)
A C26H31N6O4S3 587.15634 587.15594 -0.7
B C21H26N5O2S3 476.12431 476.12399 -0.7
C C20H23N4O2S3 447.09776 447.09778 0.0
D C17H22N5O3S3 440.08793 440.08771 -0.5
E C13H20N5O2S3 374.07736 374.07742 0.2
F C12H17N4O2S3 357.05081 357.05066 -0.4
G C12H17N4O2S3 345.05081 345.05072 -0.3
H C16H17N2OS2 317.07768 317.07761 -0.2
I C8H11N2OS2 215.03073 215.03064 -0.4
J C5H10N3OS 160.05391 160.05379 -0.7
K C5H7N2OS 143.02736 143.02736 0.0
 




73636lcmsp #6224-6794 RT: 52.70-57.38 AV: 285 NL: 1.45E6
T: FTMS + p ESI Full ms [150.00-2000.00]































73656LCMSP #9090-9843 RT: 50.93-54.95 AV: 754 NL: 6.83E6
T: FTMS + p ESI Full ms [150.00-2000.00]

































73650LCMSP #6049-6480 RT: 52.98-56.77 AV: 216 NL: 2.58E6
T: FTMS + p ESI Full ms [150.00-2000.00]
































2 day 3 day 4 day








Figure F11 MS analysis to quantify relative ratios of aerucyclamide C (3) and its oxidized 
analog (3b) over 2 to 4 days from heterologous expression in E. coli. 
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73611lcmsp #7724-8307 RT: 40.82-43.58 AV: 26 NL: 1.95E3
F: FTMS + p ESI Full ms2 537.00@hcd35.00 [50.00-1115.00]




































Relative ratios of microcyclamide B analogs observed from mca WT operon expression in E. coli
73609lcmsp #10082-10601 RT: 52.61-55.18 AV: 24 NL: 6.85E3
F: FTMS + p ESI Full ms2 535.00@hcd35.00 [50.00-1110.00]






































Relative ratios of aerucyclamide A analogs observed from mca WT operon expression in E. coli
 
73609lcmsp #9233-9510 RT: 48.33-49.66 AV: 13 NL: 2.69E3
F: FTMS + p ESI Full ms2 587.00@hcd35.00 [50.00-1215.00]


































73609lcmsp #10128-10634 RT: 52.90-55.36 AV: 23 NL: 1.11E4
F: FTMS + p ESI Full ms2 519.00@hcd35.00 [50.00-1075.00]




































Relative ratios of aerucyclamide C analogs observed from mca WT operon expression in E. coli
Relative ratios of aerucyclamide D analogs observed from mca WT operon expression in E. coli
 
Figure F12 MSMS analysis to quantify relative ratios of microcyclamide and aerucyclamide 
oxidative analogs from heterologous expression in E. coli. Relative abundance approximates are 
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